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Introduction
1
Postpartum hemorrhage is characterized by 
excessive blood loss during delivery and is 
defined by the World Health Organization 
as blood loss exceeding 500 mL, while se-
vere postpartum hemorrhage is defined as 
blood loss exceeding 1000 mL.1 This thesis 
describes studies concerning severe prima-
ry postpartum hemorrhage, using the term 
postpartum hemorrhage for blood loss ex-
ceeding 1000 mL.
Postpartum hemorrhage has been a major 
cause of maternal death and morbidity for as 
long as physicians have studied and written 
about childbirth. Despite considerable ad-
vances in medical care in the last centuries, 
postpartum hemorrhage is still a frequent 
cause of death in many parts of the world 
and continues to plague obstetricians even 
in developed countries. Nowadays, the inci-
dence is 4-8% in the developed world while 
it runs up to 19% in developing countries.2,3 
Moreover, an increase in the incidence of 
postpartum hemorrhage has been reported 
in developed countries during the last dec-
ade.4-11 Treatment of acute anemic women 
after postpartum hemorrhage is often based 
on red blood cell transfusion. The ability to 
safely transfuse, however, was absent for a 
long period of time. While attempts to trans-
fuse blood have been described since the 
15th century, blood transfusion remained 
unsuccessful until the 19th century. The first 
successful human blood transfusion was 
performed in 1818 by the British obstetrician 
James Blundell, for the treatment of post-
partum hemorrhage. Doctor Blundell used 
the patient’s husband as a donor and ex-
tracted four ounces of blood from his arm 
to transfuse into his wife. During 1825-1830, 
doctor Blundell performed ten transfusions, 
of which five were successful. It was not 
until the beginning of the 20th century that 
blood transfusion became safer due to the 
discovery of human blood group systems. 
Storage of blood was not achieved until 
1910-1915 and the first blood banking ser-
vice was established by a US army officer in 
France during World War I. Nowadays, over 
500.000 red blood cell units are used yearly 
in the Netherlands of which 4% because of 
obstetric complications, mainly postpartum 
hemorrhage.12,13 These transfusions are as-
sociated with infectious disease risks and 
immune-mediated risks.14 In patient blood 
management, hemoglobin (Hb) concen-
tration is the main trigger to transfuse. Be-
sides the Hb concentration, depending on 
the physician amount of blood loss, physical 
complaints and social environment are also 
taken into consideration. Despite the advice 
of several guidelines,15-17 transfusion triggers 
vary widely between physicians. Besides im-
provement of clinical status and oxygen sup-
ply,14,18 an important purpose of transfusion 
is to improve a patients health-related quality 
of life (HRQoL). 
The use of HRQoL measures is upcoming 
in the decision making processes in health 
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care nowadays. HRQoL is a multidimension-
al concept that includes domains related to 
physical, mental, emotional and social func-
tioning. To score HRQoL, several measures 
have been developed. These measures, 
provided as questionnaires, can be classi-
fied into three categories. Generic question-
naires measure HRQoL in scores that can 
be compared among differing populations, 
regardless the presence or absence of spe-
cific diseases. Disease-specific question-
naires score the consequences of a specific 
disease, for example pain and stiffness with 
arthritis. Domain-specific questionnaires are 
developed to score a specific domain of 
HRQoL, for example fatigue.
In the studies described in this thesis three 
HRQoL measures were used: the generic 
measures ShortForm-36 and EuroQol-5D 
and the domain-specific measure Multidi-
mensional Fatigue inventory.
aim of the thesis
With the increasing incidence of postpartum 
hemorrhage in developed countries, the vari-
ation in incidence, prevention and treatment 
of postpartum hemorrhage and its sequel-
ae become of great importance. Therefore, 
the aim of this thesis was to investigate the 
incidence of postpartum hemorrhage in the 
Netherlands, adherence to the protocol in 
the management of the third stage of labor 
and red blood cell transfusion management 
in patients with acute anemia after postpar-
tum hemorrhage. 
Specific research questions were:
•	  What is the incidence of postpartum hem-
orrhage in the Netherlands and does vari-
ation across the regions exists? 
•	  Is active management of the third stage 
of labor, as recommended by the Inter-
national Confederation of Midwives (ICM) 
and the International Federation of Gyne-
cology and Obstetrics (FIGO), well imple-
mented in the Netherlands? 
•	  Is non-intervention inferior to red blood cell 
transfusion in acutely anemic women af-
ter postpartum hemorrhage with regard to 
HRQoL, especially physical fatigue? 
•	  Which parameters predict the need for es-
cape red blood cell transfusion in anemic 
women, after postpartum hemorrhage, in-
itially treated expectantly? 
•	  What are the economic consequences of 
red blood cell transfusion versus non-in-
tervention in acutely anemic women after 
postpartum hemorrhage? 
•	  Which baseline characteristics and clinical 
parameters influence HRQoL in the post-
partum period? 
thesis outline 
This thesis displays the results of a large 
cohort study, a clinical observational study 
and a multicenter randomized controlled 
trial. Cost-effectiveness analyses were per-
formed and prediction models created, 
based on data of the randomized controlled 
trial. Furthermore, data of three randomized 
11
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1
controlled trials were merged to create a 
large cohort.
In Chapter 1 an introduction on the subject 
is provided. Chapter 2 presents results of a 
large cohort study, investigating postpartum 
hemorrhage incidence and variation across 
regions in the Netherlands. The cohort was 
created in collaboration with the Dutch Per-
inatal Registry and consists of deliveries in 
the Netherlands from 2000 to 2008. Data of 
maternal mortality due to postpartum hem-
orrhage were made available by the Dutch 
Maternal Mortality Committee.
We studied the performance of the active 
management of the third stage of labor to 
prevent postpartum hemorrhage after vagi-
nal deliveries. A clinical observational study 
was conducted in one academic and one 
teaching hospital in the Netherlands. Results 
are described in Chapter 3.
Chapter 4 presents several studies based 
on data of the WOMB (‘Well-being of Ob-
stetric patients on Minimal Blood transfu-
sions’) trial, a multicenter randomized trial 
that randomized women with acute anemia 
after postpartum hemorrhage between RBC 
transfusion and non-intervention. Primary 
outcome of this trial was physical fatigue, 
measured with the Multidimensional Fatigue 
Inventory. The trial was conducted in collab-
oration with the Dutch Obstetric Consorti-
um; 37 Dutch hospitals participated in this 
trial.
Chapter 4.1 presents the protocol of the 
WOMB trial. In Chapter 4.2 results of a sur-
vey, held among Dutch gynecologists, are 
demonstrated. This survey inventoried prior 
beliefs on clinical questions regarding post-
partum transfusion policy that were to be 
evaluated by the WOMB trial. Results of the 
WOMB trial itself are presented in Chapter 
4.3. In Chapter 4.4 we describe formulas 
predicting the need for escape RBC trans-
fusion in anemic women, after postpartum 
hemorrhage, initially treated expectantly. 
Also, a cost-effectiveness analysis of RBC 
transfusion versus non-intervention in acute-
ly anemic women after postpartum hemor-
rhage was performed: results of this analysis 
are presented in Chapter 4.5. 
To explore the relation of several baseline 
characteristics and clinical parameters with 
HRQoL in the postpartum period, data of the 
WOMB trial were combined with data of two 
other large randomized controlled trials, the 
Digitat and Hypitat trial (Chapter 5). These 
three multicenter trials were all conducted in 
collaboration with the Dutch Obstetric Con-
sortium. 
A general discussion is presented in Chap-
ter 6.
In Chapter 7 this thesis was summarized.
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Chapter 2
reasons for regional 
differences in severe 
postpartum hemorrhage:  
a nationwide comparative 
study of 1.6 million deliveries
B.W. Prick, J.F. von Schmidt auf Altenstadt, C.W.P.M. Hukkelhoven, G.J. Bonsel,  
E.A.P Steegers, B.W. Mol, J.M. Schutte, K.W.M. Bloemenkamp, J.J. Duvekot 
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abstract 
Objective 
The incidence of severe postpartum hem-
orrhage (PPH) is increasing. Regional differ-
ences in its incidences may be attributed to 
variation in provision of care. We aimed to 
assess the reasons for regional variation in 
severe PPH in the Netherlands.
Design 
All deliveries (2000 through 2008) from 
the Netherlands Perinatal Registry and the 
Dutch Maternal Mortality Committee were 
used to study severe PPH incidences (de-
fined as blood loss ≥ 1000 mL) across both 
regions and neighborhoods of cities. First, 
incidences were presented crude and after 
exclusion of multiple pregnancies. Logistic 
multilevel regression analyses, with hospital 
or community midwife practice as second 
level, were performed to explore further rea-
sons for regional variation.
results 
A total of 1 599 867 deliveries was studied. 
The national incidence of severe PPH was 
4.5%. Up to 3-fold differences in crude in-
cidences were observed between regions 
and differences between neighborhoods 
were even larger. Using multilevel analy-
ses, regional variation was not explained by 
maternal characteristics (age, parity, ethnic 
background, socioeconomic status), preg-
nancy characteristics (singleton, gestational 
age, birth weight, pre-eclampsia, perinatal 
death), medical interventions (induction of 
labor, mode of delivery, perineal laceration, 
placental removal) and health care setting.
 
Conclusion 
The variation in severe PPH could not be 
explained by maternal characteristics, 
pregnancy characteristics, medical interven-
tions or health care setting. Regional varia-
tion is either unavoidable or subsequent to 
regional variation of a yet unregistered vari-
able. 
17
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Background 
Severe postpartum hemorrhage (PPH), a 
major obstetric complication and an import-
ant cause of maternal morbidity and mortality 
worldwide,3,19-21 reported to occur in 2-6% of 
pregnancies,2,21 has increased over the last 
decade.4-11 The World Health Organization de-
fines severe PPH as blood loss of ≥ 1000 mL,1 
not taking in consideration the mode of deliv-
ery i.e. vaginal versus cesarean section (CS). 
Carolli et al. described variation in severe 
PPH incidence worldwide varying from 0.3 to 
3.8% within the continent Africa, 0.7 to 2.7% 
in Asia and 1.7 to 5.5% in Europe.2 With an 
increasing severe PPH incidence in several 
developed countries, assessment of PPH at 
the national and regional level is important. 
Intercountry variation, particularly between 
developed and developing countries, may 
mainly result from differences in medical in-
terventions and health care. At the national 
level, regional differences are also observed, 
e.g. 3-fold differences among regions in Cal-
ifornia.22 Understanding of variation need to 
go beyond investigation of incidences as ex-
ploring reasons for differences can be help-
ful in guiding practice improvements. There 
may be a tendency to attribute the variation 
at the national level to differences in health 
care: adjustments for the characteristics of 
mothers and pregnancies are necessary to 
understand the variation better. 
In this paper, we studied severe PPH inci-
dences in the 12 provinces and four largest 
cities in the Netherlands, as well as in the 
neighborhoods of the two largest cities. 
Variation may be due to the combined effect 
of maternal and pregnancy characteristics, 
medical interventions and variation in PPH 
policy in hospital and community midwife 
practices. We performed logistic multilevel 
regression analyses to study if these vari-
ables could explain the variation in our data-
set. We also present the severe PPH-related 
mortality per region as PPH-related mortality 
accounts for almost 8% of all direct maternal 
deaths in the period 1993-2005.23
Methods
We studied all deliveries in the period 2000-
2008, registered in the Netherlands Perinatal 
Registry (PRN). The PRN is a linked national 
registry in which information on 96% of all 
pregnancies and pregnancy outcomes are 
registered by care providers.24 Predefined 
information is directly extracted from the 
mothers’ record and sent to the PRN. The 
PRN distinguishes between data from com-
munity midwife practices (LVR1, primary 
care) providing care to low-risk pregnan-
cies and data from hospitals providing care 
to women with an increased perinatal risk 
by obstetricians (LVR2, secondary/ tertiary 
care). Data on active third stage manage-
ment and professional performance are 
not available. Neonatal admissions and 
complications for each newborn are regis-
tered by pediatricians (LNR).24 The Nether-
lands comprises 12 provinces. The eight 
tertiary care hospitals are located within six 
provinces (Noord-Holland, Zuid-Holland, 
Utrecht, Gelderland, Limburg and Gronin-
gen) while teaching hospitals are present in 
all provinces. In each of the four largest cities 
(Amsterdam, Rotterdam, Utrecht and The 
Hague) a tertiary care hospital is located, 
except in the city of The Hague. In the Neth-
erlands low-risk women are cared for by in-
dependent community midwife practices or 
general practitioners. Part of these low-risk 
women deliver at home, which results in a 
18
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Dutch home delivery incidence of 24% (Ta-
ble 1).25 High-risk women are cared for by 
gynecologists and deliver in hospital. 
The incidence of severe PPH was analyzed 
per province, the four largest cities were 
separately analyzed: it is known from previ-
ous studies that perinatal outcomes in these 
cities are inferior to those in the other regions 
(provinces) of the Netherlands.26-28 Addition-
ally, the incidence of severe PPH across 
neighborhoods was analyzed for the two 
largest cities: Amsterdam and Rotterdam. 
Differences between neighborhoods were 
investigated to compare the magnitude of 
these differences to differences between 
provinces. In the previous study we men-
tioned earlier, differences in perinatal mor-
bidity and mortality were also demonstrated 
between neighborhoods.26 Incidences were 
calculated for every province, city and neigh-
borhood using the four-digit zip codes of the 
women’s address as geographical classifier. 
Therefore, a woman from a rural area de-
livering in a tertiary hospital was analyzed 
as woman from that rural region. Maternal 
mortality numbers were independently ob-
tained from the Maternal Mortality Commit-
tee of the Dutch Society of Obstetrics and 
Gynecology. The committee’s methods have 
been previously described.23
Statistical analysis
Primary outcome was the crude incidence of 
severe PPH across Dutch provinces and the 
four largest cities. Secondary outcomes were 
the severe PPH incidence across neighbor-
hoods in the two largest cities, and PPH-relat-
ed maternal mortality across regions. Deliver-
ies with a gestational age below 24+0 weeks 
were excluded. Crude severe PPH incidences 
were tabulated, as well as crude incidences 
after exclusion of multiple pregnancies. Data 
were stratified for mode of delivery as there are 
known differences in PPH incidence between 
different modes of delivery.29 The distribution of 
the severe PPH incidences was projected on a 
map of the Netherlands. For this figure, quar-
tiles of standardized incidences were chosen 
as cut offs. We performed logistic multilevel 
regression analyses to explore the origin of the 
observed geographical variation using hospi-
tals and community midwife practices as the 
second level in the analyses. For this purpose, 
each hospital and community midwife practice 
was anonymized and identified by a code.
We performed 6 model specifications fol-
lowing the same pattern. All models were fit 
on the exact same data. First, we estimated 
a model including regions only to assess the 
outcome (severe PPH) across regions. Then, 
we repeated the analysis after addition of co-
variates, which were added block-wise. Every 
subsequent model thus consisted of the first 
model and one specific block of covariates. 
The second model included maternal char-
acteristics (age, parity, ethnic background, 
socioeconomic status) as covariates, the third 
model pregnancy characteristics (singleton, 
gestational age, birth weight, pre-eclampsia, 
perinatal death), the fourth model medical in-
terventions (induction of labor, mode of deliv-
ery, perineal laceration, placental removal) and 
the fifth model health care setting (place of 
delivery). Finally, the last model was performed 
after inclusion of all blocks (maternal charac-
teristics, pregnancy characteristics, medical 
interventions and health care setting).
The following definitions were used. Severe 
PPH was defined as peripartum blood loss 
≥ 1000 mL in the 24 hours following delivery. 
We categorized maternal age in ≤ 35 and 
> 35 years and parity into nulliparous wom-
en (i.e., women who had never given birth) 
or multiparous women (i.e., women who 
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had given birth at least once). Ethnicity was 
categorized in Western or non-Western. So-
cioeconomic status was derived from the re-
corded zip code of the women.30 Gestation-
al age at delivery was categorized into ≥ 37 
weeks and < 37 weeks. Pre-eclampsia was 
defined as a diastolic blood pressure of min-
imal 90 mmHg in the presence of proteinuria 
after 20 weeks of gestation.31 Birth weight 
percentiles were derived from sex and par-
ity specific growth curves32 and considered 
to be undefined for multiple pregnancies 
and neonates with congenital anomalies or 
perinatal death. We distinguished between 
spontaneous onset of labor and induction of 
labor. Mode of delivery was categorized into 
spontaneous vaginal, assisted vaginal deliv-
ery, elective CS or emergency CS. Perineal 
laceration was split into ‘none or first degree’ 
or ‘at least second degree’ and a distinction 
between spontaneous placental delivery and 
manual placenta delivery was made. The 
Dutch health care setting was described in 
more detail above. In case of a discrepancy 
between LVR1 and LVR2 source data, LVR2 
data prevailed, with the exception for the 
variable ethnic background. 
A funnel plot was created using Excel. Tests 
for differences between groups were per-
formed using SPSS; multilevel analyses were 
performed using proc glimmix in SAS version 
9.3 software. 
results 
A total of 1 599 867 pregnancies was stud-
ied. General characteristics of all deliveries 
are tabulated in Table 1. Severe PPH was 
reported in 69 719 (4.5%) of all deliveries; 
severe PPH incidence increased from 3.8 to 
5.8% during the study period (p < 0.001). 
PPH was unknown in 44 859 deliveries. 
Mode of delivery affected the incidence as 
follows: spontaneous delivery 4.3%, assist-
ed vaginal delivery 6.4%, elective CS 4.3% 
and emergency CS respectively 3.2%. 
Severe PPH incidence per region
In Appendix 1 crude incidence in regions are 
tabulated. 
Crude incidences 
The average national crude severe PPH in-
cidence was 4.5%. Figure 1 demonstrates 
the wide variation in crude incidence per re-
gion related to the regional population size. 
When stratifying by mode of delivery, severe 
PPH incidence was up to 3 times higher in 
the region with the highest incidence com-
pared to that with the lowest. After sponta-
neous delivery, the incidence ranged from 
3.3% to 5.1%. After assisted vaginal delivery 
this range was 4.8% to 7.9% while the rang-
es after elective and emergency CS were the 
widest: respectively 2.7% to 6.8% and 1.5% 
to 4.9%. Crude incidences of severe PPH 
in the four largest cities exceeded regional 
results. Altogether, without stratification for 
mode of delivery, the crude severe PPH inci-
dence in the four cities was 4.9% compared 
to 4.4% in the provinces (p < 0.001). 
Singleton pregnancies 
After exclusion of multiple pregnancies, aver-
age crude severe PPH incidence was 4.2% 
after spontaneous delivery, 6.2% after as-
sisted vaginal delivery, and 3.5% and 3.0% 
after respectively elective and emergency 
CS (Appendix 1). The severe PPH incidence 
decreased in most regions after exclusion of 
multiple pregnancies. Ranges in incidence per 
mode of delivery as well as regional ranks in 
severe PPH incidence remained similar.
20
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Table 1  Maternal characteristics, pregnancy characteristics, medical interventions, health care 
setting and severe PPH incidences.
 
All Spontaneous Assisted  vaginal delivery Elective CS Emergency CS
% 
inci-
dence
%
inci-
dence
%
inci-
dence
%
inci-
dence
%
inci-
dence
Maternal  
characteristics
Age, n (%)
≤ 35 years 85.6 4.4 86.0 4.3 88.4 6.2 78.9 3.9 83.6 3.0
> 35 years 14.4 5.1 14.0 4.8 11.6 7.7 21.1 5.5 16.4 4.3
Parity
0 46.2 5.0 39.1 5.1 82.1 6.6 42.0 3.8 67.7 2.8
≥ 1 53.8 4.0 60.9 3.9 17.9 5.5 58.0 4.6 32.3 3.9
Ethnicity 
Western 84.5 4.6 83.9 4.4 88.2 6.6 86.7 4.1 83.5 3.2
non-Western 15.5 4.1 16.1 4.0 11.8 4.8 13.3 5.3 16.5 3.3
Socioeconomic 
status
highest (> p80) 17.2 4.9 17.0 4.7 18.2 7.2 18.0 4.7 17.0 3.3
moderate (p20-80) 57.8 4.5 57.8 4.3 58.4 6.4 58.9 4.1 57.0 3.2
lowest (< p20) 25.0 4.2 25.3 4.2 23.5 5.7 23.1 4.2 26.0 3.0
Pregnancy  
characteristics
Singleton pregnancy
yes 98.0 4.3 98.6 4.2 98.2 6.2 94.1 3.5 96.1 3.0
no 2.0 12.1 1.4 11.1 1.8 17.4 5.9 16.0 3.9 7.5
Gestational age 
≥ 37 weeks 93.3 4.4 94.3 4.2 95.2 6.3 81.9 3.7 91.0 3.1
< 37 weeks 6.7 6.0 5.7 5.9 4.8 8.3 18.1 6.6 9.1 3.9
Pre-eclampsia
yes 2.2 7.4 1.3 8.9 2.7 12.1 8.1 4.6 4.8 4.1
no 97.8 4.2 98.7 4.1 97.3 6.1 91.9 3.9 95.2 2.8
Birth weight neonate 
< 10th percentile 9.7 3.4 9.5 3.5 8.5 4.4 12.0 3.0 11.5 1.7
10-90 percentile 79.7 4.3 81.0 4.2 79.0 5.9 75.6 4.3 72.3 3.0
> 90st percentile 10.5 7.0 9.5 6.8 12.5 10.7 12.4 5.4 16.2 5.0
Perinatal death
yes 0.8 7.5 0.8 7.3 0.4 10.3 1.0 8.8 0.7 5.5
no 99.2 4.5 99.2 4.3 99.6 6.4 99.0 4.2 99.3 3.2
Medical  
interventions
Induction of labor
yes 14.8 6.2 14.0 6.3 18.7 8.5 NA 29.5 3.6
no 85.2 4.2 86.0 4.0 81.3 5.9 NA 70.5 3.0
Delivery
spontaneous 74.7 4.3 NA NA NA NA
assisted vaginal  
delivery
10.7 6.4 NA NA NA NA
elective CS 6.5 4.3 NA NA NA NA
emergency CS 8.1 3.2 NA NA NA NA
21
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All Spontaneous Assisted  vaginal delivery Elective CS Emergency CS
% 
inci-
dence
%
inci-
dence
%
inci-
dence
%
inci-
dence
%
inci-
dence
Perineal laceration
intact/ ≤1st degree  
rupture
71.4 3.8 74.0 3.7 14.8 5.1 NA 99.2
≥ 2nd degree  
rupture/ episiotomy
28.6 6.3 26.0 6.2 85.2 6.6 NA 0.8
Manual placenta 
removal
yes 1.9 58.3 2.0 59.6 3.8 53.2 NA NA
no 98.1 3.5 98.0 3.2 96.2 4.6 NA NA
Health care setting 
Delivery
home (community  
midwife)
24.2 2.3 32.4 2.2 NA NA NA
hospital (community  
midwife)
10.9 4.2 14.6 4.2 NA NA NA
tertiary care  
hospital
5.8 7.4 4.8 7.3 7.3 8.1 11.5 7.9 8.7 6.5
teaching hospital 30.4 5.6 25.1 6.0 46.9 6.6 44.4 4.0 45.4 3.1
non-teaching  
hospital 
28.8 4.7 23.2 5.0 45.9 5.9 44.1 3.6 45.9 2.7
Total deliveries: 1 599 867, PPH unknown: 44 859, Mode of delivery unknown: 2350 
NA = not applicable, CS = cesarean  
Figure 1 Funnel plot: variation in regional PPH incidence related to regional population size.
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Logistic multilevel regression analyses
Table 2 presents OR’s of severe PPH per re-
gion taking into account the level hospital or 
community midwife practice. Crude, unad-
justed regional OR’s (the first model) ranged 
from 0.80 to 1.10 while the OR’s of severe 
PPH in the four largest cities were similar to 
those in the provinces.
Adjustment for maternal characteristics led 
to higher severe PPH OR’s compared to the 
unadjusted model although differences were 
relatively small except for the cities Amster-
dam and Rotterdam. Compared to the un-
adjusted model, adjustment for pregnancy 
characteristics revealed overall lower severe 
PPH OR’s while adjustment for medical in-
terventions led to an ambiguous effect on 
the severe PPH OR’s. Health care setting 
adjustment also produced an ambiguous 
effect with mainly higher severe PPH OR’s 
compared to the unadjusted model. Of the 
four blocks of variables that were added to 
the unadjusted model, pregnancy character-
istics and health care setting influenced the 
severe PPH OR’s the most.
Compared to the unadjusted model, ad-
justment for all variables simultaneously had 
the largest effect on the severe PPH OR’s 
although this too was an ambiguous effect.
 
The regional variation in severe PPH OR was 
largest after adjustment for all variables. Af-
ter stratification for mode of delivery, adjust-
ment for all variables demonstrated ambig-
uous effects for each mode of delivery too 
(data not shown). 
Severe PPH incidence in amsterdam
Crude incidences in neighborhoods in Am-
sterdam are demonstrated in Appendix 2. 
Crude incidences 
The average crude incidence was 5.0%. 
There was a wide variation in incidence be-
tween neighborhoods with differences up to 
7.3%, depending on the mode of delivery. 
After spontaneous delivery, the incidence 
ranged from 3.6% to 6.4%. After assist-
ed vaginal delivery this range was 3.8% to 
10.4% while the ranges after elective and 
emergency CS were the widest: 1.6% to 
8.9% and 0.8% to 5.3%.
Singleton pregnancies 
Average crude incidence after exclusion of 
multiple pregnancies was 4.9% after spon-
taneous delivery, 7.4% after assisted vaginal 
delivery and 3.7% and 2.4% after respec-
tively elective and emergency CS. 
Severe PPH incidence in rotterdam
Crude incidences in neighborhoods in Rot-
terdam are demonstrated in Appendix 3. 
Crude incidences 
The average crude incidence was 4.4%. Dif-
ferences between neighborhoods were large 
and reached differences up to 8.0%. After 
spontaneous delivery, the incidence ranged 
from 3.8% to 6.2%. After assisted vaginal 
delivery, the incidence ranged from 4.1% to 
12.1% while ranges were widest after elec-
tive and emergency CS: 1.8% to 6.6% and 
0% to 4.9%, respectively. 
Singleton pregnancies 
Average crude incidence after exclusion of 
multiple pregnancies was 4.3% after spon-
taneous delivery, 5.3% after assisted vaginal 
delivery and 3.4 and 3.2% after respectively 
elective and emergency CS.
23
Chapter 2 - Reasons for regional differences in severe postpartum hemorrhage
2
Ta
b
le
 2
 R
es
ul
ts
 o
f l
og
is
tic
 m
ul
til
ev
el
 re
gr
es
si
on
 a
na
ly
se
s 
of
 P
P
H
 p
er
 re
gi
on
. 
U
na
d
ju
st
ed
A
d
ju
st
ed
 f
o
r
M
at
er
na
l  
ch
ar
ac
te
ri
st
ic
s
P
re
g
na
nc
y 
ch
ar
ac
te
ri
st
ic
s
M
ed
ic
al
 
in
te
rv
en
tio
ns
 
H
ea
lth
 c
ar
e 
se
tt
in
g
A
ll
%
 C
ha
ng
e 
in
 O
R
: 
un
ad
ju
st
ed
 v
s 
ad
ju
st
ed
 f
o
r 
al
l
R
eg
io
n
A
m
st
er
da
m
a
1.
02
 (0
.9
2-
1.
13
)
1.
12
 (1
.0
1-
1.
24
)
1.
08
 (0
.9
6-
1.
20
)
1.
02
 (0
.9
2-
1.
13
)
1.
00
 (0
.9
1-
1.
10
)
1.
05
 (0
.9
4-
1.
17
)
3
R
ot
te
rd
am
a
0.
94
 (0
.8
5-
1.
04
)
1.
05
 (0
.9
4-
1.
17
)
0.
97
 (0
.8
6-
1.
08
)
0.
91
 (0
.8
2-
1.
02
)
0.
86
 (0
.7
8-
0.
94
)
0.
90
 (0
.8
0-
1.
01
)
-5
Th
e 
H
ag
ue
a
1.
00
 (0
.8
9-
1.
12
)
1.
04
 (0
.9
3-
1.
16
)
0.
99
 (0
.8
8-
1.
12
)
0.
91
 (0
.8
1-
1.
03
)
0.
91
 (0
.8
2-
1.
02
)
0.
84
 (0
.7
4-
0.
94
)
-2
0
U
tr
ec
ht
a
0.
89
 (0
.8
2-
0.
97
)
0.
92
 (0
.8
5-
1.
00
)
0.
94
 (0
.8
6-
1.
02
)
1.
00
 (0
.9
1-
1.
10
)
0.
89
 (0
.8
2-
0.
96
)
1.
02
 (0
.9
2-
1.
13
)
12
G
ro
ni
ng
en
0.
80
( 0
.6
9-
0.
92
)
0.
83
 (0
.7
2-
0.
96
)
0.
77
 (0
.6
6-
0.
90
)
0.
73
 (0
.6
3-
0.
84
)
0.
75
 (0
.6
6-
0.
86
)
0.
71
 (0
.6
1-
0.
82
)
-1
3
Fr
ie
sl
an
d
0.
88
 (0
.7
6-
1.
03
)
0.
91
 (0
.7
9-
1.
06
)
0.
78
 (0
.6
6-
0.
91
)
0.
73
 (0
.6
3-
0.
85
)
0.
86
 (0
.7
5-
0.
98
)
0.
70
 (0
.6
0-
0.
82
)
-2
6
D
re
nt
e
0.
83
 (0
.7
2-
0.
95
)
0.
85
 (0
.7
4-
0.
97
)
0.
78
 (0
.6
7-
0.
90
)
0.
73
 (0
.6
3-
0.
83
)
0.
80
 (0
.7
0-
0.
90
)
0.
71
 (0
.6
2-
0.
82
)
-1
6
O
ve
rij
ss
el
0.
91
 (0
.8
2-
1.
01
)
0.
92
 (0
.9
3-
1.
03
)
0.
84
 (0
.7
4-
0.
94
)
0.
81
 (0
.7
3-
0.
91
)
0.
92
 (0
.8
3-
1.
01
)
0.
83
 (0
.7
4-
0.
93
)
-1
0
G
el
de
rla
nd
1.
01
 (0
.9
3-
1.
08
)
1.
02
 (0
.9
4-
1.
09
)
0.
95
 (0
.8
8-
1.
03
)
0.
92
 (0
.8
5-
1.
00
)
1.
02
 (0
.9
5-
1.
09
)
0.
92
 (0
.8
5-
1.
01
)
-9
U
tr
ec
ht
R
ef
R
ef
R
ef
 
R
ef
R
ef
R
ef
N
oo
rd
 H
ol
la
nd
1.
10
 (1
.0
1-
1.
21
)
1.
12
 (1
.0
2-
1.
22
)
1.
06
 (0
.9
7-
1.
17
)
1.
02
 (0
.9
3-
1.
12
)
1.
08
 (1
.0
0-
1.
18
)
0.
98
 (0
.8
9-
1.
08
)
-1
3
Zu
id
 H
ol
la
nd
1.
05
 (0
.9
6-
1.
15
)
1.
07
 (0
.9
8-
1.
16
) 
1.
03
 (0
.9
4-
1.
14
) 
0.
96
 (0
.8
8-
1.
05
)
0.
99
 (0
.9
1-
1.
07
)
0.
89
 (0
.8
1-
0.
98
)
-1
8
Ze
el
an
d
1.
05
 (0
.8
7-
1.
26
)
1.
07
 (0
.8
9-
1.
28
)
0.
96
 (0
.7
9-
1.
16
)
0.
98
 (0
.8
1-
1.
18
)
0.
94
 (0
.8
0-
1.
12
)
0.
88
 (0
.7
3-
1.
07
)
-1
9
N
oo
rd
 B
ra
ba
nt
1.
03
 (0
.9
4-
1.
13
)
1.
04
 (0
.9
5-
1.
14
)
1.
02
 (0
.9
2-
1.
12
)
0.
95
 (0
.8
6-
1.
04
)
1.
02
 (0
.9
4-
1.
11
)
0.
97
 (0
.8
8-
1.
06
)
-7
Li
m
bu
rg
1.
04
 (0
.9
2-
1.
17
)
1.
05
 (0
.9
3-
1.
18
) 
1.
00
 (0
.8
8-
1.
14
)
0.
90
 (0
.8
0-
1.
02
)
0.
97
 (0
.8
7-
1.
08
)
0.
86
 (0
.7
6-
0.
98
)
-2
0
Fl
ev
ol
an
d
1.
07
 (0
.9
4-
1.
23
)
1.
10
 (0
.9
6-
1.
26
)
0.
93
 (0
.8
0-
1.
08
)
0.
93
 (0
.8
1-
1.
07
)
1.
05
 (0
.9
3-
1.
20
)
0.
87
 (0
.7
4-
1.
01
)
-2
4
a 
C
ity
Le
ve
l u
se
d 
w
as
 th
e 
un
iq
ue
 c
od
e 
fo
r 
ea
ch
 h
os
pi
ta
l a
nd
 c
om
m
un
ity
 m
id
w
ife
 p
ra
ct
ic
e
M
at
er
na
l c
ha
ra
ct
er
is
tic
s:
 A
ge
, P
ar
ity
, E
th
ni
c 
ba
ck
gr
ou
nd
, S
oc
io
ec
on
om
ic
 s
ta
tu
s
P
re
gn
an
cy
 c
ha
ra
ct
er
is
tic
s:
 S
in
gl
et
on
, G
es
ta
tio
na
l a
ge
, B
irt
h 
w
ei
gh
t, 
P
re
-e
cl
am
ps
ia
, P
er
in
at
al
 D
ea
th
M
ed
ic
al
 in
te
rv
en
tio
ns
: I
nd
uc
tio
n 
of
 la
bo
r, 
M
od
e 
of
 d
el
iv
er
y,
 P
er
in
ea
l l
ac
er
at
io
n,
 P
la
ce
nt
al
 re
m
ov
al
H
ea
lth
 c
ar
e 
se
tt
in
g:
 P
la
ce
 o
f d
el
iv
er
y
24
Clinical aspects of Postpartum Hemorrhage 
Table 3 Crude maternal mortality per region. 
Deliveriesa PPH casesa Mortality, 
totalb
Mortality, 
due to PPHb
(% of total)
Region
Amsterdamc 90 738 4656 9 0 
Rotterdamc 63 571 2891 17 1
Den Haagc 53 509 2812 9 0 
Utrechtc 37 098 1583 4 0
Groningen 50 823 1912 5 0
Friesland 56 079 2201 7 1 
Drente 44 942 1795 6 1 
Overijssel 118 003 4227 15 2 
Gelderland 197 320 9575 15 1 
Utrecht 93 408 3828 19 3 
Noord-Holland 173 166 8613 16 0
Zuid-Holland 226 040 10 843 20 2 
Zeeland 27 505 1047 6 1 
Noord-Brabant 230 043 11 081 20 1 
Limburg 88 794 3833 10 0 
Flevoland 40 107 1941 5 0
Unknown region 8721 430 4 1 
Total 1 599 867 73 268 187 14 (7.5%)
a Data derived from PRN
b Data derived from Maternal Mortality Committee
c City
Figure 2 Crude incidence of PPH following spontaneous delivery per region.
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PPH-related mortality
Almost eight percent of total maternal mor-
tality was related to PPH (see Table 3). 
PPH-related mortality varied from 0.16% to 
0.59% across regions. It showed a pattern 
dissimilar from the crude severe PPH inci-
dence pattern across regions. 
Discussion 
The national incidence of severe PPH in the 
period 2000-2008 was almost 5%. Our re-
sults, stratified by mode of delivery, showed 
a wide variation in severe PPH incidence 
across regions (provinces, cities) and neigh-
borhoods in the Netherlands: crude inci-
dences ranged from below 2% to well over 
8%. Figure 1 demonstrates that variation 
tends to be larger when the population size 
is smaller. After elective and emergency CS, 
the variation in severe PPH incidence was 
most extreme. As expected, exclusion of 
multiple pregnancies decreased crude in-
cidences.21,33,34 A significant higher severe 
PPH incidence was observed in the four cit-
ies compared to the 12 provinces. Across 
neighborhoods in the two largest cities, 
variation in severe PPH incidence was even 
larger than across regions. 
Following logistic multilevel regression anal-
yses, to adjust for maternal characteristics, 
pregnancy characteristics, medical interven-
tions and health care setting, the variation 
in OR’s per region even increased (Table 2). 
Therefore, the epidemiological data cannot 
elucidate the sources of the remnant vari-
ation: results imply they are unavoidable or 
subsequent to regional variation of a yet un-
registered variable. 
Regional differences in PPH incidence were 
previously described. Carolli et al.2 de-
scribed similar variation in severe PPH in-
cidence worldwide and Fong et al.22 found 
similar variation in PPH incidence in Cali-
fornia. Causes of these variations were not 
investigated in these studies. In addition, Lu 
et al. found large differences across hospi-
tals in California and also found higher ob-
stetrical trauma, chorioamnionitis, and pro-
tracted labor (used as proxy of the quality 
of health care) in hospitals with a high PPH 
incidence.35 To date, various risk factors for 
PPH in different populations have been de-
scribed in literature. Risk factors for PPH can 
be divided in maternal characteristics, preg-
nancy characteristics, medical interventions 
and health care setting. In literature, higher 
PPH incidences are reported with increased 
maternal age and decreasing socioeco-
nomic status while literature is contradic-
tive regarding ethnicity and parity.21,33,34,36-38 
Other risk factors for PPH that have been 
described in literature are induction of labor, 
augmentation of labor, perineal laceration, 
manual placental removal and an increas-
ing fetal weight.21,33,34 Additionally, variation 
in Dutch obstetric care has previously been 
described.39 Although these risk factors var-
ied to a large extent across regions (data not 
shown), PPH variation remained after adjust-
ment for these factors. 
In this study, we presented the geographical 
distribution while taking into account hospi-
tal or community midwife practice because 
on average 24% of women in the Nether-
lands deliver at home.25 Regarding place of 
birth, Davis et al. described no relation to 
occurrence of PPH in a recent study.40 The 
incidence of severe PPH varied for mode of 
delivery, and conditional on mode of delivery, 
variation was not uniform. Although reported 
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in previous studies too,2,5,9,41 the relatively 
low severe PPH incidence after (emergency) 
CS was remarkable. Overall, mean blood 
loss during delivery is higher in case of CS.42 
However, in case of severe PPH an aggres-
sive policy to halt the bleeding is more quick-
ly available at the surgery ward and might 
contribute to lower incidence of severe PPH 
after CS. Also, we cannot neglect the pos-
sibility of registration errors. If present how-
ever, the magnitude of these errors is not 
expected to vary across regions and will 
therefore not have influenced the variation 
across regions to a great extent.
Almost 8% of maternal mortality in this 
study was PPH-related while the PPH-re-
lated mortality incidence across regions var-
ied between 0.16 and 0.59%. In California, 
PPH-related mortality across regions has 
been described to vary between 0.08 and 
0.21%.22 Variation was thus larger in our 
study, yet our dataset was about 3 times 
smaller and mortality numbers on average 
were lower. Haeri et al. described that 13% 
of maternal mortality in developed countries 
is caused by PPH.43 The distribution of mor-
tality was not like the severe PPH pattern, 
unlike findings of Fong et al.22 However, mor-
tality numbers in this study were very small.
 
The following limitations of this study are to 
consider. Despite the large dataset, num-
bers of deliveries in some neighborhoods 
were relatively small. Also, a small number 
of care providers does not participate in the 
PRN (5% of community midwife practices, 
1% of gynecologists), however it is unlike-
ly non-participation is related to the occur-
rence of postpartum hemorrhage. Another 
limitation concerns data on PPH determi-
nants. Body mass index (BMI) data were 
unavailable which may be relevant as BMI 
is proposed to be a risk factor for PPH44-46 
and public health reports show regional BMI 
variation.47 However, at the aggregate lev-
el epidemiological patterns apparently do 
not relate. Also, data on active third stage 
management and professional performance 
were unavailable.
Although literature has shown that estima-
tion of the amount of blood loss is often 
inaccurate,42,48,49 blood loss is not routinely 
weighed in the Netherlands in all deliveries. 
After vaginal deliveries blood loss is mostly 
estimated in case of normal blood loss and 
usually weighed in case of persisting blood 
loss. In case of CS, abdominal blood loss 
is collected through suction in a measuring 
pot and estimated postoperatively based on 
the amount of fluid in the pot and the vaginal 
blood loss. To our knowledge, no validation 
studies on blood loss estimation have been 
performed in the Netherlands. Blood loss is 
recorded in the PRN dataset as binary vari-
able with a cut off of 1000 mL (irrespective 
of the mode of delivery). This cut off was de-
rived from the definition of severe PPH by 
the World Health Organization1 and is the 
most widely used in literature. While blood 
loss of 1000-2000 mL is usually not a major 
threat to the maternal condition in developed 
countries, we believe this cut off is accurate. 
Results with this cut off are more trustworthy 
due to the (relatively) large number of cases 
than with a higher cut off. However, in our 
dataset the method for blood loss mea-
surement is not registered and might vary. 
Consequently, reported differences in severe 
PPH incidence might have their origin also in 
regional differences in methods of measure-
ments. Despite the inaccuracy of the blood 
estimation procedure in general,50 we as-
sume the cut off of 1000 mL to be sufficient-
ly accurate for our purposes, as the great 
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majority of such cases will involve weighed 
blood loss. Bias through differences in these 
estimations is expected to be small as, if 
present, misclassification is expected to be 
similar across regions. The major weakness 
in the dataset is the lack of registration of 
preventive and therapeutic measures.
The major strength of this study is the very 
large dataset containing 96% of all deliveries 
in the Netherlands in the period 2000-2008. 
These numbers strengthen external validity 
of the study. Since data were extracted elec-
tronically from the medical records, data are 
trustworthy. Data were prechecked through 
built-in checks and through post-hoc algo-
rithms of the PRN; note however that the 
dataset was anonymized excluding the po-
tential for individual retrospective checks. 
In conclusion, a large variation in severe PPH 
incidence exists nationwide in the Nether-
lands. This variation could not be explained 
by maternal characteristics, pregnancy 
characteristics, medical interventions or 
health care setting. Regional variation may 
be unavoidable or subsequent to regional 
variation of a yet unregistered variable.
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Appendix 1 Crude incidences of PPH per region. 
Total Spontaneous 
delivery
Assisted vaginal 
delivery
Elective CS Emergency CS
All All Singleton  
pregnancies
All Singleton  
pregnancies
All Singleton  
pregnancies
All Singleton  
pregnancies
Region
Amsterdama 5.0 4.9 4.9 7.6 7.4 4.9 3.8 2.6 2.4
Rotterdama 4.4 4.4 4.3 5.5 5.3 4.3 3.4 3.3 3.2
The Haguea 5.4 5.1 5.0 7.6 7.3 6.4 5.5 4.2 4.0
Utrechta 4.8 4.8 4.6 5.9 5.7 4.8 4.1 3.1 2.6
Groningen 3.7 3.4 3.3 4.8 4.5 3.7 3.3 3.0 2.9
Friesland 3.8 3.6 3.4 6.0 5.8 2.9 2.4 3.1 3.1
Drente 3.8 3.8 3.7 6.3 6.1 2.9 2.4 1.5 1.4
Overijssel 3.5 3.3 3.2 5.4 5.2 3.1 2.4 2.6 2.5
Gelderland 4.7 4.3 4.2 6.7 6.4 6.0 5.2 4.9 4.6
Utrecht 4.2 4.1 4.0 5.7 5.4 4.3 3.7 2.6 2.1
Noord Holland 4.9 4.8 4.7 7.9 7.7 3.4 2.7 2.1 2.0
Zuid Holland 4.6 4.5 4.4 6.3 6.1 4.5 3.6 3.8 3.6
Zeeland 4.2 3.5 3.4 6.8 6.6 6.8 6.2 4.5 4.5
Noord Brabant 4.6 4.5 4.4 6.3 6.1 4.4 3.8 3.6 3.3
Limburg 4.2 4.3 4.2 5.9 5.7 2.7 2.2 2.0 1.8
Flevoland 4.6 4.7 4.6 5.2 5.1 4.5 3.7 2.4 2.2
Total 4.5 4.3 4.2 6.4 6.2 4.3 3.5 3.2 3.0
a City
CS = cesarean section 
Appendix 2 Crude incidences of PPH in Amsterdam. 
Total Spontaneous Assisted vaginal Elective CS Emergency CS
All All Singleton 
pregnancies
All Singleton 
pregnancies
All Singleton 
pregnancies
All Singleton 
pregnancies
Neighborhood
Centrum 5.4 5.6 5.6 7.5 7.6 4.4 4.0 2.4 2.4
de Baarsjes 4.7 4.6 4.5 10.4 10.0 3.2 0.6 1.0 1.0
Bos en Lommer 5.0 5.2 5.1 8.3 8.0 2.9 1.3 0.9 0.9
Geuzenveld-Slotermeer 4.1 4.4 4.3 5.9 5.6 1.6 1.1 1.5 1.5
Noord 4.4 3.6 3.5 6.7 6.5 8.9 7.6 5.3 5.1
Osdorp 5.2 5.3 5.2 9.9 9.8 2.4 1.1 1.4 1.2
Oud-West 5.6 5.9 6.2 7.3 7.0 3.5 3.9 2.7 3.1
Oud-Zuid 5.5 5.8 5.6 7.9 7.5 4.1 2.1 1.6 1.5
Oost-Watergraafsmeer 4.8 4.5 4.4 8.0 7.8 5.1 3.2 3.5 3.4
Slotervaart 5.1 5.3 5.3 9.3 9.0 2.6 0.4 0.8 0.8
Westerpark 6.0 6.4 5.9 8.5 7.6 3.4 1.4 1.4 1.1
Westpoort 4.4 4.6 4.4 5.6 5.2 3.3 3.5 2.0 2.1
Zeeburg 4.8 4.9 4.7 6.7 6.6 4.6 4.1 2.6 2.4
Zuideramstel 5.2 5.1 5.1 9.4 9.4 3.6 1.6 2.2 1.7
Zuid Oost 4.7 4.6 4.5 3.8 3.7 8.1 7.9 3.8 3.7
Total 5.0 4.9 4.9 7.6 7.4 4.9 3.7 2.5 2.4
CS = cesarean section 
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Appendix 3 Crude incidences of PPH in Rotterdam. 
Total Spontaneous Assisted vaginal Elective CS Emergency CS
All All Singleton 
pregnancies
All Singleton 
pregnancies
All Singleton 
pregnancies
All Singleton 
pregnancies
Neighborhood
Stadscentrum 4.5 4.2 4.2 6.0 6.1 5.7 4.5 3.8 3.9
Charlois 4.2 4.0 3.8 5.3 5.0 3.8 2.8 4.5 4.4
Delfshaven 4.1 4.0 3.9 4.1 4.2 4.4 3.7 4.9 5.0
Feijenoord 3.7 3.8 3.8 4.2 4.2 3.3 3.0 2.1 2.0
Hilligersberg Schiebroek 5.8 6.2 6.2 7.1 7.1 3.8 3.6 1.4 1.4
Hoogvliet 5.0 5.0 4.9 5.8 4.9 4.6 3.9 3.6 3.3
Hoek van Holland 5.0 4.4 4.5 12.1 9.5 3.1 3.3 3.9 4.0
Ijsselmonde 4.2 4.5 4.3 4.5 4.6 4.0 2.8 1.2 1.0
Kralingen Crooswijk 4.4 4.4 4.3 5.8 5.6 4.4 3.4 2.9 2.7
Noord 4.4 4.4 4.3 6.5 6.0 1.8 1.9 2.3 2.4
Overschie 5.1 5.6 5.5 5.2 4.7 3.3 3.5 0.8 0.9
Prins Alexander 4.8 4.3 4.3 6.1 6.0 6.6 4.7 4.9 4.7
Pernis 5.0 5.1 4.8 8.2 8.5 4.6 0 0 0
Total 4.4 4.4 4.3 5.5 5.3 4.3 3.4 3.3 3.2
CS = cesarean section 
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Chapter 3
the current state of active 
third stage management 
to prevent postpartum 
hemorrhage: a cross-sectional 
study
B.W. Prick, A.A. Vos, W.C.J. Hop, H.A. Bremer, E.A.P. Steegers, J.J. Duvekot
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abstract
Objective
To investigate the implementation of the 
International Confederation of Midwives/ 
International Federation of Gynecology and 
Obstetrics (ICM/ FIGO) guideline on active 
third stage management in vaginal deliveries 
in daily clinical practice. 
Design
Observational, cross-sectional study. 
Setting
One tertiary and one teaching hospital in the 
Netherlands. 
Population 
Women undergoing vaginal deliveries. 
Methods 
A case record form was completed after ev-
ery vaginal delivery. Primary outcome was 
adequate guideline adherence, defined as 
initial administration of 10 IU oxytocin, per-
formance of controlled cord traction and 
uterine massage. Adequate guideline adher-
ence was a priori estimated to be 10%. With 
a sample size of 600, i.e. 300 women per 
hospital, the standard error of the resulting 
percentage would be less than 2% for each 
hospital. 
results
Six hundred and twenty six women were 
included. Guideline adherence was ade-
quately performed in 48% of vaginal deliv-
eries. Oxytocin was administered after birth 
in 98% of deliveries and in 80% the correct 
dose was used. Controlled cord traction 
was performed in 63% and uterine massage 
in 93%; however, the latter was performed 
as advised (at least eight times) in only 8%. 
The amount of blood loss was not associ-
ated with the use of either 5 or 10 IU oxy-
tocin (p = 0.818). Controlled cord traction 
and uterine massage were more frequently 
performed when blood loss exceeded 500 
mL (p < 0.001). 
Conclusion 
Active third stage management according to 
the ICM/ FIGO guideline is adequately per-
formed in only 48% of all vaginal deliveries.
Results of this study call for training pro-
grams to increase adherence to the ICM/ 
FIGO guideline.
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Introduction
Severe postpartum hemorrhage (PPH), de-
fined as more than 1000 mL blood loss af-
ter childbirth, is the global leading cause of 
maternal death with an estimated mortality 
rate of 140 000 women a year.3,20 Moreover, 
an unexplained increase in the frequency of 
PPH was recently described in developed 
countries.2,4-6,9,10 Active third stage man-
agement involves interventions that prevent 
PPH. The primary goal of these interventions 
is to assist delivery of the placenta, encour-
aging the uterus to contract. In 2004, the In-
ternational Confederation of Midwives (ICM) 
and the International Federation of Gyne-
cology and Obstetrics (FIGO) made a joint 
statement and developed a guideline to as-
sist clinicians and midwives in the prevention 
of PPH. The recommended management in 
the guideline consists of three interventions: 
administration of uterotonic medication, 
controlled cord traction for placental deliv-
ery and uterine massage after delivery of the 
placenta.51 The guideline is also embedded 
in the recommendations of the World Health 
Organization for the prevention of PPH.1 
However, the benefit of the combined use 
of uterotonic medication, controlled cord 
traction and uterine massage remains con-
troversial for many clinicians and midwifes.52 
Assessment of the adherence to the guide-
line is essential to optimize prevention of 
PPH and maternal health, especially since a 
great disparity in performance of these inter-
ventions among hospitals and clinicians was 
suspected. This study, the Très Active study, 
was conducted to investigate the implemen-
tation of the ICM/ FIGO guideline for active 
third stage management in daily clinical 
practice. We hypothesized that active third 
stage management is often inadequately 
performed. 
Material and methods
This prospective, observational study, the 
Très Active study, was conducted at one 
tertiary hospital (Erasmus MC – Universi-
ty Medical Center Rotterdam, Rotterdam) 
and one teaching hospital (Reinier de Graaf 
Gasthuis, Delft) in the Netherlands between 
September 2010 and December 2010. In 
both hospitals, active third stage manage-
ment consisting of administration of 10 IU 
oxytocin immediately after childbirth (intrave-
nous or intramuscular), controlled cord trac-
tion and uterine massage was the standard 
policy before initiation of the study. The pri-
mary outcome of the Très Active study was 
adherence to the ICM/ FIGO guideline. ‘Ad-
equate guideline adherence’ was defined as 
the performance of the three interventions 
described in the guideline: the administration 
of 10 IU oxytocin after childbirth, controlled 
cord traction and palpation for a contracted 
uterus and/ or uterine massage for at least 
once. ‘Inadequate guideline adherence’ was 
used if one or more interventions were not 
performed. According to the ICM/ FIGO 
guideline, uterine palpation should be per-
formed every 15 minutes for the first two 
hours after childbirth (eight times in total), 
followed by uterine massage if appropriate. 
If palpation and/ or uterine massage (further 
defined as uterine massage) was performed 
at least eight times, this was defined as 
‘complete guideline adherence’. Secondary 
outcomes were postpartum blood loss, ad-
ditional use of uterotonic medication, severe 
PPH (≥ 1000 mL blood loss), duration of the 
third stage of labor, and manual removal of 
the placenta. Women aged 18 years and 
older who delivered vaginally were eligible. 
Women who underwent termination of preg-
nancy because of congenital fetal anomalies 
as well as cases of stillbirth were excluded. 
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All physicians and midwives were asked to 
complete a case record form after every 
vaginal delivery. They were informed about 
the definitions used in the ICM/ FIGO guide-
line and these definitions were printed on 
the reverse side of each case record form.51 
No instructions regarding active third stage 
management were given at the start of the 
study. Compliance was monitored for study 
purposes only, there were no disciplinary 
actions for non-compliance. Data regard-
ing the performance of active third stage 
management and the method for measur-
ing blood loss (estimated or weighed) were 
collected from the case record form. In ad-
dition, we obtained a copy of the data for 
the Dutch Perinatal Registry. Institutional ap-
proval was obtained from the Ethical Review 
Boards of the participating hospitals and 
the need for informed consent was waived 
because of the observational character of 
this study. Sample size was based on the 
estimation of the percentage of adequately 
performed active third stage management 
as recommended by the ICM/ FIGO. A priori, 
the composite measure of adequately per-
formed active third stage management was 
estimated to be 10%. With a sample size of 
600, 300 women per hospital, the standard 
error of the resulting percentage would be 
less than 2% for each hospital. 
Statistical analysis 
Descriptive statistics were used to describe 
the study population. Differences between 
groups were assessed using a chi-squared 
test for categorical data, and an unpaired 
t-test (normally distributed) or Mann-Whitney 
U-test (not normally distributed) for numeri-
cal data. Multiple linear regression was used 
to evaluate the relationship of initial oxytocin 
dose postpartum to the amount of blood 
loss, while adjusting for considered risk 
factors obtained from the literature. These 
risk factors include maternal age, multiple 
pregnancy, multiparity, gestational age, in-
duced labor with oxytocin or prostaglandins, 
labor augmentation with oxytocin, instru-
mental delivery (vacuum or forceps), dura-
tion of active first stage of labor (dilation of 
3-10 cm), duration of second stage of labor, 
episiotomy, second, third or fourth degree 
perineal tear and birthweight.53-55 For this 
analysis, blood loss was log-transformed to 
obtain an approximate normal distribution. 
Significance was defined as p < 0.05. When 
data were missing, women were exclud-
ed from those specific analyses. Statistical 
analysis was performed using SPSS 17.0 for 
WINDOWS software (SPSS Inc., Chicago, 
IL, USA). 
results
Between September 2010 and December 
2010, 697 women delivered vaginally in 
both hospitals. Twenty-one deliveries were 
excluded at the tertiary hospital and three at 
the teaching hospital. In 47 vaginal deliveries 
no case record form was completed (7% of 
all vaginal deliveries during the study period). 
A total of 626 vaginal deliveries were ana-
lyzed (Figure 1). In the tertiary hospital, 157 
women delivered with a midwife, 126 with 
a resident and 29 with an obstetrician, and 
in the teaching hospital these numbers were 
respectively 113, 188 and 11. In the teaching 
hospital, two women delivered with a nurse. 
Table 1 shows the general characteristics 
of the women who delivered in both hospi-
tals. Gestational age, birth weight, duration 
of second stage and intention to breastfeed 
significantly differed between both hospi-
tals. It is noteworthy that extreme preterm 
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Total vaginal deliveries
n = 697
Vaginal deliveries included
n = 626
Tertiary hospital
n = 350
Eligible for inclusion
n = 314
Teaching hospital
n = 347
Eligible for inclusion
n = 312
Randomized
(n = 521)
Not included (missed)  
(n = 32)
Did not meet inclusion 
criteria (n = 21):
•  termination of 
pregnancy: 14
• stillbirth: 6
•  maternal age  
<18 years: 1
Did not meet inclusion 
criteria (n = 3):
•  termination of 
pregnancy: 1
• stillbirth: 1
•  maternal age  
<18 years: 1
Figure 1 Flow chart of the women included in the Très Active study.
deliveries (before 32 weeks of gestation) 
occur preferably at tertiary hospitals in the 
Netherlands. Median blood loss was lower 
at the tertiary hospital (300 mL versus 400 
mL, p < 0.001) but the incidences of PPH 
and manual removal of the placenta were 
similar in both hospitals. However, in 36% of 
deliveries at the teaching hospital, blood loss 
was weighed, compared with 12% at the 
tertiary hospital. Adequate guideline adher-
ence was achieved in 48% (95% CI 44-52%) 
of all deliveries and complete guideline ad-
herence (including uterine massage at least 
eight times) in only 5% (95% CI 3-7%). Oxy-
tocin was administered immediately after 
childbirth in 98% of all deliveries, with a cor-
rect dose of ≥ 10 IU administered in 80%. 
Controlled cord traction was performed in 
63%. Uterine massage was performed (at 
least once) in 93% though in only 8% this 
was performed at least eight times.
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Table 1 General characteristics of women and their deliveries observed in this study.
Tertiary hospital
(n = 314)
Teaching hospital 
(n = 312)
p 
Characteristics
Maternal age (y) 30 ± 6 31 ± 5  0.105a
Nulliparous 147 (47) 168 (54)  0.093
Twin gestation 11 (4) 3 (1)  0.060
Gestational age 38+4 40+0 < 0.001
   extreme preterm (< 32 wk)
   preterm (≥ 32 and < 37 wk)
   term (≥ 37 wk)
22 (7)
18 (6)
274 (87)
0
17 (5)
295 (95)
Duration active first stage (h) 4.5 (1-14) 4.0 (1-16)  0.744
Induction of labor 115 (37) 100 (32)  0.262
Oxytocin augmentation 125 (40) 145 (47)  0.109
Duration second stage (min) 15 (0-206) 20 (1-161) < 0.001
   nulliparous
   multiparous
 27 (0-206)
 8 (0-110) 
39 (1-161)
10 (1-85) 
Instrumental delivery 60 (19) 74 (24)  0.205
Episiotomy 126 (40) 140 (45)  0.263
2nd – 4th degree lacerations 125 (40) 129 (41)  0.081
Blood loss (mL) 300 (50-3000) 400 (30-4500) < 0.001
Measured blood loss 36 (12) 112 (36) < 0.001
PPHb 21 (7) 23 (7)  0.858
Manual removal of the placenta 16 (5) 14 (5)  0.866
Blood transfusion 8 (3) 5 (2)  0.577
Birth weight (g) 3290 (425-4700) 3433 (1900-5200) < 0.001
Breastfeeding 266 (85) 227 (73) < 0.001
Secondary PPHc 0 0
Data are mean ± standard deviation, median (range), or n (%). 
a Student-t test.
b Defined as more than 1000 mL blood loss postpartum within the first 24 hours postpartum.
c Defined as PPH occurring between 24 hours and 6 weeks postpartum.
Overall, no difference in guideline adherence 
was found between the hospitals, although 
the performance of the single interventions 
did differ significantly. At the tertiary hospi-
tal, more controlled cord traction was per-
formed, whereas at the teaching hospital 
oxytocin use (≥ 10 IU) and uterine massage 
were more frequently performed (Table 2). 
Total blood loss was comparable between 
deliveries with adequate and inadequate 
guideline adherence (p = 0.078). A tenden-
cy towards increased blood loss was found 
in deliveries with adequate guideline adher-
ence. We therefore stratified for the amount 
of blood loss by creating three categories 
(≤ 500 mL, 501-1000 mL and > 1000 mL). 
We observed that controlled cord traction 
and uterine massage were more frequent-
ly performed in cases with greater blood 
loss, although this difference was not sig-
nificant (performance of both interventions 
increased from 58% when blood loss was 
less than 500 mL to 71% when there was 
> 1000 mL blood loss, p = 0.305). As ex-
pected, additional uterotonic medication 
was more frequently administrated with in-
creasing blood loss (in 4%, 30% and 65% 
with blood loss of respectively ≤ 500 mL, 
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Table 2 Adherence to ICM/ FIGO guideline in the participating hospitals.
ICM / FIGO guideline Total Tertiary hospital 
(n = 314)
Teaching hospital 
(n = 312)
p 
Interventions
1. Oxytocin use (≥ 10 IU) 498 (80) 235 (75) 263 (84) 0.005
5 IU oxytocin 117 (19) 78 (25) 39 (13) < 0.001
no oxytocin 11 (2) 1 (0.3) 10 (3) 0 .015
2. Controlled cord traction (≥ once) 393 (63) 227 (72) 166 (53) < 0.001
Frequency of controlled cord traction 1 (0-11) 1 (0-11) 1 (0-10) < 0.001
3. Uterine massage (≥ once) 576 (93) 280 (90) 296 (96) 0.004
Uterine massage (≥ 8 times)a 47 (8) 19 (6) 28 (10) 0 .194
Frequency of uterus massage 3 (0-30) 2 (0-30) 3 (0-30) < 0.001
Adequate guideline adherenceb 297 (48) 154 (49) 143 (46) 0.541
Complete guideline adherencec 28 (5) 10 (3) 18 (6) 0.153
Data are n (%) or median (range) unless otherwise specified. 
a Defined as performance of uterine massage at least 8 times during the first 2 hours. 
b Defined as the performance of all three interventions of active third stage management according the guideline (≥ 10 IU 
oxytocin, controlled cord traction and uterine massage at least once).
c Defined as the performance of all three interventions of active third stage management according the guideline, includ-
ing uterine massage at least 8 times. 
Table 3  Oxytocin dose (5  and 10 IU) in relation to total blood loss, duration of third stage, PPH, manual 
 removal of the placenta and additional use of uterotonic medication. 
5 IU oxytocin
(n = 117)
10 IU oxytocin
(n = 486)
p 
Blood loss (mL)
300 (100-3000) 300 (30-2540)
0.103
0.818a
Duration third stage (min) 7 (1-120) 6 (0-129) 0.721
PPH 7 (6) 32 (7) 0.812
Manual removal of the placenta 4 (3) 21 (4) 0.856
Additional use of uterotonic medication 12 (10) 47 (10) 0.964
Data are median (range) or n (%) unless otherwise specified. 
a Ratio (5 versus 10 IU oxytocin) of geometric mean blood loss equals 0.99 (95% CI: 0.87−1.11; p = 0.818), adjusted for 
multiple gestation, oxytocin augmentation, labor induction, multiparity, instrumental delivery, age, maternal age, gesta-
tional age, birth weight, 2nd-4th degree lacerations, duration first and second stage in multiple linear regression analysis. 
501-1000 mL and > 1000 mL, p < 0.001), 
while the administration (and dose) of the 
initial oxytocin administration was not re-
lated to the amount of blood loss. As the 
initial administration of oxytocin is the only 
intervention that cannot be influenced by 
the amount of blood loss during delivery, we 
were able to study differences between the 
most frequently administered doses (5 and 
10 IU). Total blood loss had a tendency to be 
lower in women who received 10 IU oxytocin 
than in women who received 5 IU (1% af-
ter adjustment for risk factors), although this 
finding was not significant (p = 0.817). Dura-
tion of the third stage of labor, PPH, manual 
removal of the placenta, and administration 
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of additional uterotonic medication did not 
significantly differ between the doses (Ta-
ble 3). In 94% of all deliveries, the placenta 
was expelled within 30 minutes after child-
birth. For a third stage lasting longer than 
30 minutes, median blood loss increased 
significantly (300 mL [range 30-2540] ver-
sus 650 mL [range 100–4500], p < 0.001). 
When the third stage lasted longer than 30 
minutes, 42% of the placentas were still ex-
pelled spontaneously. 
Discussion
This study provides an insight into the im-
plementation of the ICM/ FIGO guideline 
regarding active third stage management in 
vaginal deliveries. We observed suboptimal 
adherence to the guideline in two Dutch hos-
pitals. All three interventions of the guideline 
were performed in less than 50% of vaginal 
deliveries. Moreover, there was complete 
guideline adherence in only 5%, including 
the correct frequency for uterine massage 
(at least eight times after childbirth) (Table 2). 
Poor adherence was especially found for the 
interventions controlled cord traction and 
uterine massage. Uterine massage (includ-
ing palpation to reassure uterine contraction) 
was performed at least eight times in only 
8% of deliveries. Presumably the poor ad-
herence to the guideline has its origin in a 
lack of belief in the recommended interven-
tions, especially controlled cord traction and 
uterine massage.
Regarding total blood loss, no significant 
difference was observed between adequate 
and inadequate guideline adherence. We ob-
served a tendency towards increased blood 
loss when adequate or complete guideline 
adherence was achieved. This finding, also 
described by Davis et al.,56 can be explained 
by the fact that treatment of PPH contains 
similar interventions: in case of abundant 
blood loss directly after childbirth, controlled 
cord traction and uterine massage may be 
performed more adequately. An interesting 
finding in our study was the lack of a sig-
nificant relationship between initial oxytocin 
dose and the amount of postpartum blood 
loss. Also, no difference between 5 and 
10 IU oxytocin was found regarding manual 
removal of the placenta and administration 
of additional uterotonic medication. 
A strength is that our study accurately re-
flects all vaginal deliveries in the defined 
study period, since 93% of all vaginal deliv-
eries were included and missing data were 
very minimal. During the study period, we 
did not detect a learning curve among the 
birth attendants due to guideline aware-
ness: no significant increase in guideline 
adherence, oxytocin administration, perfor-
mance of controlled cord traction or uterine 
massage was measured in time (data not 
shown). Another major strength of this study 
is that we emphasized the performance of 
each intervention in relation to their influence 
on the third stage of labor. 
The following limitations are acknowledged. 
There were significant differences in the gen-
eral characteristics of the two hospitals (Ta-
ble 1). The main reason for these differences 
was presumably the selection of high risk 
pregnancies and extreme preterm deliveries 
in tertiary hospitals in the Netherlands. The 
observational design of the study limits the 
ability to analyze the influence of each inter-
vention on blood loss. Although the literature 
shows that estimation of blood loss is often 
inaccurate,42,48,49 blood loss is routinely not 
weighed in the Netherlands, except in cas-
es with major blood loss. Although we trust 
that the results are largely generalizable to 
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the Netherlands, we should be aware that 
this study was performed in two hospitals 
only. The influence of controlled cord trac-
tion and uterine massage on the amount 
of blood loss cannot be investigated based 
on our data, since the amount of blood loss 
may influence the performance of these in-
terventions. Our finding that outcomes did 
not differ significantly between different ini-
tial oxytocin doses (5 or 10 IU) should be 
interpreted with care, since our study was 
not designed to study the optimal oxytocin 
dose. To investigate the effect of 5 and 10 IU 
on total blood loss, as well as on manual 
removal of the placenta, administration of 
additional uterotonic medication, and dura-
tion of the third stage of labor, a randomized 
controlled trial should be performed. Further 
studies are needed to investigate the effica-
cy of the interventions: if clearly proven ef-
fective, these measures can be implement-
ed more easily. Finally, we cannot discount 
the possibility of a responder bias, since we 
asked all birth attendants to report their own 
actions.
The ICM/ FIGO based its guideline on sev-
eral randomized trials, Cochrane system-
atic reviews and WHO trials, among which 
were four large randomized trials investigat-
ing active third stage management versus 
expectant management (summarized by 
Litch).51,57-59 The effectiveness of oxytocin 
administration on postpartum blood loss 
is confirmed in several trials, also without 
the performance of other active third stage 
management interventions, and its adminis-
tration immediately after childbirth is widely 
recommended nowadays.60 However, to our 
knowledge, the optimal dose for oxytocin 
in vaginal deliveries was never investigat-
ed. Whereas the effectiveness of uterotonic 
medication seems evident, this is less the 
case for the other interventions.61 
Recently two randomized controlled trials 
demonstrated little effect of controlled cord 
traction on the occurrence of PPH.62,63
Hofmeyr published a Cochrane review re-
garding uterine massage for the prevention 
of PPH, supporting the ICM/ FIGO guideline. 
However, due to limitations and a small num-
ber of trials, trials with sufficient numbers 
to estimate the effects of sustained uterine 
massage more precisely are needed.64 Our 
findings regarding guideline adherence are 
partly consistent with other studies. A com-
parable study performed in Nigeria showed 
42% adherence to the ICM/ FIGO guideline 
and no significant difference in postpar-
tum blood loss, additional oxytocin use or 
placental retention between adequately and 
inadequately performed active third stage 
management.65 Unfortunately, the studied 
populations are not completely comparable, 
since the Nigerian study only included wom-
en during daytime, excluded instrumental 
deliveries and performed the study in anoth-
er health care setting. A nested case-control 
study in Australia reports lower performance 
rates of oxytocin administration (91% com-
pared with 98% in our study), but higher 
rates of controlled cord traction (84% com-
pared with 63%).66 Performance of uterine 
massage was not reported and no compari-
son of total blood loss was made. 
Active third stage management according 
to the ICM/ FIGO guideline is inadequately 
performed in vaginal deliveries in daily clin-
ical practice in the Netherlands. Prevention 
of PPH becomes even more important con-
sidering the increasing incidence that has 
been observed in several developed coun-
tries.6The results of this implementation 
study indicate the necessity of a training 
program to enhance adherence to the ICM/ 
FIGO guideline.
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abstract
Background
Primary postpartum hemorrhage is an ob-
stetrical emergency often causing acute ane-
mia that may require immediate red blood 
cell (RBC) transfusion. This anemia results in 
symptoms such as fatigue, which may have 
a major impact on the health-related quality 
of life (HRQoL). RBC transfusion is generally 
thought to alleviate these undesirable effects 
although it may cause transfusion reactions. 
Moreover, the postpartum hemoglobin con-
centration seems to influence fatigue only for 
a short period of time. At present, there are 
no strict transfusion criteria for this specif-
ic indication, resulting in a wide variation in 
postpartum policy of RBC transfusion in the 
Netherlands.
Methods
The WOMB trial is a multicenter random-
ized non-inferiority trial. Women with acute 
anemia due to postpartum hemorrhage, 
12-24 hours after delivery and not initially 
treated with RBC transfusion, are eligible for 
randomization. Patients with severe phys-
ical complaints are excluded. Patients are 
randomized for either RBC transfusion or 
expectant management. HRQoL will be as-
sessed at inclusion, at three days and one, 
three and six weeks postpartum with three 
validated measures (Multidimensional Fa-
tigue Inventory, ShortForm-36, EuroQol-5D). 
Primary outcome of the study is physical 
fatigue three days postpartum. Secondary 
outcome measures are general and mental 
fatigue scores and generic health related 
quality of life scores, the number of RBC 
transfusions, length of hospital stay, compli-
cations and health care costs.
The primary analysis will be by inten-
tion-to-treat. The various longitudinal scores 
will be evaluated using Repeated Measure-
ments ANOVA. A costs benefit analysis will 
also be performed. The power calculation 
is based on the exclusion of a difference in 
means of 1.3 points or greater in favor of 
RBC transfusion arm regarding the physi-
cal fatigue subscale. With missing data not 
exceeding 20%, 250 patients per arm have 
to be randomized (one-sided alpha = 0.025, 
power = 80%).
Discussion
This study will provide evidence for a guide-
line regarding RBC transfusion in the post-
partum patient suffering from acute anemia. 
Equivalence in fatigue score, remaining 
HRQoL scores and physical complications 
between both groups is assumed, in which 
case an expectant management would be 
preferred to minimize transfusion reactions 
and costs.
trial registration
ClinicalTrials.gov NCT00335023. 
Nederlands Trial Register NTR335
trial website
http://www.studies-obsgyn.nl/womb/
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Background
One of the most frequent complications of 
delivery is primary postpartum hemorrhage 
(PPH), defined as blood loss greater than 
or equal to 500 mL within 24 hours after 
birth and severe PPH as blood loss greater 
than or equal to 1000 mL within 24 hours.1 
Between four and five percent of all vaginal 
deliveries are complicated by severe PPH.34 
Blood loss during cesarean section is usually 
50-100% more than during vaginal delivery.67 
An important clinical effect of obstetric hem-
orrhage is the development of acute anemia, 
with fatigue as an important symptom. This 
fatigue is not an isolated physical symptom 
but rather involves lethargy, decreased men-
tal alertness, physical weakness and poor 
concentration.68 It is especially important as 
it affects women who just have delivered, 
who have to care for and feed a newborn 
baby and who are usually full of emotions. 
RBC transfusion is one of the few treatments 
that adequately restore tissue oxygenation 
when oxygen demand exceeds supply. 
Apart from the life-saving restoration of the 
initial hemodynamic instability, RBC transfu-
sion is also used to alleviate the side-effects 
of acute anemia, including the fatigue men-
tioned above. This treatment is applied fre-
quently. Previously, a significant correlation 
between hemoglobin (Hb) concentration 
postpartum and fatigue scores was found 
in postpartum patients using the HRQoL 
measure Multidimensional Fatigue Inventory 
(MFI), but this correlation was already lost 
one week after delivery.69 Thus, postpartum 
Hb concentration seems to influence fa-
tigue for only a short period of time. Other 
arguments against RBC transfusion are that 
RBC transfusion is costly and may cause 
formation of RBC alloantibodies and other 
direct and indirect transfusion complica-
tions.70
Although the respiratory function of blood 
has been studied intensively, the trigger for 
RBC transfusion remains controversial, and 
doctors still rely primarily on clinical expe-
rience. At present, criteria for transfusion 
are not based on alternative criteria, such 
as HRQoL scores. Worldwide there is no 
consensus on the optimal transfusion trig-
ger.15,70-72 A questionnaire study in 2003 
on the subject of RBC transfusion practice 
postpartum in the Netherlands demonstrat-
ed large differences between hospitals.73 
Based on Hb concentrations, the transfusion 
triggers varied between 3.0 and 5.5 mmol/L 
(4.8 and 8.9 g/dL). Clinical symptoms were 
used as more or less subjective additional 
criteria. 
The official Dutch guideline for RBC trans-
fusion is the “4-5-6 flexinorm” for patients 
with acute or chronic anemia.15 This rule 
states that ASA I patients should have RBC 
transfusion when their Hb is below 4 mmol/L 
(6.4 g/dL), ASA II when their Hb is below 
5 mmol/L (8.1 g/dL) and ASA III and IV 
patients when their Hb is below 6 mmol/L 
(9.7 g/dL). However, during pregnancy 
the circulating blood volume increases by 
100 mL/kg to a total blood volume of six to 
seven liters. The several blood components 
contribute differently to this increase: plas-
ma increases with 40% whereas red blood 
cell volume increases with 15-20%. Conse-
quently Hb concentration decreases with a 
maximum of approximately 10%. This nat-
ural process of hemodilution improves the 
placental circulation. As a result of these 
changes, it is doubtful whether the Hb trig-
gers for RBC transfusion, as described 
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above, can be used for patients with post-
partum hemorrhage. 
In the Netherlands all women with PPH will 
be treated by a gynecologist in a clinical 
setting. Although almost one third of Dutch 
women deliver at home with supervision by 
a midwife, women that experience exces-
sive blood loss during or immediately after 
delivery will be transferred to a hospital for 
further treatment by a gynecologist. Most 
Dutch women that deliver in hospital, leave 
the hospital a couple of hours after delivery 
since there is an adequately organized dom-
iciliary postnatal care service. The necessity 
of RBC transfusion may prolong their stay 
in hospital.
In the Netherlands, blood products are pro-
duced by one blood banking organization. 
The present study is performed in cooper-
ation with Sanquin, the Dutch blood bank 
organization, which initiated and funded the 
costs of the first part of this study.
Acute anemia postpartum, with fatigue as 
important symptom, is a clinical problem 
with wide practice variation in treatment re-
garding RBC transfusion. There are several 
arguments against RBC transfusion and the 
postpartum Hb concentration seems to in-
fluence fatigue for only a short period of time. 
We therefore aim to show non-inferiority of 
expectant management versus a transfusion 
policy regarding physical fatigue, three days 
after delivery, in postpartum women with an 
acute anemia following PPH. The develop-
ment of a guideline based on clinical param-
eters, laboratory determinations and HRQoL 
measures may lead to a more adequate use 
of RBC transfusions in the postpartum peri-
od and possibly reduces costs due to lower 
frequency of transfusions and hospitalization 
duration.
Methods/ design
aims
The aim of this study is to solve the dilem-
ma for the obstetrician regarding the opti-
mal treatment of women with acute anemia 
postpartum. For that reason we aim to de-
termine whether women with acute anemia 
postpartum benefit from RBC transfusion.
Our hypothesis is that there is no important 
difference with regard to physical fatigue, 
as well as other HRQoL scores and physi-
cal complications between RBC transfusion 
and expectant management as treatment 
for women with acute postpartum anemia in 
the absence of (severe) physical complaints. 
If this hypothesis is true, an expectant man-
agement is to be preferred to minimize 
transfusion related reactions and costs.
Study design
The study is a multicenter randomized 
non-inferiority trial in women with an acute 
postpartum anemia. It is an open label study. 
This trial is embedded in the Dutch Obstetric 
Consortium, a collaboration of hospitals in 
the Netherlands.74 Approximately 40 hospi-
tals, including university hospitals, teaching 
hospitals and non-teaching hospitals will 
participate in this trial.
Participants/ eligibility criteria
Women, older than 18 years of age, who 
deliver in hospital or are transferred after 
home delivery because of PPH, are eligible. 
Patients will be included with an Hb between 
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3.0 and 5.0 mmol/L (4.8 and 8.1 g/dL), de-
termined 12 to 24 hours after vaginal deliv-
ery or cesarean section, and a decrease in 
Hb of at least 1.2 mmol/L (1.9 g/dL) and/ 
or a total peripartum blood loss of at least 
1000 mL. The initial Hb concentration will 
be determined when the patient is admitted 
during the first stage of labor at the labor 
ward. In other instances, when an initial Hb 
is absent, inclusion is purely based on the 
total amount of blood loss. Exclusion criteria 
include severe (anemic) physical complaints, 
previous RBC transfusion directly after de-
livery, severe pre-eclampsia, severely active 
infectious disease, congenital hemolytic dis-
ease, severe compromised immunological 
status, malignancy, severe comorbidity (ASA 
II/III), peripartum death or critical condition 
of the newborn. Severe (anemic) physical 
complaints were defined as fatigue, head-
ache, dizziness, confusion, dyspnea, syn-
cope, orthostatic complaints, tachycardia 
(> 100 bpm), angina pectoris and/ or tran-
sient ischemic attacks (TIA). Finally, good 
working knowledge of the Dutch language 
is required. 
Procedures, recruitment, randomization 
and collection of baseline data
Eligible patients receive participant informa-
tion. After written consent, participants are 
randomized by means of a web-based ap-
plication.75 Randomization will be blocked in 
a 1:1 ratio for RBC transfusion or expectant 
management. Stratification will be applied 
for mode of delivery and participating hos-
pital. 
All data will be collected, coded and pro-
cessed with adequate precautions to ensure 
patient confidentiality. 
Intervention and control
RBC transfusion will be compared with ex-
pectant management. In patients allocat-
ed to RBC transfusion, at least one unit of 
packed cells will be given. The desired Hb 
concentration after transfusion is 5.5 mmol/L 
(8.9 g/dL). The units of blood will be 
matched, pre-treated and tested according 
to the Dutch guidelines for RBC transfusion. 
Before and 15-90 minutes after transfusion 
maternal body temperature, blood pressure 
and heart rate will be checked and a blood 
sample is taken to determine Hb, hemato-
crit, platelet and white blood count. 
In the group allocated to expectant manage-
ment, i.e. no RBC transfusion, it is allowed 
to give a patient ‘escape’ RBC transfusion if 
this is clinically indicated. The indications to 
give ‘escape’ RBC transfusion are second-
ary PPH, resulting in hemodynamic insta-
bility or an Hb concentration < 3.0 mmol/L 
(4.8 g/dL), serious physical complaints or 
other serious general complications. Pos-
sible serious physical complaints are: dys-
pnea, syncope, orthostatic complaints, 
tachycardia (> 100 bpm), myocardial isch-
emia or transient ischemic attacks (TIA). 
Additional use of medication to treat anemia, 
like oral and parenteral iron medication and 
other types of medication, is allowed in both 
groups and may be prescribed according to 
local protocol. Type and duration of the use 
of this medication will be recorded.
Outcome
Primary outcome is physical fatigue on day 
three postpartum, scored with a dimension 
of the HRQoL measure MFI. We aim to show 
non-inferiority of the expectant management 
arm and therefore this primary assessment 
day was chosen: if there would be any 
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difference between randomized groups, this 
difference is expected to be the largest three 
days postpartum.69 In total three measures 
of HRQoL will be scored. Secondary out-
comes will be the remaining HRQoL mea-
sures and the number of RBC transfusions. 
In addition an anemia related symptoms list 
will be filled in before randomization and at 
six weeks postpartum. 
Medical process parameters to be evaluat-
ed include the increase of Hb concentration 
after RBC transfusion and acute transfu-
sion complications. Moreover, we will com-
pare the length of hospital stay and serious 
physical complications during the first six 
weeks postpartum (infections, thromboem-
bolic events, hemodynamic events, cardiac 
events, neurologic events, secondary PPH, 
obstetric interventions, ‘escape’ RBC trans-
fusion). A costs benefit analysis will also be 
performed (see ‘Economic Evaluation’). 
HrQoL questionnaires
HRQoL will be scored with three measures: 
the generic measures ShortForm-36 (SF-
36) and EuroQol-5D and the fatigue specific 
measure MFI. 
The SF-36 is a multi-purpose, shortform 
health survey with only 36 questions. It con-
sists of 36 items, organized into eight scales: 
Physical Functioning, Role-Physical, Bodily 
Pain, General Health, Vitality, Social Func-
tioning, Role-Emotional, and Mental Health. 
The number of response choices per item 
ranges from two to six. The SF-36 yields an 
eight-dimensional profile, each scale ranging 
from 0 to 100 (100 = optimal). The SF-36 
furthermore provides a physical summary 
score and a mental summary score. The 
SF-36 has proven useful in surveys of gen-
eral and specific populations, comparing the 
relative burden of diseases, and in differenti-
ating the health benefits produced by a wide 
range of different treatments.76,77 
The EuroQol-5D is a standardized mea-
sure of health status and provides a simple, 
generic measure of health for clinical and 
economic appraisal. It consists of five items 
(Mobility, Self-Care, Usual Activities, Pain/ 
Discomfort, and Anxiety/ Depression), each 
following the general form: 1 = no problems, 
2 = some problems, 3 = extreme prob-
lems. The sixth item is a global evaluation of 
own health on a visual analogue scale (Eu-
roQol-5D VAS) with a range from 0 (worst 
imaginable health state) to 100 (best imag-
inable health state). Applicable to a wide 
range of health conditions and treatments, 
it provides a simple descriptive profile and a 
single index value for health status that can 
be used in the clinical and economic evalu-
ation of health care as well as in population 
health surveys.78
The MFI is a 20-item self-report instrument 
designed to measure fatigue. It covers the 
following dimensions: General Fatigue, 
Physical Fatigue, Mental Fatigue, Reduced 
Motivation and Reduced Activity. Each di-
mension is covered by a five-item scale. The 
number of response choices per item is four. 
Each scale ranges from 4 to 20 (4 = optimal). 
The MFI was developed as a tool to assess 
fatigue in a comprehensive way, with a spe-
cial interest in fatigue as experienced by pa-
tients and provides information on the nature 
of the experience, and its intensity.79
The international standard HRQoL measures 
MFI, EuroQol-5D, and SF-36 have been 
evaluated in a pilot study; feasibility, reliabili-
ty, and validity of these measures in a clinical 
obstetric setting were established.69
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Follow-up
The follow-up period consists of six weeks. 
At fixed moments during this period (at inclu-
sion, three days, one, three and six weeks) 
HRQoL questionnaires will be completed. 
The EuroQol-5D and MFI will be completed 
at all these fixed moments while the SF-36 
will be used at one, three and six weeks 
postpartum.
Details of the delivery, RBC transfusion 
(when prescribed) and follow-up are record-
ed in the case record form. During the study 
period all transfusion complications will be 
recorded. An anemia related symptoms list 
is filled in before randomization and at six 
weeks postpartum. Hb concentrations will 
be determined at inclusion and six weeks 
postpartum. Six weeks postpartum patients 
visit the outpatient clinic. 
In case of severe adverse events (SAE) 
during follow-up, a SAE form will be down-
loaded from the website and completed. 
SAE forms will be judged and based on this 
conclusion the study will be discontinued if 
participation in the study is considered irre-
sponsible. 
Patients that withhold informed consent for 
randomization will be asked to complete the 
questionnaires and identical case record 
forms will be used. 
Statistics
Sample size:
The HRQoL assessments were tested in 
postpartum women in a pilot study.69 For the 
comparison between RBC transfusion and 
an expectant management a sample size of 
400 patients is planned (200 patients in the 
RBC transfusion group and 200 patients in 
the expectant management group). Power 
calculations showed that with these num-
bers a difference of 1.3 points or greater in 
favor of the RBC arm regarding the physical 
fatigue subscale on day three, the primary 
outcome, can be excluded with a power of 
80% at one-sided alpha of 0.025 assuming 
that there is no difference on this day.69 In 
view of the scale of physical fatigue (ranging 
from 4 to 20) we think that such a difference 
is not clinically relevant. Since missing data 
are not expected to exceed 20%, a total of 
500 patients will be included.
Data analysis:
Data will be analyzed according to the inten-
tion to treat principle. The primary outcome, 
the MFI physical fatigue score at three days 
postpartum, will be compared between 
groups using Repeated Measurement ANO-
VA. This analysis allows for occasional miss-
ing values and will be performed using an 
unstructured covariance matrix, while tak-
ing account of baseline value (at inclusion) 
and mode of delivery as covariates. If the 
two-sided 95% confidence interval for the 
adjusted difference of means at day three 
excludes a difference of 1.3 points or greater 
in favor of the RBC arm, non-inferiority of the 
expectant policy is considered to be demon-
strated.80 A per-protocol analysis, including 
only patients without severe protocol viola-
tions, will also be performed. 
The mean profiles along time of other MFI 
subscales, SF-36 and EuroQol-5D will be 
compared similarly to the primary outcome 
measure. The other secondary outcome 
measures will be assessed by calculating 
rates in groups, risk differences and 95% 
confidence interval.
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economic evaluation
The aim of the economic evaluation is to 
compare the costs and health effects of 
RBC transfusion versus expectant man-
agement in women with acute anemia after 
PPH. As the clinical study is designed as an 
equivalence study, the primary economic 
evaluation is a cost-minimization analysis. 
If RBC transfusion is shown to improve the 
quality of life, the economic analysis will be 
a cost-effectiveness analysis (time horizon: 
six weeks postpartum). The analysis will be 
performed from a hospital perspective. We 
will calculate direct costs (days in hospital, 
number of RBC transfusions and costs of 
complications). Real medical costs will be 
calculated by multiplying the volumes of 
health care use with the corresponding cost 
prices. Unit costs of health care consump-
tion will be estimated according to national 
guidelines. Data on the volume of care will 
be available from hospital information sys-
tems in the participating hospitals.
Univariate analyses will be used for the anal-
ysis of economic outcome data. We will use 
non-parametric methods to test for differ-
ences between treatment groups.
ethical considerations
This study has been approved by the ethics 
committee of the Erasmus Medical Center 
Rotterdam (Ref. No. MEC-2003-247) and by 
the management of all participating hospi-
tals. 
Discussion
Yearly, almost 200.000 women deliver in the 
Netherlands.81 The number of women that 
receive one or more RBC transfusion post-
partum is estimated less than 1% after vagi-
nal delivery and between 1% and 7% follow-
ing cesarean section.67 The present study 
may lead to transfusion guidelines that are 
not only based on Hb concentrations and/ 
or clinical symptoms but also on HRQoL 
measures. This may lead to a more judicious 
use of RBC transfusions.
To our knowledge, this is the first study 
worldwide investigating the effect of RBC 
transfusion on postpartum HRQoL in wom-
en with acute anemia due to PPH. A pilot 
study investigating the relation between 
postpartum Hb concentrations and HRQoL 
measures during the first six weeks postpar-
tum, which is discussed below, was pub-
lished by our group in 2007.82 
Several national health organizations have 
tried to define transfusion triggers.83-87 Gen-
eral consensus of these guidelines is that 
RBC transfusion above 6 mmol/L (9.7 g/dL) 
is not very useful, RBC transfusion below 
4 mmol/L (6.4 g/dL) is probably useful, but 
in case of an Hb concentration between 4 
and 6 mmol/L individual characteristics have 
to be taken in consideration for the decision 
to prescribe RBC transfusion. In the Neth-
erlands, the Dutch “4-5-6 flexinorm” is em-
pirically based and is intended for use in the 
treatment of acute and chronic cases of ane-
mia.15 However, considering the physiologic 
hemodynamic changes during pregnancy 
and the postpartum period in obstetric pa-
tients, the guideline might not be applicable 
for this specific patient group.
The hypothesis of the present study is that 
HRQoL is not or only to a small extent in-
fluenced by treatment with RBC transfusion 
in this group of patients. The results of our 
previous pilot study showed no correlation 
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between postpartum Hb concentrations 
and HRQoL after the first week postpar-
tum. The health effects of this study will be 
the direct reduction of RBC transfusions, 
which will result in a decrease of RBC trans-
fusion-related complications (formation of 
RBC alloantibodies, transfusion complica-
tions and infectious complications) and days 
in hospital. Another possible finding of this 
study may be the definition of the desired Hb 
concentration after RBC transfusion. 
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In this chapter results of an inventorial survey 
are presented. The aim of this survey was 
to assess the professional beliefs regarding 
red blood cell (RBC) transfusion policy and 
health-related quality of life (HRQoL) after 
postpartum hemorrhage (PPH). More spe-
cifically, questions in this survey inventoried 
transfusion triggers in daily clinical practice, 
the expected effect of transfusion on HRQoL 
and occurrence of physical complications 
as well as the expected economic conse-
quences of RBC transfusion versus non-in-
tervention policy. 
The survey was performed before the results 
of a randomized controlled trial (the WOMB 
trial; ‘Well-being of Obstetric patients on 
Minimal Blood transfusions’ trial),88 in which 
RBC transfusion is compared to non-inter-
vention in acute anemic women after PPH, 
were elaborated and presented. 
A questionnaire was sent to all gynecolo-
gists primarily responsible for the training of 
gynecological residents in the Dutch teach-
ing hospitals (one gynecologist per teaching 
hospital). 
A total of 46 gynecologists were invited; the 
response was 72% (33/46). 
Results are presented below.
In almost 50% of the hospitals a local proto-
col concerning the treatment of postpartum 
anemia was available. Hemoglobin (Hb) con-
centration was used in 91% as transfusion 
trigger, but also the amount of blood loss 
and physical complaints were frequently re-
ported. In Table 1 the reported transfusion 
triggers are presented.
Table 1 Transfusion triggers for RBC trans- 
 fusion in Dutch teaching hospitals of 
 33 (out of 46) respondents.
Trigger n %
Hb concentration 30 91
Amount of blood loss 19 58
Physical complaints 30 91
HRQoL 6 18
(Social) environment 6 18
Other
   ASA classification
   combination of all
1
1
3
3
We investigated below which Hb concen-
tration RBC transfusion was considered and 
below which Hb concentration RBC transfu-
sion was actually prescribed.
The Hb concentration below which RBC 
transfusion was considered was reported 
as 4.8 mmol/L (mean, SD 0.4; in g/dL mean 
7.7 and SD 0.6), while the Hb concentration 
below which RBC transfusion actually was 
prescribed was 4.1 mmol/L (mean, SD 0.3; 
in g/dL mean 6.6 and SD 0.5).
In 2004 a similar survey was performed by 
our research group using the same meth-
ods. This survey demonstrated similar re-
sults: RBC transfusion was then consid-
ered in case of a Hb concentration below 
5.0 mmol/L (mean, SD 0.6; in g/dL mean 
8.1 and SD 0.9) while RBC transfusion was 
actually prescribed in case of an Hb concen-
tration below 4.2 mmol/L (mean, SD 0.5; in 
g/dL mean 6.8 and SD 0.8).73
The survey also investigated whether 
RBC transfusion was expected to improve 
HRQoL at day three postpartum, and if so, 
when the respondents would consider the 
improvement to be clinically relevant. 
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Of the respondents, 94% expected an im-
provement in HRQoL following RBC transfu-
sion at day three postpartum. If RBC trans-
fusion would reduce physical fatigue, most 
respondents (70%) considered this to be 
clinically relevant if the reduction lasted at 
least 14 days. The results of this question 
are demonstrated in Figure 1.
The following questions concerned physical 
complications due to postpartum anemia 
and evaluated whether the respondents 
expected that a non-intervention policy 
would result in a higher incidence of physical 
complications (infections, thromboembol-
ic events, cardiovascular ischemia, and so 
on)? 
Twenty-seven percent of the respondents 
expected that a non-intervention policy 
would result in a higher rate of physical com-
plications postpartum while 18% was uncer-
tain (Figure 2).
Regarding medical costs (including compli-
cations and readmissions), 71% (22/31) of 
the respondents reported that costs were 
expected to be higher in case of RBC trans-
fusion, compared to non-intervention policy. 
One respondent reported to be uncertain 
while 30% (8/31) believed it would be more 
costly.
With regard to implementation of the WOMB 
trial results, 91% of the respondents de-
clared to be willing to adjust their current 
RBC transfusion policy if trial results would 
support adjustment.
reduction of 1-3 days
reduction of 4-7 days
reduction of 1-2 weeks
reduction of 2-4 weeks
reduction of > 4 weeks
no reduction
missing
46%
21%
3%
3%
9%
6%
12%
Figure 1  Response to the question ‘Would you expect RBC transfusion to reduce physical 
 fatigue at day three postpartum? If so, when would you consider the reduction to be 
 clinically relevant?’
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no
yes
don’t know
no difference
missing 0%
27%
18%
9%
46%
Figure 2  Response to the question ‘Do you expect that a non-intervention policy leads to a 
 higher physical complication rate?’
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abstract 
Objective 
To assess the effect of red blood cell (RBC) 
transfusion on quality of life in acutely ane-
mic women after postpartum hemorrhage.
Design
Randomized non-inferiority trial.
Setting 
37 Dutch university and general hospitals. 
Population 
Women with acute anemia (hemoglobin 
4.8-7.9 g/dL [3.0-4.9 mmol/L] 12-24 hours 
postpartum) without severe anemic symp-
toms or severe comorbidities. 
Methods 
Women were allocated to RBC transfusion 
or non-intervention. 
Main outcome measures 
Primary outcome was physical fatigue 3 
days postpartum (Multidimensional Fatigue 
Inventory, scale 4-20; 20 represents maxi-
mal fatigue). Non-inferiority was demonstrat-
ed if the physical fatigue difference between 
study arms was maximal 1.3. Secondary 
outcomes were health-related quality of life 
and physical complications. Health-related 
quality of life questionnaires were completed 
at five time points until 6 weeks postpartum. 
results 
521 women were randomized to non-in-
tervention (n = 262) or RBC transfusion 
(n = 259). Mean physical fatigue score at 
day 3 postpartum, adjusted for baseline and 
mode of delivery, was 0.8 lower in the RBC 
transfusion arm (95% confidence interval: 
0.1-1.5, p = 0.02) and 1 week postpar-
tum 1.06 lower (95% confidence interval: 
0.3-1.8, p = 0.01). A median of two RBC 
units was transfused in the RBC transfusion 
arm. In the non-intervention arm, 33 women 
received RBC transfusion, mainly because 
of anemic symptoms. Physical complica-
tions were comparable. 
Conclusions 
Statistically, non-inferiority could not be 
demonstrated as the confidence interval 
crossed the non-inferiority boundary. Never-
theless, with only a small difference in phys-
ical fatigue and no differences in secondary 
outcomes, implementation of restrictive 
management seems clinically justified.
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Introduction 
Postpartum hemorrhage (PPH) is an import-
ant cause of maternal mortality. It causes 
acute anemia with physical sequelae varying 
from fatigue to severe hemodynamic distur-
bance. A recent systematic review showed 
a worldwide incidence of severe PPH (blood 
loss of at least 1000 mL during delivery)1 of 
1.9% in the period 1997 till 2006.2 The most 
important treatment of severe PPH is red 
blood cell (RBC) transfusion. RBC transfu-
sion should be aimed to reduce morbidity. In 
the past few years increasing concerns have 
arisen about the supply and safety of this 
treatment, encouraging a conservative man-
agement.18 Despite the introduction of sev-
eral new guidelines,14,15 transfusion criteria 
still vary widely between clinicians. The de-
cision whether to prescribe RBC transfusion 
is mainly based on postpartum hemoglobin 
(Hb) concentrations, as guidelines recom-
mend RBC transfusion when Hb concentra-
tion is < 6 g/dL and no transfusion in women 
with an Hb concentration > 10 g/dL.15-17 A 
survey among Dutch gynecologists revealed 
that RBC transfusion for anemic postpartum 
women was considered in case of an Hb 
concentration below 5.0 mmol/l (8.1 g/dL).73 
To provide insight in potential risks of anemia 
and benefits of transfusion in patients with 
severe PPH we conducted the Well-being of 
Obstetric patients on Minimal Blood transfu-
sions (WOMB) study, a multicenter random-
ized non-inferiority trial assessing the effect 
of RBC transfusion on HRQoL in women 
with acute anemia due to severe PPH. A 
non-inferiority design was chosen as the 
non-intervention treatment in this study has 
greater availability, reduced costs, less inva-
siveness and leads to fewer adverse effects. 
Physical fatigue was chosen as primary out-
come since it was considered the earliest 
arising complaint in acute anemia. Based on 
results of a pilot study the largest difference 
was expected at day three.82
Methods 
The study was approved by the University 
of Rotterdam’s Institutional Review Board 
(MEC-2003-247), and had local approval 
from the boards of all participating hospitals. 
The study was registered at ClinicalTrials.gov 
NCT00335023 and at the Dutch Trial Regis-
ter (NTR335).
The methods have already been reported in 
detail.89
Patients
We enrolled women in 37 Dutch hospitals 
from May 2004 to February 2011. Eligi-
ble women sustained PPH (blood loss of 
≥ 1000 mL and/ or a decrease in Hb con-
centration of ≥ 1.9 g/dL [1.2 mmol/L]) and 
had an Hb concentration between 4.8 and 
7.9 g/dL (3.0-4.9 mmol/L) 12 to 24 hours 
after delivery. The lower Hb threshold was 
formulated on request of the Institutional Re-
view Board as in the original protocol no low-
er threshold was defined. Participants either 
delivered in hospital or were admitted after 
a home birth. Exclusion criteria were severe 
symptoms of anemia (defined as dyspnoea, 
syncope, tachycardia (> 100 bpm), angi-
na pectoris, and/ or transient ischemic at-
tacks), RBC transfusion administered during 
or within 12 hours after delivery, severe 
pre-eclampsia, severe infectious disease, 
congenital hemolytic disease, compromised 
immunological status, malignancy, severe 
comorbidity (ASA II/III), and death or criti-
cal condition of the neonate. Finally, a good 
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knowledge of the Dutch language was re-
quired. Participants were seen by research 
midwives and nurses who provided counsel-
ing, obtained informed consent, monitored 
the study protocol, and collected data. 
randomization
After informed consent, women were ran-
domly allocated in a 1:1 ratio to receive 
RBC transfusion or non-intervention, using 
a web-based application for block random-
ization with a variable block size of two to 
eight. Randomization was stratified for mode 
of delivery and participating hospital. Due to 
the intervention’s nature, the study was not 
blinded. From 2005 onwards, women who 
declined informed consent were asked to 
complete questionnaires; follow-up was 
identical. 
Women allocated to RBC transfusion re-
ceived at least one unit of red blood cells; 
we aimed to reach an Hb concentration of at 
least 8.9 g/dL (5.5 mmol/L). Hb and hema-
tocrit concentrations were recorded before 
and after RBC transfusion. In women allo-
cated to non-intervention, RBC transfusion 
was allowed if severe symptoms of anemia 
developed or at their physicians’ discretion. 
Additional use of iron and/ or folic acid sup-
plementation according to local protocol 
was allowed. 
Follow-up and Outcome measures
The follow-up period was limited to six 
weeks postpartum. HRQoL questionnaires 
were to be completed at five points in time: 
at inclusion, three days, one week, three 
weeks, and six weeks postpartum. Physical 
complications during follow-up were record-
ed. Hb concentration was determined at in-
clusion and six weeks postpartum. 
The primary outcome was physical fatigue at 
day 3, measured with the Multidimensional 
Fatigue Inventory (MFI).79 This time point was 
chosen as the difference between arms was 
expected to be largest at day 3 since data 
of the pilot study showed that Hb 12-24 
hours postpartum was related to HRQoL at 
the same time point but not to HRQoL one 
week after delivery.69 Secondary outcomes 
were remaining HRQoL scores, number of 
RBC units transfused, transfusion reactions, 
length of hospital stay, and physical compli-
cations during follow-up (infections, throm-
boembolic events, secondary PPH and oth-
er physical complications). 
Ethnicity was assessed according to the 
definition of Statistics Netherlands.90 In twin 
pregnancies, we used the data of the first 
child in the analyses. With more than one 
mode of delivery method, one mode was 
recorded using the following order: cesarean 
section, operative vaginal delivery, sponta-
neous vaginal delivery. With more than one 
method of analgesia, this was recorded us-
ing the following order: general anesthesia, 
locoregional anesthesia, opiates.
Health-related quality of life
We used internationally validated HRQoL 
measures: the MFI and the Medical Out-
come Study 36-Item Short-Form Health 
Survey version one (SF-36). The MFI is a 
domain-specific measure for physical and 
mental fatigue. The MFI consists of 20 items 
grouped into five dimensions: general fa-
tigue, physical fatigue, reduced activity, re-
duced motivation, and mental fatigue.79 The 
MFI scores range from 4 to 20; higher scores 
indicate a higher degree of fatigue. The 
HRQoL questionnaire MFI scores fatigue on 
several domains and has a high feasibility, 
reliability and validity in chronically anemic 
67
Chapter 4.3 - Transfusion policy after severe postpartum hemorrhage: a randomized non-inferiority trial
4
patients.91 The SF-36 is a generic HRQoL 
measure with eight dimensions: physical 
functioning, role limitations due to physical 
health problems (role-physical), bodily pain, 
general health perception, vitality, social 
functioning, role limitations due to emotional 
health (role-emotional), and mental health.77 
The SF-36 scores range from 0 to 100; 
higher scores indicate better functioning or 
well-being. The SF-36 is a generic question-
naire widely used for measuring patient-re-
ported outcomes.92 Population-based norm 
scores are available for the Dutch adapta-
tion of SF-36.93 Both HRQoL questionnaires 
were previously validated in postpartum 
women in a pilot study.82 The MFI was to be 
completed at all five time points, while the 
SF-36 was to be completed at one week, 
three weeks, and six weeks. 
Sample size
For the subscale physical fatigue (MFI), a 
minimum clinical important difference had 
not been established prior to our study. 
Therefore data from a pilot study, assess-
ing HRQoL in postpartum women,82 were 
used. We calculated that, with a sample size 
of 400 women (200 per arm), a difference 
of 1.3 points or greater (in favor of the RBC 
transfusion arm regarding physical fatigue 
at day 3) could be excluded (power: 80%, 
one-sided alpha: 0.025). This difference was 
considered small and clinically irrelevant and 
therefore used as non-inferiority boundary. 
Because we observed that 20% of HRQoL 
data were missing, in 2008 we decided to 
include 500 women. 
Statistics
Analyses were conducted on an inten-
tion-to-treat basis. Continuous variables 
were summarized as means with standard 
deviations (SD), or medians with interquartile 
ranges (IQR). HRQoL scores were presented 
as differences in adjusted means with 95% 
confidence intervals (CI). 
Non-inferiority is intended to show that the 
effect of one treatment is not worse than that 
of an active control by more than a pre-spec-
ified boundary. When the difference between 
study arms does not exceed this boundary, 
non-inferiority is demonstrated. A difference 
can be statistically significant but too small 
to be clinically relevant: only when the dif-
ference exceeds the non-inferiority bound-
ary, clinical relevance is demonstrated. The 
significance of the difference between study 
arms is therefore of minor importance. 
Besides evaluation of physical fatigue in 
both study arms, we tested non-inferiori-
ty of the primary outcome measure by as-
sessing if the upper 95% CI lay within the 
non-inferiority boundary. Adjusted means of 
primary outcome and remaining MFI scores 
were calculated using repeated measure-
ment ANOVA with an unstructured covari-
ance matrix, including baseline value (at in-
clusion) and mode of delivery as covariates. 
The same statistical method was used for 
the SF-36 scores, with only mode of de-
livery as a covariate, since the SF-36 was 
not completed at inclusion. Additionally, the 
influence of mode of delivery was analyzed 
using repeated measurement ANOVA, with 
an unstructured covariance matrix including 
baseline value as covariate. 
MFI scores were analyzed if data were avail-
able at inclusion and at least one addition-
al time point. SF-36 scores were analyzed 
if at least one questionnaire (1 week, three 
weeks, or six weeks) was completed. In-
ternal consistency within questionnaires 
was assessed for each MFI and SF-36 
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subscale by calculating Cronbach’s alpha; 
this showed high reliability, with α > 0.70 for 
all HRQoL subscales except the SF-36 di-
mension bodily pain (α > 0.5). 
Pre-specified exploratory subgroup analy-
ses of the primary outcome were performed 
for Hb concentration at inclusion with cat-
egories 4.8-6.5, 6.6-7.3, and 7.4-7.9 g/dL 
(3.0-4.0, 4.1-4.5, and 4.6-4.9 mmol/L) and 
for physical fatigue score at inclusion using 
quartiles. The significance of differences in 
primary outcome between subgroups (effect 
modification) was calculated. A post-hoc 
per-protocol analysis was performed after 
excluding women allocated to non-inter-
vention who received RBC transfusion, and 
women allocated to RBC transfusion who 
did not receive RBC units. ANOVA estimates 
of HRQoL means were calculated to create 
graphics. Superiority analyses were used to 
analyze secondary outcomes. For second-
ary analyses, we used the chi-square test for 
comparing proportions and the Mann-Whit-
ney test for comparing continuous variables. 
Two-sided p-values are given and 0.05 was 
considered the limit of significance. Data 
was analyzed using SPSS version 17.0 
(SPSS Inc., Chicago, IL).
results 
During the study, 1011 women were ap-
proached; 521 gave informed consent for 
randomization: 259 were allocated to RBC 
transfusion and 262 to non-intervention. 
After randomization, two participants were 
excluded because they did not meet the 
inclusion criteria (Figure 1). Table 1 shows 
the baseline characteristics of both random-
ized and non-randomized women. Among 
randomized women, no significant differ-
ences were found between study arms. Two 
neonatal deaths in preterm neonates oc-
curred during follow-up due to sepsis and 
necrotising enterocolitis. 
Baseline characteristics of responders ver-
sus non-responders (at least one complet-
ed questionnaire versus no questionnaires) 
showed significant differences for ethnic-
ity, age, and blood loss (responders ver-
sus non-responders; Western ethnicity in 
81% versus 54%, mean age 31 versus 28 
years, median blood loss 1500 mL versus 
1150 mL). 
Hb concentration at inclusion was compa-
rable between study arms (Table 1). Women 
randomized to RBC transfusion received a 
median of two RBC units. In these women, 
median Hb concentration after transfusion 
was 9.0 g/dL and median Hb concentration 
at discharge was significantly higher than in 
women allocated to non-intervention (Table 
2). Among women allocated to RBC trans-
fusion, seven received no RBC transfusion: 
four withdrew consent, one appeared to 
have no health insurance, one had fever, 
and one had irregular erythrocyte alloanti-
bodies. Of women allocated to non-inter-
vention, 33/261 (13%) received RBC trans-
fusion during follow-up. Indications were 
anemic symptoms (n = 28), blood loss fol-
lowing retained placenta (n = 3), discomfort 
with parenteral iron supplementation (n = 1) 
and readmission for endometritis (n = 1). 
Compared to women who did not receive 
a transfusion on second instance, these 
women had lower Hb concentrations and 
higher physical fatigue scores at inclusion 
(median Hb 7.4 versus 6.9 g/dL, p = 0.02 
and median physical fatigue score 19 versus 
17, p = 0.08). In those women who suffered 
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1011: Women assessed for eligibility
490: Declined informed consent
  415: Willing to complete questionnaires
     53: chose for red blood cell transfusion
     362: chose for non-intervention
521: Randomized
259: Allocated to  
RBC transfusion
1 Excluded from analysis (inclusion 
at day three postpartum)
HRQoL data available for  
primary outcome analysis: 
81% (208/258)
262: Allocated to  
non-intervention
1 Excluded from analysis  
(Hb > 7.9 g/dL)
HRQoL data available for  
primary outcome analysis: 
78% (204/261)
Figure 1 Randomization flow chart.
from symptoms of anemia, RBC transfusion 
was given at a median of two days (IQR 
1-3), and five were readmitted. Three trans-
fusion reactions (3/291) were recorded, all in 
the RBC transfusion arm: one developed a 
rash (WHO Category 1, mild transfusion re-
action) and two a rise in temperature (WHO 
Category 2, moderate-severe transfusion 
reaction).94 Hb concentrations at six weeks 
were comparable between study arms, as 
demonstrated in Table 2. 
Primary outcome (physical fatigue at day 
three) was analyzed in 208 women in the 
RBC transfusion arm and in 204 women in 
the non-intervention arm. Women random-
ized to non-intervention had a 0.78 higher 
mean physical fatigue score at day three 
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Table 1 Baseline maternal characteristics of randomized and non-randomized women.
Randomized women Non-randomized women
Transfusion 
(n = 258)
Non- 
intervention  
(n = 261)
Transfusion 
(n = 53)
Non- 
intervention 
(n = 362)
Characteristics
Age (y) 30.7 ± 5.0 30.9 ± 5.3 31.8 ± 4.8 31.2 ± 5.2
Preconception body mass indexa 23.3
(21.1-26.6)
22.9
(20.8-26.5)
22.3
(20.9-25.1)
23.4
(21.1-26.0)
Western ethnic originb 186 (78%) 177 (76%) 38 (91%) 255 (84%)
Highest educationc
   none/ primary school 4 (3%) 5 (3%) 0 4 (2%)
   lower/ senior secondary vocational  
   education
88 (56%) 77 (51%) 6 (24%) 91 (46%)
   higher professional education and university 64 (41%) 70 (46%) 19 (76%) 102 (52%)
Nulliparous 152 (59%) 143 (55%) 31 (59%) 207 (57%)
Delivery by community midwifed 41 (16%) 29 (11%) 8 (15%) 58 (16%)
Mode of delivery 
   vaginal 213 (83%) 206 (79%) 45 (85%) 292 (81%)
   of which operativee 62 (30%) 48 (24%) 6 (15%) 55 (20%)
   elective CS 8 (3%) 15 (6%) 2 (4%) 23 (6%)
   emergency CS 37 (14%) 40 (15%) 6 (11%) 47 (13%)
Twin pregnancies 13 (5%) 16 (6%) 5 (9%) 18 (5%)
Gestational age (weeks+days) 40+1
(38+5-41+1)
40+0
(38+3-41+0)
40+2
(38+6-41+1)
40+0
(38+4-41+0)
Birth weight neonatef
   < 10th percentile 8 (3%) 20 (8%) 3 (6%) 16 (5%)
   10 ≤ percentile ≤ 90 188 (75%) 189 (74%) 34 (69%) 258 (74%)
   > 90st percentile 54 (22%) 47 (18%) 12 (25%) 75 (22%)
Estimated blood loss during delivery (mL) 1485
(1000, 1950)
1500
(1000, 1975)
1500
(925, 2000)
1500
(1000, 2000)
Hb concentration at inclusion (g/dL) 7.3 (6.8-7.7) 7.4 (6.8-7.7) 6.9 (6.4-7.4) 7.4 (6.9-7.7)
Data are n (%), mean ± SD, or median (Interquartile Range). CS = cesarean section. aRandomized: n = 232 and n = 234 
respectively. Non-randomized: n = 49 and n = 322 respectively. bRandomized: n = 239 and n = 232 respectively. 
Non-randomized: n = 42 and n = 304 respectively. cRandomized: n = 156 and n = 152 respectively. Non-randomized: n 
= 25 and n = 197 respectively. dRandomized: n = 253 and n = 255 respectively. Non-randomized: n = 52 and n = 352 
respectively. eRandomized: n = 205 and n = 197 respectively. Non-randomized: n = 39 and n = 279 respectively. fRan-
domized: n = 250 and n = 256 respectively. Non-randomized: n = 49 and n = 349. 
than women randomized to RBC transfu-
sion (95% CI: 0.1-1.5, p = 0.024) (Figure 
2, Table 3). The non-inferiority boundary is 
just exceeded by the 95% CI. At one week, 
the difference in physical fatigue scores be-
tween study arms was 1.06 (95% CI: 0.3-
1.8, p = 0.007) (Table 3). In Figure 3, mean 
differences in physical fatigue scores be-
tween study arms and confidence intervals 
are presented with the non-inferiority bound-
ary. Primary outcome was not significantly 
affected by mode of delivery (interaction p 
= 0.40). 
The remaining HRQoL scores are presented in 
Table S1. All MFI subscales, with the exception 
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Table 2 Blood loss, hemoglobin concentration and RBC transfusion.
  Transfusion
(n = 258)
Non-intervention
(n = 261)
p
Variable
RBC units per woman 2 (2-2) 0 (0-0) < 0.001
Total RBC unitsa 517 88 < 0.001
Hb concentration after transfusion, g/dLb 9.0 (8.5-9.6) 8.9 (8.2-9.7) 0.56
Hb concentration at discharge (g/dL)c 9.0 (8.5-9.5) 7.4 (6.8-7.7) < 0.001
Crossover 7 (3%) 33 (13%) < 0.001
   refused RBC transfusion 5
   fever 1
   erythrocyte alloantibodies 1
   anemic symptoms 28
   retained products of conception 3
   parenteral iron intolerance 1
   infection (endometritis) 1
Hb concentration at six weeks (g/dL)d 12.1 (11.3-12.6) 11.9 (10.9-12.6) 0.18
Data are n (%) or median (Interquartile Range). 
aIncluding units transfused during follow-up. bNon-intervention: n = 220. RBC transfusion: n = 25 (transfusion on second 
instance). cNon-intervention: n = 231. RBC transfusion: n = 238. dNon-intervention: n = 165. RBC transfusion n = 178. 
Blood samples for determining Hb at six weeks postpartum were collected at 45 (41-53) and 43 (40-48) days postpar-
tum in the RBC transfusion and non-intervention arm respectively. 
of mental fatigue at three days, showed 
slightly higher mean scores in the RBC 
non-intervention arm: the largest difference 
was 1.1 (physical fatigue at one week). Re-
garding the SF-36, differences in subscale 
scores between arms ran up to 5.5 points 
(physical functioning at one week) with 
a tendency to lower health scores in the 
non-intervention arm. The difference was 
significant only in the subscale physical 
functioning at one and three week (scores 
respectively 5.5 and 4.3 points lower in the 
non-intervention arm). Again though, signifi-
cance of the difference is of secondary inter-
est to its magnitude, which seems relatively 
small on the scale of SF-36. 
HRQoL results were similar after excluding 
questionnaires not completed within pre-
scribed time frames after follow-up (0-2, 2-5, 
6-10 days, 2-4, and 5-7 weeks postpartum) 
(138/1803 questionnaires excluded).  
Length of hospital stay after delivery was 
equal in both study arms (median days: 2, 
p = 0.37) and physical complications were 
comparable (Table 4). Use of iron supple-
mentation was more frequent in women al-
located to non-intervention. The percentage 
of women who breastfed initially, as well as 
those who continued until six weeks post-
partum, was not different between study 
arms (Table 4).
Results were consistent in a per-protocol 
analysis (mean physical fatigue score at day 
three was 0.80 higher in the non-intervention 
arm, p = 0.03, 95% CI: 0.1-1.5). 
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Figure 2 Physical fatigue score in randomized women. n = 447.
ANOVA estimates of means, error bars represent standard errors. Reference curve obtained from the pilot study that 
included 141 consecutive women delivering in hospital. 71 women delivered vaginally. In these women, median blood 
loss was 300 mL82
Figure 3 Mean differences and confidence intervals for physical fatigue in view of the non-inferiority 
  boundary.
Table 3 Difference in mean physical fatigue in randomized women, n = 382.
Mean adjusted for baseline and mode of delivery
Non-inferiority 
boundary 
Transfusion Non-intervention Difference p 95% Confidence 
Interval 
Lower limit Upper limit
Time point
Three days 1.30 15.68 16.45 0.78 0.024 0.1 1.5
One week 1.30 14.02 15.08 1.06 0.007 0.3 1.8
Three weeks 1.30 10.88 11.54 0.66 0.14 -0.2 1.5
Six weeks 1.30 8.69 8.95 0.26 0.56 -0.6 1.1
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Table 4 Follow-up in randomized women.
  Transfusion Non-intervention p
n n
Variable
Iron supplementation 231 246 < 0.001
   oral 93 (40%) 187 (76%)
   continued until six weeksa 66 37 (56%) 130 84 (65%) 0.31
   intravenous 0 30 (12%)
   none 138 (60%) 29 (12%)
Breastfeeding at randomization 252 194 (77%) 250 193 (77%) 1.00
   continued until six weeks 154 99 (64%) 143 101 (71%) 0.30
Complications
   transfusion reactions 227 3 (1%) 30 0 0.54
   thromboembolic event 227 2 (0.9%) 226 2 (0.9%) 1.00
   urinary tract infection 228 10 (4.4%) 225 14 (6.2%) 0.52
   infected surgery wound 41 0 46 1 (2.2%) 1.00
   infected episiotomy/ rupture 145 6 (4.1%) 137 6 (4.4%) 1.00
   endometritis 228 5 (2.2%) 225 3 (1.3%) 0.74
Infectious complications, total 209 22 (10.5%) 211 24 (11.4%) 0.90
n are number of women in which variable is known. Data are n (%) unless otherwise specified. 
aOral supplementation users. 
The difference at day three in mean physical 
fatigue scores per category Hb at inclusion 
(Hb 4.8-6.5, 6.6-7.3, and 7.4-7.9 g/dL) was 
1.19 (± SE 1.07), 0.91 (± SE 0.60), and 0.73 
(± SE 0.44) respectively. These differences 
did not significantly differ from each oth-
er (p = 0.91). Per category physical fatigue 
score at inclusion (< 14, 14-17, 18-19, 20) 
these differences were 1.58 (± SE 1.02), 
1.22 (± SE 0.68), 0.61 (± SE 0.71), and 0.10 
(± SE 0.49) respectively and did not signifi-
cantly differ from each other (p = 0.42). 
Ten randomized women were retrospec-
tively identified with an exclusion criterion: 
HIV (three), severe pre-eclampsia (four), and 
thalassemia (three). Primary outcome analy-
sis after excluding these women gave similar 
results (data not shown). 
Non-randomized women
Of the 490 women who declined informed 
consent; 415 (85%) were willing to complete 
questionnaires: 53 chose RBC transfusion 
and 362 non-intervention. Characteristics of 
non-randomized participants are described 
in Table 1. Compared to randomized wom-
en, non-randomized women were less often 
of Western ethnicity: 363/471 (77%) versus 
293/346 (85%), p = 0.01; and had less often 
had an operative vaginal delivery (110/402 
[27%] versus 61/318 [19%], p = 0.01). 
Among non-randomized women, Hb con-
centration was significantly lower in women 
who chose RBC transfusion (median Hb 
7.4 versus 6.9 g/dL, p < 0.001). The wom-
en who chose RBC transfusion all received 
RBC units. Of women who chose non-inter-
vention, 41/362 (11%) received RBC trans-
fusion, 34 (9%) because of anemic symp-
toms. These rates are comparable to the 
rates in randomized women. 
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Discussion 
Main findings
In this study, the difference in physical fa-
tigue at day three postpartum between both 
study arms was small. While the difference 
was only 0.78, the 95% CI of this difference 
(0.1-1.5) just exceeded the non-inferiority 
boundary of 1.3. Although non-inferiority 
cannot be demonstrated, clinically relevance 
of this difference seems negligible. No differ-
ences were found between study arms for 
secondary outcomes.
Regarding non-inferiority, its boundary is 
ideally based on the minimum clinical im-
portant difference, however, minimum clin-
ical important differences for the MFI sub-
scales had not been established in 2004. 
The pre-specified level of 1.3 was the feasi-
ble detectable difference in physical fatigue 
calculated using data obtained in a pilot 
study:82 this was not considered a valid esti-
mate of the score’s clinical relevance. Retro-
spectively, our pre-specified level seems too 
strict considering the following arguments. 
First, the minimum clinical important differ-
ence for physical fatigue has recently been 
determined to be larger, namely 2.04, in ra-
diotherapy patients.95 Second, the difference 
in physical fatigue score in this study is very 
small, given the large difference between 
scores after uncomplicated deliveries (de-
rived from the pilot study) and scores after 
PPH (this study). These scores, demonstrat-
ed in Figure 2, indicate that PPH greatly in-
creases physical fatigue irrespective of the 
treatment policy. Third, in social sciences, 
Cohen’s effect size (d) is used to deter-
mine a relevant difference (relevant when 
d ≥ 0.50).96 In our data, d’s were < 0.20 for all 
MFI subscales (calculated at all time points), 
indicating no relevant differences. The disad-
vantage of Cohen’s effect size, and reason 
not to include this in study design, is that the 
measure is distribution-based, whereas we 
think determining clinical relevance should 
be content-based. In addition, we analyzed 
all randomized and non-randomized pa-
tients together and found that the difference 
in physical fatigue between study arms was 
equal (0.8) to the difference in randomized 
patients alone, while its 95% CI was smaller 
(0.23-1.27) and thus does not exceed the 
non-inferiority boundary. 
Interpretation 
Most trials investigating transfusion policy 
were conducted in intensive care, cardio-
vascular, and orthopedic patients97-105 while 
recently a trial in patients with gastrointesti-
nal bleeding has been published.106 Six trials 
used as restrictive trigger an Hb threshold 
of ≤ 8 g/dL98-102,106 and two used hemato-
crit thresholds of 24% and 30%.103,104 To our 
knowledge, only Hébert conducted a ran-
domized controlled trial with Hb thresholds 
below 8 g/dL (Hb < 7g/dL versus < 9 g/dL).97 
This study in intensive care patients showed 
that a restrictive threshold was at least as 
effective regarding mortality, multi-organ fail-
ure, and length of hospital stay in patients 
without cardiac disease. A recent update 
on Cochrane evidence regarding Hb thresh-
olds, including 19 randomized trials and 
more than 6000 patients, demonstrated a 
relative risk for 30-day all-cause mortality of 
0.85 (95% CI: 0.70-1.03) in patients allocat-
ed to a lower Hb threshold (threshold varying 
from 7-10 g/dL) compared to a more liberal 
transfusion policy. Also, a lower threshold 
was not associated with any significant dif-
ferences in major complications.107 In our 
study, physical complications between study 
arms were also comparable, as was dura-
tion of hospital stay. 
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Previously, few studies investigated post-
partum HRQoL. The MFI was only used in 
our pilot study, to validate HRQoL measures 
in Dutch postpartum women.82 This study 
found significant differences in MFI scores 
after different modes of delivery though the 
present study has not confirmed this find-
ing. After vaginal delivery, women in the pilot 
study had significantly more favorable scores 
than in the present study, while the scores 
after cesarean section in the pilot study were 
comparable to scores in the present study. 
Differences in physical fatigue between 
modes of delivery might be concealed by 
the large effect of PPH on physical fatigue.
Minimum clinical important differences of 
SF-36 subscales have not yet been deter-
mined in a postpartum population. Minimum 
clinical important differences determined 
in orthopedic, COPD, asthma and cardiac 
disease are at least 10 points so the differ-
ences found in SF-36 subscales in this study 
(maximal difference 5.5) seem not clinically 
relevant.108-110
Strengths and limitations
Main strengths of this study are the com-
parison of randomized arms and the large 
study population. Questionnaires to score 
HRQoL outcomes were internationally 
validated. Primary outcome was available in 
412/519 (80%) of randomized participants, 
a usual response rate in HRQoL studies. A 
large percentage of eligible women declined 
informed consent, mainly because they did 
not want an intervention. Baseline charac-
teristics of randomized versus non-random-
ized participants showed only differences in 
ethnicity and frequency of operative delivery. 
The majority of participants in our study de-
livered vaginally. Women presumably receive 
RBC transfusions more reluctantly in operat-
ing theatres than after vaginal deliveries. As 
a result of the small numbers, comparisons 
between emergency and elective cesarean 
sections could not be made. Although iron 
supplementation is assumed to have no ef-
fect after RBC transfusion, still a remarkable 
percentage of women in the RBC transfu-
sion arm used iron supplementation. Wide 
variations in type, dosage, and duration of 
iron supplementation made it impossible to 
make comparisons. Though the assumption 
is that anemia compromises breastfeed-
ing,111 our study showed that more wom-
en in the non-intervention arm were still 
breastfeeding six weeks postpartum while 
the intention to breastfeed had been similar 
in the study arms. These results should be 
interpreted with caution, since reasons for 
discontinuation of breast feeding were not 
reported. 
A minority of clinicians is unaware of or re-
luctant to accept lower transfusion thresh-
olds.112 Implementing a restrictive approach 
to RBC transfusion would lead to a striking 
decrease in demand for RBC units and 
adverse events. In our study, the use of 
RBC units in the non-intervention arm was 
88/517 (17%) of that in the RBC transfusion 
arm (Table 2). A high percentage of women 
in the non-intervention arm (28/261, 11%) 
secondarily received RBC units for anemic 
symptoms. Among non-randomized wom-
en this percentage was similar, even though 
they were expected to be more motivated 
for non-intervention. 
The randomized women allocated to non-in-
tervention that received RBC transfusion on 
second instance had significantly lower Hb 
concentrations at inclusion. Also, a trend to-
wards a larger difference in physical fatigue 
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between study arms was seen in the wom-
en in the lowest category Hb concentrations 
and in highest category of physical fatigue 
scores at inclusion. Therefore, Hb concen-
tration should be considered when coun-
seling postpartum anemic women: RBC 
transfusion seems to have the largest effect 
in women with the lowest Hb and highest 
physical fatigue scores.
The difference in mean physical fatigue 
score between study arms was only small 
(0.78). The clinical relevance of this differ-
ence seems negligible even though non-in-
feriority of non-intervention policy could sta-
tistically not be demonstrated. The recently 
established minimum clinical difference of 
physical fatigue,95 suggests that non-inter-
vention policy is safe with regard to physi-
cal complications and only accompanied by 
slightly higher physical fatigue scores; we 
feel that our results justify implementation 
of non-intervention in daily clinical practice. 
Future studies are needed to establish the 
optimal iron supplementation in these wom-
en and justify implementation of non-inter-
vention policy.
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abstract 
Objective 
To determine clinical predictors of escape 
red blood cell (RBC) transfusion in post-
partum anemic women, initially managed 
expectantly, and the additional predictive 
value of health-related quality of life (HRQoL) 
measures.
Design 
Secondary analysis of women after postpar-
tum hemorrhage, either randomly allocated 
to, or opting for expectant management. 
Setting 
Thirty-seven hospitals, the Netherlands.
Population 
261 randomized and 362 non-randomized 
women. 
Methods 
We developed prediction models to assess 
the need for RBC transfusion: one using 
clinical variables (model 1), and one extend-
ed with scores on the HRQoL-measures 
Multidimensional Fatigue Inventory (MFI) 
and EuroQol-5D (model 2). Model perfor-
mance was assessed by discrimination and 
calibration. Models were internally validated 
with bootstrapping techniques to correct for 
overfitting.
Main outcome measures 
Escape RBC transfusion. 
results 
Seventy-five women (12%) received escape 
RBC transfusion. Independent predictors 
of escape RBC transfusion (model 1) were 
primiparity, multiple pregnancy, total blood 
loss during delivery and hemoglobin con-
centration postpartum. Maternal age, body 
mass index, ethnicity, education, medical 
indication of pregnancy, mode of delivery, 
preterm delivery, placental removal, perineal 
laceration, Apgar score and breastfeeding 
intention had no predictive value. Addition 
of HRQoL-scores (model 2), significantly 
improved the model’s discriminative ability: 
c-statistics of model 1 and 2 were 0.65 (95% 
CI: 0.58-0.72) and 0.72 (95% CI: 0.65-0.79), 
respectively. The calibration of both models 
was good.
Conclusions 
In postpartum anemic women, several clin-
ical variables predict the need for escape 
RBC transfusion. Adding HRQoL-scores 
improves model performance. After external 
validation, the extended model may be an 
important tool for counseling and decision 
making in clinical practice. 
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Introduction
Severe postpartum hemorrhage (PPH), de-
fined as peripartum blood loss of at least 
1000 mL,1 is a common obstetric complica-
tion with a worldwide incidence of 1.9%.2 An 
increase in incidence has been described in 
several developed countries.4-6,8-10,113 During 
the acute phase of postpartum hemorrhage, 
transfusion of blood components may be 
inevitable. After the acute phase, however, 
anemia can be treated by either red blood 
cell (RBC) transfusion or expectantly, using 
iron and/ or folic acid supplementation. 
Recently, we performed a randomized trial 
comparing RBC transfusion with expect-
ant management in acute anemic women, 
without severe anemic complaints, following 
PPH. This multicenter trial, the Well-being of 
Obstetric patients in Minimal Blood transfu-
sions (WOMB) trial, hypothesized non-infe-
riority in physical fatigue, measured by val-
idated health-related quality of life (HRQoL) 
questionnaires, of expectant management 
compared to RBC transfusion.89 Although 
non-inferiority could not been proven, results 
of this trial demonstrate that RBC transfu-
sion leads only to a small, probably clinical 
irrelevant improvement in physical fatigue. 
No differences were found in physical com-
plications. Based on this trial, expectant 
management seems justified in an obstetric 
population and thus current standard care is 
to avoid RBC transfusion. However, 13% of 
randomized women in the expectant man-
agement arm of the WOMB trial received an 
escape RBC transfusion, mainly for anemic 
complaints.88 Averting escape RBC transfu-
sion would prevent unnecessary burden for 
the patient, as this changeable policy leads 
to commotion and possible readmission, 
and avoid higher costs. For these reasons, 
we believe that identification of those women 
with a very high probability of escape RBC 
transfusion would be useful and will prevent 
suboptimal health care in those women. It 
could also lead to a uniform policy and less 
uncertainty for both patient and physician 
when formulas would identify and diminish 
the probability of escape RBC transfusion. 
To avert escape RBC transfusion in post-
partum anemic women, initially treated with 
expectant management, predictors need to 
be identified.
Data of the WOMB trial comprise clinical 
variables and scores on the HRQoL mea-
sures Multidimensional Fatigue Inventory 
(MFI) and EuroQol-5D. We hypothesized 
that, besides clinical variables, HRQoL-
scores measured 12-24 hours postpartum 
have incremental value in the prediction of 
RBC transfusion. Therefore, two study aims 
were formulated: to investigate which com-
bination of variables, available in daily clinical 
practice, predicts escape RBC transfusion 
(model 1) best and, whether HRQoL-scores 
have additional predictive value over these 
variables (model 2).
Methods 
For this study, we used data from the 
WOMB trial, a multicenter randomized trial 
conducted in the Netherlands. In short, af-
ter informed consent, women with an acute 
anemia (Hb 4.8-7.9 g/dL [3.0-4.9 mmol/L]) 
after postpartum hemorrhage (blood loss of 
≥ 1000 mL and/ or a decrease in Hb con-
centration of ≥ 1.9 g/dL [1.2 mmol/L]) were 
randomized between RBC transfusion and 
expectant management. Main outcomes 
were HRQoL-scores and physical complica-
82
Clinical aspects of Postpartum Hemorrhage 
tions up to six weeks postpartum. HRQoL-
scores were measured at inclusion (12-24 
hours after delivery) by two validated ques-
tionnaires: the MFI and the EuroQol-5D.78,79 
Women who declined randomization, were 
asked if they were willing to complete ques-
tionnaires. They were treated by RBC trans-
fusion or expectant management based on 
their preference and at discretion of their 
physician. Non-randomized women were 
registered and had identical follow-up as 
randomized women. The design and results 
of the trial are presented elsewhere.88,89 We 
used data of all randomized and non-ran-
domized women in the expectant manage-
ment arms. Thus, women who were initially 
treated with RBC transfusion were exclud-
ed. For this particular study, a study protocol 
was written and is available upon request. 
Outcome
The outcome of the study was the need for 
escape RBC transfusion, which was defined 
as RBC transfusion prescribed secondari-
ly within women randomized to expectant 
management and non-randomized wom-
en who chose expectant management. As 
follow-up in the trial lasted up to six weeks 
postpartum, all escape RBC transfusions up 
to six weeks postpartum were analyzed.
Candidate predictors 
Based on clinical reasoning we selected 
candidate predictors that are available 12-
24 hours after delivery and are readily avail-
able in daily clinical practice. Candidate 
predictors for model 1 were the following: 
maternal age, preconceptional body mass 
index (BMI), non-Western ethnicity, low 
maternal education, primiparity, multiple 
pregnancy, high-risk pregnancy, mode of 
delivery, preterm delivery, placenta removal, 
perineal laceration, Apgar score below 7 at 5 
minutes, total blood loss, Hb concentration 
(12-24 hours after delivery) and intention to 
breastfeed. 
Preconceptional BMI, determined at first 
pregnancy visit, was defined as the maternal 
weight in kilograms divided by the maternal 
height in meters squared. Non-Western eth-
nicity was assessed according to the defi-
nition of Statistics Netherlands in which the 
category ‘Western’ consists of persons from 
Europe (excluding Turkey), North America, 
Oceania, Japan and Indonesia (including the 
former Dutch East Indies).90 None or prepa-
ratory vocational education was considered 
as low maternal education. Mode of deliv-
ery was registered as vaginal delivery (used 
as reference), elective cesarean section or 
emergency cesarean section. Preterm de-
livery was defined as gestational age less 
than 37 weeks at delivery. The following cat-
egories were analyzed: gestational age less 
than 34 weeks at delivery, gestational age 
of 34 to 37 weeks and no preterm delivery 
(gestational age of 37 weeks and/ or more; 
used as reference). Placenta removal was 
categorized in complete (no manual placen-
tal removal) or incomplete (manual placen-
tal removal directly postpartum). High-risk 
pregnancies are characterized by pre-exist-
ing maternal disease, complicated obstetric 
history, pregnancy and delivery.24 Perineal 
laceration was defined episiotomy or at least 
second degree perineal rupture.
Additionally, the interaction of Hb concen-
tration (12-24 hours after delivery) with to-
tal blood loss was investigated. On top of 
the identified candidate predictors of model 
1, the following candidate predictors were 
considered for model 2: all subscales 
of the MFI, as well as the EurQol-5D 
index score and VAS score. See below 
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for a more extensive description of the 
HRQoL measures. As both randomized and 
non-randomized women were analyzed, the 
association of the randomization status with 
the outcome (escape RBC transfusion) was 
also investigated in both models. 
HrQoL measures
The MFI and EuroQol-5D are validated 
HRQoL measures. The MFI is a 20-item 
self-report instrument designed to measure 
fatigue. It covers the following dimensions: 
General Fatigue, Physical Fatigue, Mental 
Fatigue, Reduced Motivation and Reduced 
Activity. Each dimension is covered by four 
questions on a five-item scale. MFI scores 
range from 4 to 20 (20 represents maximal 
fatigue).79 The MFI was developed as a tool 
to assess fatigue in a comprehensive way 
and provides information on the nature of 
the experience, and its intensity. 
The EuroQol-5D is a standardized measure 
of health status and provides a simple, ge-
neric measure of health for clinical and eco-
nomic appraisal. The questionnaire consists 
of a short questionnaire and a visual ana-
logue scale (index score and VAS score, re-
spectively). The index score is based on five 
questions on the items Mobility, Self-Care, 
Usual Activities, Pain/Discomfort, and Anx-
iety/Depression, with a three-item scale (no 
problems, some problems, extreme prob-
lems). The VAS score represents the patient’s 
value of their own health state (score 0-100, 
the higher the better). Applicable to a wide 
range of health conditions and treatments, 
it provides a simple descriptive profile and a 
single index value for health status that can 
be used in the clinical and economic evalu-
ation of health care as well as in population 
health surveys.78 The international standard 
HRQoL measures MFI and EuroQol-5D have 
been evaluated in a pilot study; feasibility, re-
liability, and validity of these measures in a 
clinical obstetric setting were established.82
Data analysis
Baseline characteristics were presented as 
raw data. These data were analyzed using 
descriptive statistics and presented as mean 
with standard deviation (SD) or median with 
interquartile range (IQR) for continuous vari-
ables as appropriate, and as numbers and 
percentages of the whole population for cat-
egorical and dichotomous variables.
Various candidate predictors had missing 
values. Because these are often selectively 
missing, it is well documented that a com-
plete case analysis likely yields biased re-
sults.114-116 Hence, we used multiple impu-
tation (10 times) to handle missing values 
(see also Appendix). The imputation model 
included all potential predictors and the out-
come.
Univariable and multivariable logistic regres-
sion analyses were performed with escape 
RBC transfusion (yes/ no) as outcome mea-
sure to determine the association between 
the candidate predictors and the outcome. 
Maternal age, preconceptional BMI, Hb 
concentration (12-24 hours after delivery), 
total blood loss, MFI subscale scores and 
EuroQol-5D scores were analysed as con-
tinuous variables. For these, we assessed its 
association with the outcome (escape RBC 
transfusion) using cubic spline analyses.117 
Variables were transformed (e.g. using a 
log-transformation) or categorized when 
they showed non-linear association with es-
cape RBC transfusion. 
Although not generally recommended,118 we 
performed a pre-selection based on the p 
84
Clinical aspects of Postpartum Hemorrhage 
(< 0.10) in univariable analyses in order to 
retain a reasonable number of events per 
variable in the multivariable model.119 The 
combination of predictors that best predict-
ed escape RBC transfusion was obtained 
with a backward selection procedure using 
Akaike’s Information Criterion.120 As imputed 
data sets differ from each other, predictor 
selection was performed in each imputation 
set separately. For inclusion in the final pre-
diction model, we used the majority meth-
od, i.e. predictors were included in the final 
model if selected in at least five out of ten 
imputed data sets.121 The final model was 
applied to each imputation separately, and 
the regression coefficients and standard er-
rors of these final predictors were combined 
from the ten data sets using Rubin’s rules to 
come to the final prediction model.122 
With each model development there is a 
chance of overfitting, meaning that the model 
is too strongly fit to the data on which it was 
developed and consequently may perform 
poorly when externally validated. To assess 
the degree of overfitting or optimism in this 
study, we internally validated the model us-
ing bootstrapping techniques. One hundred 
bootstrap samples were drawn from the 
original data set with replacement, allowing 
for multiple sampling of the same individual. 
Within each sample the entire modeling pro-
cess, described above, was repeated. This 
yielded a shrinkage factor, with which the re-
gression coefficients of the predictors were 
multiplied (uniformly shrunken) to correct the 
model for optimism and overfitting.117 We 
developed two models. Model 1 was based 
on variables available in daily clinical prac-
tice (i.e. without HRQoL-scores). For model 
2, the HRQoL-scores, with p-value < 0.10 
in univariable analyses, were added to the 
first model. Again, the same procedure as 
described previously was used, including 
the backward stepwise selection, repetition 
in the imputed dataset separately, and cor-
rection for optisim using bootstrapping tech-
niques.
Model performance was assessed using 
discrimination and calibration. Discrimina-
tion refers to the ability of the models to 
distinguish between those with and without 
escape RBC transfusion, and was assessed 
with the c-statistic. The c-statistic is similar 
to the area under the Receiver Operating 
Characteristic curve.123 The c-statistic rang-
es from 0.5 (no discrimination) to a theoret-
ical maximum of 1 (perfect discrimination) 
and models are typically considered rea-
sonable when the c-statistic is higher than 
0.7. Calibration refers to the agreement of 
predicted and observed predictions: e.g. is 
in a group of women with an average 70% 
predicted chance of the outcome the av-
erage observed proportion also 70%? In 
case of perfect calibration there is perfect 
agreement between predicted probabili-
ties and observed proportions (45 degree 
line).117,124,125 To investigate whether the 
HRQoL-scores had added value over the 
identified candidate predictors in model 1 for 
the prediction of escape RBC transfusion, 
we compared the c-statistics of model 1 and 
2.126 Additionally, we investigated whether 
the second model was able to better reclas-
sify individuals using the continuous Net Re-
classification Improvement (NRI(> 0)).127-129 
The NRI(> 0) was used instead of a general 
NRI, because there are currently no clearly 
defined prediction categories to identify in-
dividuals being at low, intermediate, or high 
risk for escape RBC transfusion.130 This re-
classification measure was investigated only 
when calibration of the models was good, 
since these measures tend to be less reli-
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able when models calibrate poorly.131 Fur-
thermore, the following accuracy measures 
were assessed: sensitivity (or true positive 
rate), specificity, positive predictive value, 
negative predictive value, and false positive 
rate. Since no clear relevant cut off value 
exists, these measures were presented for 
different cut off values based on the deciles 
of the predicted probabilities.
Data were analyzed using R version 3.0.1 
(The R Foundation for Statistical Computing, 
2013).
results 
Between May 2004 and February 2011, 624 
women entered the study in the expect-
ant management arms; 262 randomized 
and 362 non-randomized (Figure 1). One 
randomized woman did not fulfil inclusion 
criteria and was excluded, resulting in 623 
women analyzed. Baseline characteristics 
of all women are presented in Table 1. No 
significant differences were found between 
randomized and non-randomized women 
expect for ethnicity (non-Western ethnicity 
in 24 versus 16% respectively, p = 0.037). 
Among randomized women, 33 (13%) re-
ceived escape RBC transfusion while 42 
non-randomized women (11%) received 
escape RBC transfusion. Indications report-
ed were retained products of conception, 
secondary PPH or infections in 5% while in 
14% the cause was unknown. About 80% of 
women who received escape RBC transfu-
sion reported anaemic complaints as primary 
cause, while 29% of these women also had 
another indication. Escape RBC transfusion 
was given at a median of 2 days (interquar-
tile range of 1-3 days) while 95% percent 
was prescribed within 14 days after delivery. 
Among women with escape RBC transfu-
sion the median physical fatigue score was 2 
points higher (worse) than in women without 
escape RBC transfusion (Table 1). Results 
for other MFI subscales were similar. Like-
wise, women with escape RBC transfusion 
scored worse on the EuroQol-5D. 
The cubic spine analyses demonstrated a lin-
ear correlation association between the out-
come (i.e., escape RBC transfusion) and Hb 
concentration (12-24 hours after delivery), 
all MFI subscale scores and the EuroQol-5D 
VAS. No linear association with the outcome 
was found for the following variables, there-
fore, these were categorized: maternal age 
(< 36, ≥ 36 years), preconceptional BMI 
(≤ 25, > 25), total blood loss (≤ 1500 mL, 
> 1500 mL) and the EuroQol-5D index score 
(< 0.88, ≥ 0.88).132
Univariable and multivariable analyses 
Predictors related to the outcome in uni-
variable analysis were primiparity, multiple 
pregnancy, complicated obstetric history, 
total blood loss > 1500 mL, Hb concen-
tration (12-24 hours after delivery) and MFI 
subscales general fatigue, physical fatigue, 
reduced motivation and mental fatigue and 
EuroQol-5D VAS score (Table 1). As no in-
teraction was found for Hb concentration 
(12-24 hours after delivery) and total blood 
loss, this interaction term was not consid-
ered a candidate predictor for the multivari-
able models. 
The multivariable analysis identified four 
clinical variables that independently predict 
escape RBC transfusion (model 1): prim-
iparity, multiple pregnancy, total blood loss 
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Table 1 Characteristics of the study population and the univariable association between 
 potential predictors and the need for escape RBC transfusion.
Total Escape RBC transfusion Univariable association
n = 623
Yes
n = 75
No
n = 548
OR (95% CI) p
Clinical variables
Participation, non-randomized 362 (58%) 42 (56%) 320 (58%) 0.91 (0.56-1.47) 0.69
Age (years), ≥ 36 yearsa 107 (17%) 10 (13%) 97 (18%) 0.728 (0.39-1.34) 0.31
Preconceptional body mass index > 25b 145 (26%) 17 (23%) 128 (26%) 0.992 (0.59-1.68) 0.98
Ethnic origin: non-Westernc 104 (19%) 12 (18%) 92 (20%) 1.18 (0.62-2.26) 0.60
Highest educationd
   none – preparatory vocational education 82 (24%) 5 (14%) 77 (25%) 0.765 (0.32-1.85) 0.38
Primiparitye 350 (56%) 50 (67%) 300 (55%) 1.653 (0.99-2.75) 0.05
Multiplet pregnanciese 34 (6%) 9 (12%) 25 (5%) 2.85 (1.28-6.37) 0.01
Medical indicationf
   pre-existent disease 47 (8%) 4 (6%) 43 (8%) 0.691 (0.24-1.98) 0.48
   obstetric history 112 (19%) 8 (12%) 104 (20%) 0.52 (0.24-1.11) 0.08
   pregnancy 220 (37%) 30 (44%) 190 (37%) 1.39 (0.83-2.32) 0.19
   delivery 301 (51%) 35 (51%) 266 (51%) 0.93 (0.56-1.54) 0.76
Mode of deliverye
   Elective CS 38 (6%) 5 (7%) 33 (6%) 1.266 (0.42-3.81) 0.67
   Emergency CS 87 (14%) 14 (19%) 73 (13%) 0.836 (0.31-2.23) 0.72
Preterm delivery (weeks)e
   34-37 weeks 43 (7%) 3 (4%) 40 (7%) 0.52 (0.16-1.74) 0.29
   < 34 weeks 29 (5%) 3 (4%) 26 (5%) 0.81 (0.24-2.73) 0.73
Placenta: incompleteg 162 (28%) 17 (25%) 145 (28%) 1.050 (0.62-1.77) 0.85
Perineal laceration: > 1st degreeh 384 (62%) 44 (59%) 340 (62%) 0.86 (0.53-1.41) 0.56
Apgar 5 minutes < 7i 11 (2%) 2 (3%) 9 (2%) 1.641 (0.35-7.74) 0.53
Total blood loss > 1500 mLe 244 (39%) 39 (52%) 205 (38%) 1.792 (1.10-2.91) 0.02
Hb concentration 12-24h after delivery 
(g/dL)e 
7.4 (6.8-7.7) 6.4 (6.6-7.6) 7.4 (6.9-7.7) 0.38 (0.25-0.59) < 0.001
No intention to breastfeedj 138 (22%) 15 (21%) 123 (23%) 0.87 (0.48-1.57) 0.64
HRQoL-score
Multidimensional Fatigue Inventory
   general fatigue 17 (14-19) 19 (17-20) 17 (14-19) 1.14 (1.01-1.29) 0.003
   physical fatigue 17 (14-20) 19 (17-20) 17 (14-19) 1.16 (1.04-1.28) 0.001
   reduced activity 16 (14-19) 18 (14-19) 16 (14-19) 1.06 (0.97-1.16) 0.14
   reduced motivation 12 (9-16) 15 (11-18) 12 (9-16) 1.07 (0.98-1.18) 0.02
   mental fatigue 11 (8-15) 12 (10-17) 11 (8-15) 1.05 (0.98-1.11) 0.02
EuroQol-5D
   index score < 0.88k
0.43  
(0.24-0.78)
0.31  
(0.10-0.78)
0.43  
(0.30-0.78)
0.86  
(0.38-1.93) 
0.67 
   VAS score 60 (45-65) 50 (40-60) 60 (46-69) 0.98 (0.96-1.00) 0.005
Odds ratios for dichotomous and categorical variables are presented in relation to the reference category. Hb concen-
tration and HRQoL scores are presented as median (IQR). CS = cesarean section. aTotal n = 618 (99%). bTotal n = 556 
(89%). cTotal n = 536 (86%). dTotal n = 349 (56%). eTotal n = 623 (100%). fTotal n = 588 (94%). gTotal n = 587 (94%). 
hTotal n = 622 (100%). iTotal n = 613 (98%). jTotal n = 600 (96%). k0.88 is the Dutch reference score.132 
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Women assessed for eligibility in WOMB trial
(n = 1011)
Randomized
(n = 521)
Expectant  
management
(n = 262)
Excluded from 
analysis
(n = 1)
Included
n = 261
Expectant  
management
(n = 362)
Included
n = 362
RBC transfusion
(n = 259)
Excluded
RBC transfusion
(n = 53)
Excluded
Non-randomized
(n = 415)
Declined all
(n = 75)
Figure 1 Flowchart of the WOMB trial and women included in this study.
> 1500 mL and Hb concentration (12-24 
hours postpartum) (Table 2). Addition of 
HRQoL-scores as predictors to model 1 
yielded that, in addition to predictors re-
vealed in model 1, the MFI subscales phys-
ical fatigue, reduced activity and reduced 
motivation, and the EuroQol-5D VAS score 
were independent predictors of escape RBC 
transfusion (model 2) (Table 2).
For model 1, internal validation showed 
good calibration (Figure 2) and a moderate 
discriminative ability with a c-statistic of 0.65 
(95% CI: 0.58-0.72). The predicted probabil-
ities ranged from 4.5% to 59.1%.
Model 2 showed good calibration (Figure 3) 
and an improved discriminative performance 
as compared to model 1 with a c-statistic 
of 0.72 (95% CI: 0.65-0.79), p = 0.008. The 
predicted probabilities ranged from 0.9% to 
55.7%.
Apart from the statistically significant higher 
c-statistic, also the NRI(> 0) showed a sig-
nificant difference in classification between 
the two model (0.39 (95% CI: 0.15-0.63; 
p < 0.0015)). These results suggest that 
including HRQoL-scores in the model led 
to a significant improvement of model per-
formance. The sensitivity and specificity of 
both models for different for different cut off 
values of the predicted risk are presented in 
Table 3.
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Table 2 Multivariable associations for model 1 (clinical variables) and model 2 (both clinical 
 variables and HRQoL-scores).
Model 1 Model 2
Betaa OR (95% CI) Betab OR (95% CI)
Intercept 2.15 1.38
Clinical variable
Primiparity 0.48 1.61 (0.95-2.72) 0.43 1.54 (0.90-2.64)
Multiplet pregnancy 0.92 2.51 (1.07-5.91) 0.71 2.03 (0.83-4.95)
Total blood loss > 1500 mL 0.44 1.55 (0.93-2.58) 0.46 1.58 (0.93-2.67)
Hb concentration 12-24h postpartum (g/dL) -0.66 0.52 (0.35-0.77) -0.63 0.53 (0.35-0.80)
HRQoL-score
MFI subscale physical fatigue 0.12 1.13 (0.99-1.29)
MFI subscale reduced activity -0.08 0.92 (0.81-1.04)
MFI subscale reduced motivation 0.03 1.03 (0.93-1.14)
EuroQol-5D VAS score -0.01 0.99 (0.97-1.01)
aShrunken with an average shrinkage factor of 0.88
bShrunken with an average shrinkage factor of 0.82
Figure 2 Calibration plot of Model 1 with the observed risk of escape RBC transfusion by 
 predicted probabilities. 
The dots indicate deciles of women grouped by similar predicted risk of escape RBC transfusion. The vertical bars 
through the dots indicate the 95% confidence interval of the observed risks for the grouped women.
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4Figure 3 Calibration plot of Model 2 with the observed risk of escape RBC transfusion by 
 predicted probabilities.
The dots indicate deciles of women grouped by similar predicted risk of escape RBC transfusion. The vertical bars 
through the dots indicate the 95% confidence interval of the observed risks for the grouped women.
Table 3 Accuracy measures (%) for different cut off values of the predicted risk.
Cut off value Sens Spec PPV NPV TPR FPR
Model 1
> 10% 72.0 50.1 16.5 92.9 72.0 49.9
> 20% 30.7 92.0 34.3 90.6 30.7 8.0
> 30% 12.0 98.9 60.0 89.1 12.0 1.1
> 40% 8.0 99.5 66.7 88.8 8.0 0.5
> 50% 2.7 100.0 100.0 88.2 2.7 0.0
> 60% NA NA NA NA NA NA
> 70% NA NA NA NA NA NA
> 80% NA NA NA NA NA NA
> 90% NA NA NA NA NA NA
Model 2
> 10% 77.1 54.6 18.8 94.6 77.1 45.4
> 20% 30.4 90.7 30.9 90.5 30.4 9.3
> 30% 16.8 98.4 59.2 89.6 16.8 1.6
> 40% 7.1 99.3 58.9 88.6 7.1 0.7
> 50% 3.7 99.8 71.8 88.3 3.7 0.2
> 60% 0.3 100.0 100.0 88.0 0.3 0.0
> 70% NA NA NA NA NA NA
> 80% NA NA NA NA NA NA
> 90% NA NA NA NA NA NA
Sens = sensitivity. Spec = specificity. PPV = positive predictive value. NPV = negative predictive value. TPR = true pos-
itive rate (or sensitivity). FPR = false positive rate. NA = not applicable. 
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Implications for daily clinical practice 
In expectantly managed women with acute 
anaemia after postpartum haemorrhage, the 
clinical variables primiparity, multiple preg-
nancy, total blood loss and Hb concentra-
tion (12-24 hours postpartum) influenced the 
probability of the need of an escape RBC 
transfusion. The probability was enhanced in 
case of primiparity, multiple pregnancy and 
total blood loss > 1500 mL while a higher Hb 
concentration reduced this probability. 
Addition of the following HRQoL measures 
improved the prediction of RBC transfusion 
in expectantly managed women: MFI sub-
scale physical fatigue, MFI subscale reduced 
activity, MFI subscale reduced motivation 
and the EuroQol-5D VAS score. In case of 
higher physical fatigue and less motivation 
the probability of escape RBC transfusion 
was enhanced while the probability was di-
minished in case of a poorer score on re-
duced activity and a better EuroQol-5D VAS 
score (e.g. better well-being). 
The predicted chance for escape transfu-
sion using model 1 can be calculated for 
an anemic woman after postpartum hemor-
rhage using the following formula: Predicted 
chance = 1 / (1 + exp (-(2.15-0.48*primipar-
ity + 0.92*multiple pregnancy + 0.44*total 
blood loss > 1500 mL - 0.66*Hb concen-
tration))).
This predicted chance for escape transfu-
sion using model 2 can be calculated using 
the following formula: Predicted chance 
= 1 / (1 + exp (-(1.38-0.43*primiparity + 
0.71*multiple pregnancy + 0.46*total blood 
loss > 1500 mL - 0.63*Hb concentration 
+ 0.12*MFI subscale physical fatigue – 0.08* 
MFI subscale reduced activity + 0.03*MFI 
subscale reduced motivation - 0.01*Eur-
Qol-5D VAS score))). 
In both formulas, the woman’s value of each 
continuous variable (Hb concentration, all 
MFI subscales and the EuroQol-5D VAS 
score) can be used. For the categorical 
variables (primiparity [reference: multipari-
ty], multiple pregnancy [reference: singleton 
pregnancy] and total blood loss [reference: 
≤ 1500 mL]), the value ‘0’ should be used 
in case the patient belongs to the reference 
category and ‘1’ in case she belongs to the 
non-reference category. 
Discussion 
Main findings 
In this study, we developed two models to 
predict the need for escape RBC transfusion 
in anemic women (without severe anemic 
complaints) after postpartum hemorrhage, 
treated with expectant management. In 
model 1, the clinical variables parity, multi-
ple pregnancy, total blood loss and Hb con-
centration (12-24 hours after delivery) were 
associated with escape RBC transfusion. 
The predictive value of HRQoL-scores was 
evaluated in model 2 by adding these scores 
to model 1. 
Model 2 had significantly better discrim-
inative ability according to the c-statistic 
(0.72 for model 2 and 0.65 for model 1) and 
NRI(> 0), indicating that HRQoL-scores have 
additional value over clinical variables in the 
prediction of escape RBC transfusion. 
Our study aimed to predict the need for es-
cape RBC transfusion in postpartum ane-
mic women treated with expectant man-
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agement. Predictive variables of (massive) 
RBC transfusion were previously identified 
in trauma patients133-138 and in patients un-
dergoing orthopedic surgery,139-142 cardiac 
surgery,143-146 liver transplantation,147-150 or 
liver surgery.151,152 In these studies, identified 
predictors for (massive) transfusion included 
age, gender, weight, heart rate, blood pres-
sure, preoperative Hb or Ht concentration, 
platelet concentration, creatinine concentra-
tion, base deficit, surgical time and throm-
bo-elastography. Only one study has been 
performed on prediction of RBC transfusion 
in the obstetric field. This study inventoried 
RBC transfusion requirements in women 
with placenta accreta undergoing cesarean 
section and reported no relation between 
RBC transfusion requirements and labora-
tory values.153 No previous study investigat-
ed predictors of the need for escape RBC 
transfusion in anemic postpartum patients, 
managed expectantly.
Limitations/ strengths 
We present predictors for escape RBC 
transfusion identified in anemic postpartum 
women. Results are based on data obtained 
in a randomized trial. As all patients allo-
cated to RBC transfusion in the trial were 
excluded, allocation status was not taken 
into account. We have demonstrated that 
participation status (e.g. whether women 
were included in the trial as randomized or 
non-randomized women) was no predictor 
for escape RBC transfusion. An advantage 
of these data is the prospectively collection 
in 37 hospitals, strengthening external vali-
dation and generalization of results.
Since we focussed on the prediction of es-
cape RBC transfusion using clinical informa-
tion available at 12-24 hours after delivery 
we did not account for all known causes 
of escape RBC transfusions. For example, 
secondary postpartum hemorrhage, infec-
tions and retained products of conception 
are known to be associated with escape 
RBC transfusion, but are not available within 
12-24 hours after delivery. Therefore, at the 
time point 12-24 hours after delivery, it is im-
possible to predict all escape RBC transfu-
sions: in this study 14 (19%) of the women 
who received escape RBC transfusion were 
reported to have suffered from secondary 
postpartum hemorrhage, (treatment for) re-
tained products of conception or infections 
(e.g. endometritis, urinary tract infection or 
fever without known cause). Anemic com-
plaints were reported as only cause in 50 
(67%), while the reason for escape RBC 
transfusion was unknown in 11 (14%).
The identified predictors were internally vali-
dated by bootstrapping techniques. External 
validation is needed to investigate the per-
formance of the models in other populations 
before the models can be integrated in daily 
clinical practice, especially since postpar-
tum hemorrhage incidences vary across 
countries and even across regions.2,22,113 
All variables of model 1 are readily available 
in daily clinical practice in contrary to the 
HRQoL-scores identified in model 2. As the 
predictive value of model 2 was significantly 
better than that of model 1, we believe that 
once the model is externally validated, use 
of HRQoL measures in postpartum anemic 
women should be implemented to improve 
postpartum health care and complement 
clinical decision making. We are aware that 
RBC transfusion rates and protocols may 
differ from center to center and from provid-
er to provider, e.g. by age, experience and 
years out of training. An obvious way to in-
clude these differences would be to account 
for centers in a multilevel regression model. 
92
Clinical aspects of Postpartum Hemorrhage 
Therefore, center effects were investigated 
using a logistic multilevel model of mod-
el 2 whereby we fitted a random intercept 
per center. This analysis showed that the 
random intercepts of the different centers 
were not significantly different from zero for 
all centers, suggesting there is no need to 
account for differences between centers. 
Interpretation
Model 1 demonstrated that escape RBC 
transfusion is more likely in primiparous 
women, after multiple pregnancy, in case 
of total blood loss above 1500 mL and less 
likely in case of a higher Hb concentration. 
These findings were expected: both primipa-
rous as women giving birth to multiples may 
experience more difficulties coping with the 
new situation after giving birth, possibly al-
tering the need for escape RBC transfusion. 
Also, a higher need for escape RBC trans-
fusion could be expected based on higher 
total blood loss and lower Hb concentration 
(12-24 hours after delivery). 
Model 2 showed that escape RBC trans-
fusion is more likely in women with higher 
physical fatigue and less motivation while 
it was less likely in case of a poorer score 
on reduced activity and better EuroQol-5D 
VAS score (e.g. better well-being). Of these 
findings, results on the subscales physical 
fatigue and reduced motivation were ex-
pected, in contrary to findings regarding the 
MFI subscale reduced activity and the Euro-
Qol-5D VAS score. In case of higher reduced 
activity score (worse HRQoL), the chance at 
escape RBC transfusion decreases while 
the contrary was to be expected. A possible 
explanation for this finding is that less ac-
tive women might experience fewer anemic 
complaints. The EuroQol-5D VAS had a beta 
of -0.01 and an OR of 0.99, implying low to 
no clinical relevance. 
The estimated probability of escape RBC 
transfusion ranged from 0.9 to 55.7% for 
model 2. Given that the incidence of escape 
RBC transfusion in the entire study popu-
lation was 12%, this range of probabilities 
indicates that the model may be of high val-
ue in daily clinical practice. Both prediction 
models provide the ability to make informed 
choice for all postpartum anemic women 
following postpartum hemorrhage, whereas 
this was previously not possible. Identifica-
tion of women with either a very low or very 
high risk of escape RBC transfusion may 
greatly improve counseling of these patients 
and clinical decision making. In daily clinical 
practice, considering risk at adverse events 
and costs, an unnecessarily prescribed RBC 
transfusion is worse than an escape RBC 
transfusion. While the chance of escape 
RBC transfusion is 12% in case of expectant 
policy, the clinician wants to be rather specif-
ic than sensitive in the decision to prescribe 
RBC transfusion directly postpartum.
Conclusion
Independently clinical predictors of escape 
RBC transfusion in women following post-
partum hemorrhage, initially treated by ex-
pectant management, are primiparity, multi-
ple pregnancy, blood loss > 1500 mL and 
lower Hb concentration (12-24 hours after 
delivery). Use of the MFI subscales physical 
fatigue, reduced activity and reduced moti-
vation and the EuroQol-5D VAS score sig-
nificantly improve prediction of escape RBC 
transfusion in these women. 
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After external validation and proof of gen-
eralizability, our formulas predicting escape 
RBC transfusion may be of great value in 
obstetric daily clinical practice and use of 
HRQoL measures should be implemented.
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abstract 
Background 
Red blood cell (RBC) transfusion is frequent-
ly used to treat women with acute anemia 
after postpartum hemorrhage. We aimed to 
assess the economic consequences of RBC 
transfusion compared to non-intervention in 
these women.
Methods 
A trial-based cost-effectiveness analysis 
was performed alongside the ‘Well-Being of 
Obstetric patients on Minimal Blood trans-
fusions’ (WOMB) trial. Women with acute 
anemia (hemoglobin 4.8 to 7.9 g/dL [3.0 to 
4.9 mmol/L]) after postpartum hemorrhage, 
without severe anemic symptoms, were 
randomly allocated to RBC transfusion or 
non-intervention. Primary outcome of the tri-
al was physical fatigue (Multidimensional Fa-
tigue Inventory, scale 4 to 20; 20 represents 
maximal fatigue). Total costs per arm were 
calculated using a hospital perspective with 
a six weeks time horizon. 
results 
Per woman, mean costs in the RBC transfu-
sion arm (n = 258) were €1957 compared to 
€1708 in the non-intervention arm (n = 261) 
(p = 0.024). The 13% difference in costs be-
tween study arms predominantly originated 
from costs of RBC units, as costs of RBC 
units were six times higher in the RBC trans-
fusion arm. RBC transfusion led to a small 
improvement in physical fatigue of 0.58 
points per day, thus, the costs to improve 
the physical fatigue score with one point 
would be €431. 
Conclusion 
In women with acute anemia after PPH, 
RBC transfusion is on average €249 more 
expensive per woman than non-intervention, 
with only a small gain in health-related qual-
ity of life after RBC transfusion. Taking both 
clinical and economic consequences into 
account, implementation of a non-interven-
tion policy seems justified.
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Introduction 
The use of blood components imposes a 
substantial economic burden and can gen-
erate (severe) adverse events.94 Severe post-
partum hemorrhage (PPH), defined as blood 
loss of at least 1000 mL during delivery,1 
complicates 1.9% of all deliveries worldwide2 
and represents the most important cause of 
acute anemia postpartum. PPH is common-
ly treated by red blood cell (RBC) transfu-
sion.67 Following the acute phase of PPH, 
however, the effectiveness of RBC transfu-
sion policy remains controversial and a wide 
variation in daily clinical practice exists. We 
recently performed a randomized controlled 
trial on the effectiveness of RBC transfusion 
in women with acute anemia after PPH: the 
‘Well-being of Obstetric patients on Minimal 
Blood transfusions’ (WOMB) trial. 
In that trial, we found that RBC transfusion 
led to a small improvement in physical fa-
tigue scores while physical complications 
were comparable between both study 
arms.88 Since the benefit of RBC transfusion 
on physical fatigue was only small, insight 
in the costs contributes to the decision for 
transfusion or no transfusion. At present, 
evidence on costs and cost-effectiveness of 
management of women with acute anemia 
after PPH is limited. In this paper, we report 
on the results of the economic evaluation 
that we conducted alongside the WOMB 
trial. This cost-effectiveness analysis com-
pares direct costs of RBC transfusion with 
non-intervention in women with acute ane-
mia after PPH.
Materials and methods 
Population 
This cost-effectiveness analysis was linked 
to the WOMB trial. Full details of the WOMB 
trial were reported previously.89 The trial 
was approved by the University of Rotter-
dam’s Institutional Review Board (MEC-
2003-247), and had local approval from the 
boards of all participating hospitals. The trial 
has been registered at ClinicalTrials.gov as 
NCT00335023.
In short, the study was a multicenter non-in-
feriority randomized trial conducted from 
2004 to 2011 in 37 hospitals in the Neth-
erlands (Appendix S1). Women with acute 
anemia, defined as a hemoglobin (Hb) con-
centration between 4.8 and 7.9 g/dL (3.0 
to 4.9 mmol/L), after PPH were allocated to 
either RBC transfusion or non-intervention. 
In women allocated to RBC transfusion, the 
target was to transfuse up to an Hb con-
centration of at least 8.9 g/dL (5.5 mmol/L). 
In the non-intervention arm, the use of iron 
and/ or folic acid supplementation accord-
ing to local protocol was allowed and a RBC 
transfusion was prescribed only if clinically 
indicated. Women who declined randomiza-
tion, but gave authorization for use of their 
medical records, were treated according to 
one of the two protocols at the discretion 
of the attending obstetrician. Data of these 
non-randomized women were registered 
to compare them with data of randomized 
women.
We used internationally validated health-re-
lated quality of life (HRQoL) measures, 
among which the Multidimensional Fatigue 
Inventory (MFI) and the EuroQol-5D. The 
MFI is a domain-specific measure for physi-
cal and mental fatigue with five dimensions: 
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general fatigue, physical fatigue, reduced 
activity, reduced motivation, and mental fa-
tigue. MFI scores range from 4 to 20 (20 rep-
resents maximal fatigue). The EuroQol-5D is 
a generic questionnaire consisting of a short 
questionnaire (index score) and a visual an-
alogue scale (VAS), that represents the pa-
tient’s value of their own health state (score 
0-100, 100 represents best health state). All 
measures were completed at inclusion (12-
24 hours after delivery) and 3 days, 1 week, 
3 weeks and 6 weeks postpartum. 
The primary outcome of this trial was phys-
ical fatigue three days postpartum, mea-
sured by the MFI. Secondary outcomes 
were remaining HRQoL scores, transfusion 
reactions, and physical complications until 
six weeks postpartum. The pre-specified 
non-inferiority boundary of physical fatigue 
was 1.3 and had been determined based on 
results of a pilot study.154 Five hundred wom-
en had to be randomized to exclude such a 
difference. 
economic evaluation 
A cost-effectiveness analysis was performed 
alongside the trial, using a hospital perspec-
tive and a time horizon from 12-24 hours 
postpartum to six weeks postpartum. For 
analyses, all unit costs were calculated in 
2011 Euros, as 2011 was the last year in 
which the trial was conducted. Costs were 
than updated to 2013 using the consumer 
pricing index. 
resource use and unit costs
Health care utilization was documented in 
the Case Record Form. The following items 
were collected: length of hospital stay in 
days, readmission in days, daycare, visits 
outpatients clinic, phone consultation, units 
of RBC transfused, consultation of other 
medical specialists, iron and folic acid sup-
plementation (daily dose and duration) and 
physical complications until six weeks post-
partum. 
Costs associated with health care utilization 
were calculated by multiplying volumes of 
resource use by unit costs of that item. A 
gross costing method was used to estimate 
costs. 
Unit costs were estimated using the Dutch 
Costing manual,155 standardized prices156 
and tariffs and data from the financial de-
partment of the Erasmus MC. Prices de-
rived from the Dutch Costing manual155 were 
used for costs of admission, readmission, 
daycare, outpatient clinic visits and phone 
consultations, estimated costs for laboratory 
use156 were added to costs for (re)admission 
and outpatient clinic visits, as costs for spe-
cialist care155 and medical surgeries156 were 
added to daycare costs.155 Standardized 
prices156 were used for costs of consulta-
tions of other medical specialists and med-
ical surgeries. RBC transfusion costs were 
calculated by using the bottom-up method 
as described in the Dutch costing manu-
al:155 costs for nursing hours and laboratory 
were added to transfusion costs. The num-
ber of nursing hours was estimated based 
on a protocol for nurses made available by 
the obstetric department of the Erasmus 
MC. The number of laboratory tests after 
RBC transfusions depended on the number 
of packed cells. The hourly cost of nurses 
was derived from Dutch costing manual.155 
Costs for iron supplementation were based 
on medicine prices derived from the Dutch 
website for costs of medication, Medicijn-
kosten.nl.157 In case of a missing daily dose 
and/ or duration of iron supplementation, we 
imputed the mean of the specific study arm. 
99
Chapter 4.5 - Cost-effectiveness of red blood cell transfusion versus non-intervention in women with  
acute anemia after postpartum hemorrhage
4
In case iron supplementation was admin-
istered at the hospital, nursing hours were 
added (as with RBC transfusion). Use for 
folic acid supplementation was estimated 
to be 0.5 mg daily.158 Costs were based on 
those from Medicijnkosten.nl.157
Considering complications: costs for throm-
boembolic events or pulmonary embolisms 
were derived from Dutch standardized pric-
es.156 Costs for infections (wound infections, 
urinary tract infections, endometritis, fever 
without known cause, pneumonia and mas-
titis) were based on estimated use of anti-
biotics: prices for medication were based 
on those from Medicijnkosten.nl.157 Please 
note that costs for (re)admission, outpatient 
visits, consultations of medical specialists 
and phone consultations were not included 
in the costs per complication and thus were 
calculated separately. Estimates for direct 
costs of postpartum depression were made 
available by the financial department of the 
Erasmus MC. Costs for retained products 
of conception were based on estimated 
medication use and costs157 while operative 
removal costs were based on Dutch stan-
dardized prices.156 Costs of the remaining 
complications (urinary tract infection, endo-
metritis, fever without known cause, pneu-
monia and mastitis with admission) were 
calculated bottom-up by adding costs for 
medication157 and estimated laboratory156 to 
costs for (re)admission days. 
In case of missing data regarding admission 
days (n = 7), we imputed the mean number of 
days of that specific study arm. With respect 
to a missing daily dose and/ or duration of 
iron supplementation, we imputed the mean 
of the specific study arm. Details regard-
ing use of folic acid supplementation were 
inaccurately registered and therefore daily 
dose and duration according to protocol 
were used to estimate costs. 
Statistical analysis
Normality of data was determined using the 
Shapiro-Wilk’s test and visual assessment. 
Categorical data are presented as num-
bers with percentages, and numerical data 
are presented as means ± SDs (normally 
distributed) or medians with IQRs (not nor-
mally distributed). Unit and total costs are 
presented in means as well as in medians: 
as data are not normally distributed, medi-
ans represent the best average. However, in 
cost-effectiveness analyses means are used 
for more extended calculations as these re-
sults are more trustworthy than calculations 
performed with medians. As we intended 
to present the most accurate average but 
also used means for further calculations, 
we chose to present both. Mean costs per 
woman for each study arm and mean dif-
ferences in costs between study arms were 
estimated. The 95% confidence intervals 
around the costs were determined by boot-
strapping. HRQoL figures were created us-
ing raw data for baseline HRQoL values and 
estimated means, after adjustment for base-
line and mode of delivery (Repeated Mea-
surements ANOVA), for all other time points. 
Cost-effectiveness was expressed as differ-
ences in HRQoL scores (physical fatigue, 
EuroQol-5D index score and EuroQol-5D 
VAS score) between study arms, per day: we 
calculated the difference in area under the 
curve of each HRQoL score between study 
arms and divided this difference by amount 
of days, using the time horizon of 42 days. 
For calculation of the area under the curve 
we used raw data for baseline HRQoL val-
ues and estimated means, after adjustment 
for baseline and mode of delivery (Repeated 
Measurements ANOVA), for all other time 
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points. Robustness of the findings to unit 
cost estimates were evaluated in sensitivity 
analyses. We created tornado diagrams to 
investigate and illustrate sensitivity of results, 
varying those costs with the highest impact 
on total costs per woman by 50%. Statisti-
cal, economic and sensitivity analyses were 
performed using SPSS software (version 
20.0, SPSS Inc., Chicago, IL, USA) and Mic-
rosoft Excel 2007.
results 
For the cost analysis, data of all 521 ran-
domized women were available; 259 had 
been allocated to RBC transfusion and 262 
to non-intervention. In both arms one wom-
an was excluded because she did not meet 
inclusion criteria. Baseline characteristics of 
all women included in analyses are demon-
strated in Table 1. Baseline characteristics 
of women that declined informed consent 
though participated as non-randomized 
women, were previously presented. Com-
pared to randomized women, these women 
were less often of Western ethnicity.88
 
A summary of the trial results is provided in 
Table 2. The most notable differences in out-
come between study arms were obviously 
present in the use of RBC units. As expect-
ed, a significant higher percentage of wom-
en in the non-intervention arm crossed over: 
13% of women in the non-intervention arm 
received RBC units during follow-up. Also, 
the rate of readmission was higher among 
women allocated to non-intervention. 
Physical complications were compara-
ble between study arms. Figure 1 shows 
HRQoL scores. The difference in physical 
fatigue score between study arms, adjust-
ed for baseline and mode of delivery, was 
significant at day 3 and 1 week postpartum; 
while a significant difference in estimated 
EuroQol-5D index score was found at day 3 
postpartum. No significant differences were 
found for the EuroQol-5D VAS score. 
 
Costs 
Units of resource use and unit costs are 
presented in Table 3; the mean and medi-
an costs per resource volume per woman 
are presented in Table 4. Mean costs of 
women allocated to non-intervention were 
€1708 (95% CI: €1546 - €1889) compared 
to €1957 (95% CI: €1835 - €2094) in wom-
en allocated to RBC transfusion (p = 0.024). 
Largest differences between study arms 
were found for costs of RBC transfusion 
while costs of readmission also differed. 
HrQoL and cost-effectiveness
Investigating the difference in HRQoL scores 
per day between RBC transfusion and 
non-intervention (see Statistical Analysis), 
we found that physical fatigue score (scale 
4-20, 20 represents maximal fatigue) was 
0.58 points/day lower in the transfusion arm 
than in the non-intervention arm. The Euro-
Qol-5D index score (scale 0-100, represents 
best health state) was 3.6 points/day higher 
in the RBC transfusion arm. The EuroQol-5D 
VAS score (scale 0-100, 100 represents 
best health state) was 1.3 points/day high-
er in the transfusion arms. The total price to 
improve HRQoL per day to this extent was 
€250. Thus, improvement of physical fatigue 
with one point costs €431. 
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Table 1 Basic characteristics. 
Non-intervention 
(n = 261)
Transfusion 
(n = 258)
Variable
Age (years), mean ± SD 30.9 ± 5.3 30.7 ± 5.0
Preconceptional body mass indexa 22.9 (20.8 to 26.5) 23.3 (21.1 to 26.6) 
Western ethnic originb 177 (76%) 186 (78%)
Highest educationc
   none/ primary school 5 (3%) 4 (3%)
   lower/ senior secondary 
   vocational education
77 (51%) 88 (56%)
   higher professional education and university 70 (46%) 64 (41%)
Primiparous 143 (55%) 152 (59%)
Mode of delivery 
   vaginal 206 (79%) 213 (83%)
   elective CS 15 (6%) 8 (3%)
   emergency CS 40 (15%) 37 (14%)
Twin pregnancies 16 (6%) 13 (5%)
Gestational age (weeks+days) 40+0 (38+3 to 41+0) 40+1 (38+5 to 41+1)
Birth weight neonated
   < 10th percentile 20 (8%) 8 (3%)
   10 ≤ percentile ≤ 90 189 (74%) 188 (75%)
   > 90st percentile 47 (18%) 54 (22%)
Estimated blood loss during delivery (mL) 1500 (1000, 1975) 1485 (1000, 1950)
Hb concentration at inclusion (g/dL) 7.4 (6.8 to 7.7) 7.3 (6.8 to 7.7)
Median (IQR) presented unless otherwise specified. CS = cesarean section. an = 234 and n = 232 respectively. bn = 232 
and n = 239 respectively. cn = 152 and n = 156 respectively. dn = 256 and n = 250 respectively. 
Sensitivity analysis
In Figure 2 the sensitivity analysis is illustrat-
ed. Altering admission costs had the largest 
influence on total costs: if the admission 
costs are decreased or increased with 50%, 
total costs would range from €666 to €1372. 
By halving or doubling RBC transfusion 
costs, total costs ranged from respectively 
€931 to €1107. Altering prices of costs by 
25% would lead to similar ranking of devia-
tion in total costs. By decreasing or increas-
ing admission costs with 25%, total costs 
would range from €842 to €1196 while alter-
ing transfusion costs with 25% would lead 
to total costs ranging from €975 to €1064.
additional analyses
The majority of women had Hb concentra-
tions 12-24 hours after delivery in relative-
ly higher ranges. A subgroup analysis was 
performed to investigate the total costs per 
woman for each Hb concentration (12-24 
hours after delivery) quartile. Median costs 
for the quartiles Hb concentration < 6.8 g/dL, 
6.8-7.2 g/dL, 7.3-7.7 g/dL and > 7.7 g/dL 
were for the non-intervention arm €1417, 
€1114, €1193 and €1617, respectively, and 
for the RBC transfusion arm respectively 
€1790, €1651, €1651 and €1769. 
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Figure 1 The HRQoL scores physical fatigue (A) and EuroQol-5D (EuroQol-5D index score and 
 VAS) (B) during follow-up.
Figure 2 Tornado diagram.
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Table 2 Results trial. 
  Non-intervention
(n = 261)
Transfusion
(n = 258)
Variable
Red blood cell units per woman
   median (IQR) 0 (0-0) 2 (2-2)†
   mean (SD) 0.34 (1.0) 2.0 (0.7)
Crossover, n (%)a 33 (13%) 7 (3%)†
Length of hospital stay
   median (IQR) 2 (1-4) 2 (1-3)
   mean (SD) 2.6 (1.8) 2.4 (1.5)
Readmission or daycare, n (%) 18 (7%) 6 (2%)*
   median (IQR) 0 (0-0) 0 (0-0)*
   mean (SD) 0.3 (1.2) 0.1 (0.8)
Outpatient clinic visits, n (%) 192 (74%) 200 (78%)
   median (IQR) 1 (1-1) 1 (1-1)
   mean (SD) 0.9 (0.8) 0.9 (0.7)
Visits to medical specialist (other than gynecologist), n (%) 4 (2%) 6 (2%)
   median (IQR) 0 (0-0) 0 (0-0)
   mean (SD) 0.03 (0.2) 0.03 (0.2)
Phone consultations, n (%) 12 (5%) 8 (3%)
   median (IQR) 0 (0-0) 0 (0-0)
   mean (SD) 0.06 (0.1) 0.04 (0.2)
Maternal complications
   thromboembolic event 0 2 (2%)
   pulmonary embolism 2 (0.8%) 0
   urinary tract infection 14 (5%) 11 (4%)
   treated by hospital 11 (4%) 6 (2%)
   endometritis 3 (1%) 5 (2%)
   fever without known cause 4 (2%) 3 (1%)
   pneumonia 1 (0.3%) 0
   mastitis (with admission) 1 (0.3%) 0
   postpartum depression 0 1 (0.4%)
   retained products of conception
   medication 1 (0.3%) 2 (0.8%)
   operative 10 (4%) 2 (0.8%)
aInitially or during follow-up. 
*p < 0.05, †p < 0.01.
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Table 3 Cost-analysis: resource use and unit costs. 
Unit Costs, 2013 €
Admission
Admission day 502.64
Readmission day 524.37
Daycare day 300.38
RBC transfusion 1 unit 290.48
2 units 537.15
3 units 783.80
4 units 1070.18
5 units 1316.85
10 units 2621.66
Consultation medical specialist (other than gynecologist) consultation 97.53
Outpatient clinic
Outpatient visit visit 107.79
Phone consultation consultation 15.24
Consultation other specialist consultation 97.53
Medication follow-up
Iron supplementation administered at hospital
   ferrioxidesaccharate first dose, 200 mg 92.37
each following dose 59.37
   ferric carboxymaltose first dose, 100 mg 73.61
each following dose 40.60
first dose, 500 mg 199.12
each following dose 166.12
Iron supplementation by formulation
   ferrous fumarate tablet 200 mg 0.02
   ferrous sulfate tablet 105 mg 0.08
   ferrous gluconate tablet 80 mg 0.22
Folic acid supplementation tablet 0.5 mg 0.03
Medication and specialist care for physical complications
   thromboembolic event 3476.81
   pulmonary embolism 4415.18
Medication for physical complications 
   urinary tract infection 8.46
   endometritis 44.70
   fever without known cause 46.80
   pneumonia 36.03
   mastitis 10.28
Postpartum depression 1556.69
Retained products of conception
   removal by medication 11.70
   operative removal 478.17
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Table 4 Comparison of costs between Non-intervention and RBC transfusion. 
Non-intervention Transfusion
Mean costs per 
woman (€)
Median costs 
per woman (€)
Mean costs per 
woman (€)
Median costs per 
woman (€)
Admission 1324.56 1005.27 1217.16 1005.27
Readmission and daycare 135.20 0 52.85 0
Outpatient clinic 94.16 107.79 95.68 107.79
Phone consultation 0.87 0 0.54 0
RBC transfusion 89.44 0 546.11 537.15
Consultation other medical  
specialist
0.75 0 1.89 0
Iron supplementation 6.39 0.24 0.08 0
Folic acid supplementation 1.16 1.29 - -
Complications total 55.42 0 43.24 0
Total (95% CI of the mean) 1707.95 
(1545.99-1889.19)
1212.15 1957.60
(1835.10-2093.81) 
1650.41
95% Confidence Intervals calculated using bootstrap.
Analyses repeated after exclusion of wom-
en who had not completed the physical fa-
tigue score at day 3 (primary outcome in the 
WOMB trial) demonstrated similar costs per 
women (median costs for the non-interven-
tion and RBC transfusion arms €1217 and 
€1652, respectively) and similar differences 
between study arms. 
Discussion 
This study assessed the economic con-
sequences of a RBC transfusion versus 
non-intervention strategy in women with 
acute anemia after PPH, taking into account 
direct medical costs. We showed that mean 
costs were €250 higher in women random-
ized to RBC transfusion than in women ran-
domized to non-intervention. All outcome 
measures were comparable between study 
arms, except for RBC units transfused and 
readmission rate. The readmission rate in the 
non-intervention arm was threefold higher 
though this was outweighed by the six-fold 
lower use of RBC units (88 versus 517 units). 
In search for an explanation of the difference 
in readmission rates (data not shown), we 
found that basic characteristics were not 
significantly different between study arms, 
though RBC units and crossovers were 
(p < 0.001). Additional testing showed that 
these two variables were also significantly 
related to readmission and therefore seem 
explanatory (p = 0.005 and p < 0.001, re-
spectively). Retained products of conception 
may also play a role as 46% of all patients 
randomized to non-intervention with re-
tained products of conception crossed over 
(p = 0.002). Overall, the difference in costs 
between study arms predominantly origi-
nated in costs of RBC units. Our sensitivity 
analyses demonstrated that total costs were 
influenced mostly by costs of admission. 
Mean costs generated by non-intervention 
were €250 lower than costs generated by 
RBC transfusion. The occurrence of retained 
products of conception was remarkably 
higher in the non-intervention arm (dimin-
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ishing the difference in costs between study 
arms). These differences in retained prod-
ucts of conception between study arms 
were however not significant (p = 0.1). As 
the incidence of retained placenta products 
is assumed to be unrelated to treatment al-
location, we believe this is a chance coin-
cidence. The optimal transfusion policy was 
previously studied in trials among intensive 
care and orthopedic patients.97,102 A liberal 
transfusion policy was not beneficial com-
pared to a restrictive policy regarding clinical 
parameters. Moreover, a recent meta-analy-
sis demonstrated a reduced risk of infection 
among hospitalized patients with a restric-
tive RBC transfusion strategy compared 
with a liberal transfusion strategy.159 HRQoL 
was not investigated in these studies. Lit-
tle is known about the treatment costs and 
quality of life of women after postpartum 
hemorrhage.
Considering HRQoL results, the WOMB tri-
al demonstrated that physical fatigue was 
significantly lower in women randomized to 
RBC transfusion up to one week postpar-
tum (maximal difference 1.06 at one week 
postpartum).88 However, significance does 
not indicate that this difference is clinical-
ly relevant. Regarding the MFI subscales, 
the minimal clinical important difference 
has only been determined in radiotherapy 
women, where it was set at 2.04 for the 
subscale physical fatigue.95 Regarding the 
EuroQol-5D, the minimal clinical important 
difference was estimated at average 7.4,160 
indicating that no clinical relevant differences 
were detected between study arms during 
this study. However, for none of the HRQoL 
measures a minimal clinical important differ-
ence has been determined in obstetric pa-
tients. 
To optimize health care in postpartum ane-
mic women, benefits of RBC transfusion 
(HRQoL) should be considered opposed to 
disadvantages like costs and risks of trans-
fusion reactions14,71,161 RBC transfusion led 
to an improvement of 0.58 points in physical 
fatigue per day; average costs to improve 
physical fatigue score with one point daily 
are therefore €431 per woman. In this study, 
three (mild) transfusion reactions were ob-
served, all in the RBC transfusion arm.88 
Limitations in this study are the following. 
Women included in the WOMB trial present 
a skewed Hb concentration after delivery 
with most women in the higher Hb rang-
es. We assume this results from exclusion 
of women with previous (recent) transfusion 
and/ or symptoms of severe acute anemia 
and therefore believe our study population 
is a good representation of women eligible 
for non-intervention in daily clinical practice. 
The lower Hb threshold in this study was 
formulated on request of the Institutional 
Review Board; in the original protocol no 
lower threshold was defined. Results of the 
subgroup analyses regarding Hb concentra-
tion 12-24 hours after delivery demonstrated 
no obvious trends towards lower or higher 
costs in case of differing Hb concentration. 
Data were primarily registered to determine 
differences in HRQoL between study arms 
and therefore some variables were not col-
lected in as much detail as preferable for 
cost-effectiveness analyses. It is possible 
that women were admitted for a longer 
period of time not for their own health but 
because of admission of the neonate. Un-
fortunately, reasons for admission were 
not registered in this trial. However, since 
length of hospital stay was not significantly 
different between study arms, the influence 
of this limitation seems minimal. Also, the 
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assumption was made that women who had 
not been admitted to hospital after delivery, 
had not suffered from complications that in-
flected direct medical costs. Some compli-
cations, known to be treated by the general 
practitioner, were not taken into account in 
this study. Costs of complications will there-
fore be underestimated if considered from a 
societal point of view. The time horizon used 
in this cost-effectiveness analysis has been 
limited to six weeks postpartum and costs 
were evaluated from a medical perspective. 
This was explicitly done because detailed 
information was available on both medical 
costs and effects from the WOMB trial. 
The prospective design, the large number of 
women and diversity of participating hospi-
tals, the well-organized structure of random-
ization and data collection within the Dutch 
Obstetric Consortium are strengths of this 
trial: although not tested, these are likely to 
extend both the internal and external validi-
ty of our results in Dutch non-symptomatic 
anemic women.
RBC transfusion in women with acute 
non-symptomatic anemia (Hb concentration 
4.8 to 7.9 g/dL) after PPH only leads to a 
small improvement of physical fatigue. The 
results as described in this economic evalu-
ation study indicate that this strategy is also 
associated with higher costs per woman. In 
conclusion, in otherwise healthy women with 
acute non-symptomatic anemia RBC trans-
fusion is found to be a more costly strategy 
with only marginal gain in HRQoL compared 
to non-intervention. 
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Appendix S1 Participating hospitals in the WOMB trial
Participating hospital City
Academic Medical Center Amsterdam
Albert Schweitzer Hospital Dordrecht
Amphia Hospital Breda 
Atrium Hospital Heerlen
Bronovo Hospital Den Haag
Canisius Wilhelmina Hospital Nijmegen
Deventer Hospital Deventer
Diakonessen Hospital Utrecht
Elkerliek Hospital Helmond
Erasmus Medical Center Rotterdam
Flevo Hospital Almere
Gelderse Vallei Hospital Ede
Gelre Hospital Apeldoorn
Gemini Hospital Den Helder
Groene Hart Hospital Gouda
Haga Hospital Den Haag
Ikazia Hospital Rotterdam
Jeroen Bosch Hospital s-Hertogenbosch
Kennemer Gasthuis Haarlem
Lange Land Hospital Zoetermeer
Leiden University Medical Center Leiden
Maasstad Hospital Rotterdam
Maasziekenhuis Pantein Boxmeer
Martini Hospital Groningen
Máxima Medical Center Veldhoven
Meander Medical Center Amersfoort
Medical Center Leeuwarden Leeuwarden
Mesos Medical Center Nieuwegein, Ouderijn
Onze Lieve Vrouw Gasthuis Amsterdam
Radboud University Medical Center Nijmegen
Reinier de Graaf Gasthuis Delft
Scheper / Leveste Hospital Emmen
Spaarne Hospital Hoofddorp
St. Elisabeth Hospital Tilburg
St. Fanciscus Gasthuis Rotterdam
St. Lucas Andreas Amsterdam 
University Hospital Maastricht Maastricht
University Medical Center Utrecht Utrecht
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abstract 
Objective 
To determine the influence of socio-demo-
graphic, clinical parameters and obstetric 
complications on postpartum health-related 
quality of life (HRQoL). 
Methods 
We used data of three randomized controlled 
trials to investigate HRQoL determinants 
in women after an obstetric complication. 
The DIGITAT and HYPITAT trials compared 
induction of labor and expectant manage-
ment in women with intra-uterine growth re-
striction (IUGR) and hypertensive disorders. 
The WOMB trial randomized anemic women 
after postpartum hemorrhage to red blood 
cell transfusion or expectant management. 
The HRQoL-measure ShortForm-36 was 
completed at six weeks postpartum. Multi-
variable analyses were used to identify which 
parameters affected the ShortForm-36 
physical component score (PCS) and mental 
component score (MCS).
results 
HRQoL analyses included 1391 women 
(60%) of the 2310 trial participants. HYPITAT 
and DIGITAT participants had significantly 
lower MCS scores than WOMB participants. 
In multivariable analysis, PCS after elective 
and emergency cesarean section was 5-6 
points lower than after vaginal delivery. Ges-
tational hypertension, neonatal admission 
and delivery in an tertiary hospital had a 
small negative effect on PCS. No effect was 
found for randomization status, maternal 
age, BMI, country of birth, education, parity, 
induction of labor, analgesics, birth weight, 
perineal laceration, delivery of placenta, 
postpartum hemorrhage, congenital anom-
aly, urinary tract infection, thromboembolic 
event or endometritis. MCS was influenced 
only mildly by these parameters. 
Conclusions 
IUGR and hypertensive disorders lead to 
lower HRQoL scores postpartum than PPH. 
In a heterogeneous obstetric population, 
only mode of delivery by cesarean section 
has a profound, negative impact, on physi-
cal HRQoL (PCS). No profound impacts on 
MCS were detected.
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Introduction 
Health-related quality of life (HRQoL) post-
partum is potentially influenced by socio-de-
mographic parameters as well as by clinical 
parameters and obstetric complications. 
Socio-demographic parameters described 
to influence HRQoL postpartum negatively 
are black ethnicity,162 low education,163 low 
income164 and large number of children at 
home.164 A supportive social network influ-
ences postpartum HRQoL positively.68,62,165 
Common obstetric complications are in-
tra-uterine growth restriction (IUGR), hy-
pertensive disorders of pregnancy and 
postpartum hemorrhage (PPH).3,34,166 Preg-
nancies with these complications are at in-
creased risk for neonatal and/ or maternal 
morbidity and mortality.1,167-169 Poor physical 
and mental health have been described in 
mothers with obstetric complications like 
preterm birth.170-172 HRQoL is also compro-
mised in women with postpartum compli-
cations like postpartum depression,68,173,174 
pregnancy-related deep vein thrombosis163 
and urinary and/ or fecal incontinence.175-179 
Recently, three multicenter trials were con-
ducted that investigated maternal and/ or 
neonatal outcomes and measured HRQoL 
in the postpartum period. The DIGITAT and 
HYPITAT trial primarily investigated the effect 
of induction of labor on neonatal and mater-
nal outcome in pregnancies complicated by 
respectively IUGR and hypertensive disor-
ders.180,181 The WOMB trial primarily studied 
the effect of red blood cell (RBC) transfusion 
on physical fatigue in women after PPH.88 
The availability of such large number of 
postpartum HRQoL data provided a unique 
opportunity to assess which parameters 
influence postpartum HRQoL after obstet-
ric complications by combining data of the 
three trials.
We hypothesized that several socio-demo-
graphic and clinical parameters, as well as 
obstetric complications, affect postpartum 
HRQoL. Insight in these parameters will con-
tribute to postpartum care and will provide 
the opportunity to develop individual strate-
gies after obstetric complications. 
Methods
We used data of three randomized con-
trolled trials: the DIGITAT, HYPITAT and 
WOMB trial. Details of these studies and 
their ethic approval have been previously 
published.89,182,183 The trials were conduct-
ed within the Dutch Obstetric Consortium 
(http:/www.studies-obsgyn.nl/). In the DIG-
ITAT, HYPITAT and WOMB trial 52, 38 and 
37 Dutch hospitals participated, respec-
tively. In each trial, women who refused 
randomization were asked to participate as 
non-randomized women. Results of the tri-
als have been described elsewhere.88,180,181 
The ‘Disproportionate Intrauterine Growth 
Intervention Trial At Term’ (DIGITAT) included 
women with a singleton pregnancy, a fetus 
in cephalic presentation, between 36+0 and 
41+0 weeks gestational age, with suspect-
ed IUGR (defined as fetal abdominal circum-
ference below the 10th percentile, estimated 
fetal weight below the 10th percentile and/ 
or a decreased relative growth).180 Women 
were allocated to induction of labor or ex-
pectant management. Primary outcome 
was composite neonatal adverse outcome. 
The ‘Hypertension and Pre-eclampsia Inter-
vention Trial At Term’ (HYPITAT) had a similar 
design and included women with a single-
ton pregnancy, a fetus in cephalic presen-
tation, between 36+0 and 41+0 weeks of 
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gestation, complicated by gestational hyper-
tension (defined as diastolic blood pressure 
≥ 95 mmHg, measured on two occasions, 
at least 6 hours apart) or mild pre-eclamp-
sia (defined as diastolic blood pressure ≥ 90 
mmHg measured on two occasions, at least 
6 hours apart, combined with ≥ 2+ protein 
on dipstick, > 300 mg total protein within 
24 h urine collection or protein/creatinine 
ratio > 30 mg/mml).181 Again, women were 
allocated to induction of labor or expectant 
management. Primary outcome was a com-
posite measure of poor maternal outcome. 
The ‘Well-being of Obstetric patients on 
Minimal Blood transfusions’ (WOMB) stud-
ied women after PPH (defined as peripartum 
blood loss ≥ 1000 mL and/ or decrease in 
Hb concentration ≥ 1.9 g/dL), with an Hb 
concentration between 4.8 and 7.9 g/dL 
(3.0-4.9 mmol/L) 12 to 24 hours after de-
livery. Women were allocated to RBC trans-
fusion or expectant management. Primary 
outcome was physical fatigue at day 3 post-
partum, measured by the HRQoL measure 
Multidimensional Fatigue Inventory. 
Six hundred fifty-eight DIGITAT women 
(60%), 818 HYPITAT women (71%) and all 
WOMB women participated in the HRQoL 
study. Questionnaires were completed at 
several time points; the only common time 
point in the trials was six weeks postpartum. 
Each trial used the SF-36 version 1 (SF-36), 
a generic HRQoL measure with eight scales 
(physical functioning, role limitations due 
to physical health problems [role-physical], 
bodily pain, general health perception, vi-
tality, social functioning, role limitations due 
to emotional health [role-emotional], and 
mental health) ranging from 0 to 100; higher 
scores indicate better well-being. The SF-36 
has been validated in a random nationwide 
sample of the adult Dutch population.93 For 
this study, age and gender matched refer-
ence scores were provided by this research 
group (unpublished data based on 367 
women aged from 16 to 40 years, Aaron-
son et al.). The pilot study of the WOMB 
trial69 provides postpartum reference scores 
based on 141 women that subsequently de-
livered in three Dutch hospitals. 
The SF-36 allows for computation of the 
summary scores Physical Component Score 
(PCS) and Mental Component Score (MCS). 
These are norm-based with a mean of 50 
and a standard deviation of 10, based on 
US population reference scores.184 No Dutch 
population reference scores are available for 
the summary scores.
The SF-36 is competent in the assessment 
of HRQoL differences in the postpartum pe-
riod.69,88 
Statistical analysis
We studied the PCS and the MCS at six 
weeks postpartum in women who suffered 
obstetric complications. Normality of data 
was determined by using visual assessment 
and the Shapiro-Wilk’s test. Categorical data 
are presented as numbers with percentag-
es, and numerical data are presented as 
means ± SD of the mean (normally distribut-
ed) or medians with IQRs (not normally dis-
tributed). To create a homogeneous cohort, 
women from the WOMB trial that delivered 
before 36+0 weeks of gestation and multiple 
gestations were excluded. We used multiple 
imputations to handle missing values of all 
socio-demographic and clinical parame-
ters:122 ten imputed data sets were created 
using a fully conditional specified model. 
Imputations were based on the relations 
between the covariates in the study, which 
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were used to calculate the most likely value 
for a missing response. Data were analyzed 
separately in each imputed data set to ob-
tain the effect estimates. Pooled estimates 
were generated from these ten imputed data 
sets and used to report estimates and their 
corresponding 95% confidence intervals.
SF-36 subscale scores were compared to 
Dutch population reference scores and to 
postpartum reference scores. As no Dutch 
population reference scores are available for 
the SF-36 summary scores PCS and MCS, 
these were compared to US population ref-
erence scores.184
We used univariable linear regression anal-
ysis to investigate parameters that were as-
sumed to be related to HRQoL postpartum. 
The following socio-demographic and clin-
ical parameters were analyzed: randomiza-
tion status, age, BMI, country of birth (Dutch 
versus non-Dutch), highest education, pari-
ty, hypertensive disorders, gestational age at 
birth, induction of labor, analgesics, mode of 
delivery, perineal laceration, manual placen-
ta removal, birth weight, PPH, admission of 
the neonate, congenital anomaly of the neo-
nate, urinary tract infection, thromboembol-
ic event, endometritis and hospital setting. 
To investigate the relationship of these pa-
rameters with HRQoL, we performed multi-
variable linear regression analysis, including 
those parameters with a significant relation 
to primary outcome measures in the univari-
able analyses (p < 0.10). Data were man-
aged using SPSS version 20.0. 
results
A total of 3191 women were included in the 
three trials. Figure 1 shows the flowcharts of 
this study. A total of 2310 participated: 1399 
(61%) were randomized while 911 women 
(39%) refused randomization but partici-
pated as non-randomized women. HRQoL 
data at six weeks postpartum were available 
in 1391 women as the response at this time 
point was 60% (61%, 65% and 55% in the 
DIGITAT, HYPITAT and WOMB trial, respec-
tively). We will refer to responding women as 
responders while women with no HRQoL 
data at six weeks postpartum will be referred 
to as non-responders. 
Socio-demographic and clinical para- 
meters
The mean age of women was 30 years and 
64% was primiparous. About 85% of wom-
en delivered vaginally, 46% had a hyperten-
sive disorder while 41% suffered from PPH. 
Among our study population, one maternal 
death occurred. This patient was allocated 
to induction of labor in the DIGITAT trial and 
died at home 10 days after a vaginal delivery 
of a healthy neonate. A cause for her death 
could not be found. Furthermore, one peri-
natal death occurred in the DIGITAT trial, 
among the non-randomized women. 
Table 1 shows socio-demographic and clin-
ical parameters and the differences between 
responders and non-responders. Compared 
to non-responders, responders were sig-
nificantly older, more frequently born in the 
Netherlands and had a higher education. 
Also, many differences were found in clinical 
parameters like parity, perineal laceration, 
rate of hypertensive disorders and rate of 
PPH.
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Table 1 Socio-demographic and clinical parameters. 
Total
n = 2310
Responders
n = 1391
Non-responders
n = 919
Responders vs 
Non-responders 
p-value
Socio-demographic
Maternal age in years, mean (SD) 29.9 (5.2) 30.5 (4.9) 28.9 (5.5) < 0.001
missing 7 (0.3%) 2 (0.1%) 5 (0.5%)
BMI 0.05
< 18.5 98 (4%) 59 (4%) 39 (4%)
18.5-25 1168 (51%) 698 (50%) 470 (51%)
> 25 763 (33%) 483 (35%) 280 (31%)
missing 281 (12%) 151 (11%) 130 (14%)
Country of birth < 0.001
Dutch 1838 (80%) 1199 (86%) 639 (70%)
non-Dutch 287 (12%) 111 (8%) 176 (19%)
missing 185 (8%) 81 (6%) 104 (11%)
Highest education < 0.001
none/ primary education 178 (8%) 91 (7%) 87 (10%)
secondary education 848 (37%) 506 (36%) 342 (37%)
higher professional education/ 
university
520 (23%) 376 (27%) 144 (16%)
missing 764 (33%) 418 (30%) 346 (38%)
Pregnancy
Parity 0.004
primiparous 1476 (64%) 922 (66%) 554 (60%)
multiparous 834 (36%) 469 (34%) 365 (40%)
missing 0 0 0
Hypertensive disorder < 0.001
none 1298 (56%) 747 (54%) 551 (60%)
gestational hypertension 619 (27%) 412 (30%) 207 (23%)
pre-eclampsia 373 (16%) 225 (16%) 148 (16%)
missing 20 (1%) 7 (0.5%) 13 (1%)
Delivery
Gestational age, mean (SD) 39+4 (10) 39+4 (10) 39+4 (10) 0.16
missing 0 0 0
Induction of labor 1300 (56%) 822 (59%) 478 (52%) < 0.001
none 964 (42%) 554 (40%) 410 (45%)
missing 46 (2%) 15 (1%) 31 (3%)
Mode of delivery 0.003
vaginal, spontaneous 1590 (69%) 966 (69%) 624 (68%)
vaginal, operative 346 (15%) 227 (16%) 119 (13%)
elective CS 57 (3%) 26 (2%) 31 (3%)
emergency CS 317 (14%) 172 (12%) 145 (16%)
missing 0 0 0
Fetal position 0.03
cephalic 2250 (97%) 1364 (98%) 886 (96%)
other position 20 (1%) 11 (1%) 9 (1%)
missing 40 (2%) 16 (1%) 24 (3%)
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Total
n = 2310
Responders
n = 1391
Non-responders
n = 919
p-value  
Responders vs 
Non-responders
Analgesics 0.01
none 1298 (56%) 818 (59%) 480 (52%)
opiates 288 (13%) 165 (12%) 123 (13%)
epidural/ spinal 593 (26%) 343 (25%) 250 (27%)
general anesthesia 13 (0.6%) 5 (0.4%) 8 (1%)
missing 118 (5%) 60 (4%) 58 (6%)
Birth weight 0.002
< 10th percentile 596 (26%) 362 (26%) 234 (26%)
10-90 percentile 1418 (61%) 856 (62%) 562 (61%)
> 90st percentile 266 (12%) 165 (12%) 101 (11%)
missing 30 (1%) 8 (0.6%) 22 (2%)
Perineal laceration 0.001
none or first degreea 1069 (46%) 605 (44%) 464 (51%)
second degree or higher 1228 (53%) 781 (56%) 447 (49%)
missing 13 (0.6%) 5 (0.4%) 8 (1%)
Hospital setting 0.05
tertiary 644 (28%) 367 (26%) 227 (30%)
teaching 1563 (68%) 954 (69%) 609 (66%)
non-teaching 103 (5%) 70 (5%) 33 (4%)
missing 0 0 0
Postpartum
Delivery placenta 0.13
spontaneousa 1990 (86%) 192 (14%) 124 (14%)
MPV or curettage 316 (14%) 1195 (86%) 795 (87%)
missing 4 (0.2%) 4 (0.3%) 0
PPH 940 (41%) 523 (38%) 417 (45%) 0.001
none 1339 (58%) 849 (61%) 490 (53%)
missing 31 (1%) 19 (1%) 12 (1%)
none 386 (17%) 224 (16%) 162 (18%)  0.001
RBC transfusion 1379 (60%) 873 (63%) 506 (55%)
missing 545 (24%) 294 (21%) 251 (27%)
Neonatal admission 1240 (54%) 764 (55%) 476 (52%) 0.32
none 1066 (46%) 625 (45%) 441 (48%)
missing 4 (0.2%) 2 (0.1%) 2 (0.2%)
Congenital anomaly (severe) 22 (1%) 12 (1%) 10 (1%) 0.74
none 2288 (99%) 1379 (99%) 909 (99%)
missing 0 0 0
Maternal complications
Urinary tract infection 47 (2%) 27 (2%) 20 (2%) < 0.001
none 2058 (89%) 1280 (92%) 778 (85%)
missing 205 (9%) 84 (6%) 121 (13%)
Thromboembolic event 6 (0.3%) 4 (0.3%) 2 (0.2%) < 0.001
none 2100 (91%) 1301 (94%) 799 (87%)
missing 204 (9%) 86 (6%) 118 (13%)
Endometritis 21 (1%) 11 (1%) 10 (1%) < 0.001
none 2086 (90%) 1296 (93%) 790 (86%)
missing 203 (9%) 84 (6%) 119 (13%)
aincluding cesarean sections. n (%) unless otherwise specified.
BMI = body mass index. CS = cesarean section. PPH = postpartum hemorrhage. MPV = manual placenta removal. 
RBC = red blood cell.
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Table 3 Multivariable associations between socio-demographic parameters, clinical parameters 
 and obstetric complications, and the Physical and Mental Component Score.
Physical Component Score Mental Component Score
Estimate SE p Estimate SE p
Intercept 48.142 0.975 < 0.001 53.694 0.866 < 0.001
Parameter
BMI 
< 18.5 -0.682 1.337 0.61
18.5-25 ref 1.057
> 25 -0.889 0.588 0.13
Country of birth
Dutch ref
not Dutch -1.943 0.855 0.02
Highest education
none/ primary education 0.318 1.069 0.77 -1.761 1.230 0.16
secondary education ref ref
higher professional education/ university 0.874 0.634 0.17 -0.034 0.592 0.95
Parity
primiparous ref
multiparous 1.087 0.583 0.06
Hypertensive disorder
none ref ref
gestational hypertension -1.519 0.711 0.03 0.246 0.707 0.73
pre-eclampsia -1.335 0.773 0.08 -0.144 0.782 0.85
Induction of labor
no ref ref
yes -0.161 0.517 0.76 -1.405 0.520 0.01
Mode of delivery
vaginal, spontaneous ref
vaginal, operative -0.615 0.705 0.38
CS, elective -5.566 1.868 0.003
CS, emergency -6.331 0.891 < 0.001
Analgesics
none ref
opiates -0.226 0.777 0.77
epidural/ spinal -0.066 0.626 0.92
general anesthetics -1.263 1.904 0.51
Birth weight
< 10th percentile -0.173 0.668 0.80 -0.192 0.675 0.78
10th-90st percentile ref ref
> 90st percentile -0.053 0.795 0.95 -1.172 0.788 0.14
Perineal laceration
none or first degreea ref ref
second degree or higher -0.345 0.608 0.58 0.669 0.513 0.19
Hospital setting
non-teaching 0.277 1.118 0.80 0.952 1.142 0.40
teaching ref ref
tertiary -1.174 0.565 0.04 -0.762 0.575 0.19
Delivery placenta
spontaneousa ref ref
MPV or curettage -0.473 0.809 0.56 -0.580 0.814 0.48
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Physical Component Score Mental Component Score
Estimate SE p Estimate SE p
PPH
no ref ref
yes 1.231 0.769 0.11 1.845 0.761 0.02
Neonatal admission
no ref ref
yes -1.320 0.631 0.04 -0.892 0.643 0.17
Congenital anomaly (severe)
no ref
yes -4.233 2.647 0.11
aincluding cesarean sections. 
BMI = body mass index. CS = cesarean section. MPV = manual placenta removal. PPH = postpartum hemorrhage.
Health-related quality of life
Table 2 demonstrates the SF-36 scores 
(total and per trial) and available reference 
scores. Figure 2 presents the PCS and MCS 
per trial. Maximal differences between trials 
for these summary scores were 4.6 and 3.2 
points, respectively (both p < 0.001). Women 
in the WOMB trial had higher PCS and MCS 
scores than women in the HYPITAT and DIG-
ITAT trial; though only the differences in MCS 
score were significant (p for the difference in 
MCS score 0.01 and < 0.001, respectively). 
With regard to the SF-36 summary scores, 
the average PCS in our study population 
was 4 points lower than the US popula-
tion reference score184,185 while the average 
MCS in our study was 3 points higher (both 
p < 0.001).
Dutch population reference scores for the SF-
36 subscales were made available for wom-
en aged from 16 to 40 years (unpublished 
data, see Methods). Average general health 
perception and role-emotional scores in our 
study were comparable to these reference 
scores (p = 0.04 and p = 0.053, respectively) 
while the mental health score in our study 
was six points higher (p < 0.001). The re-
maining subscales in our study population 
had lower average scores than their Dutch 
reference (all p < 0.001). Largest differences 
between subscale scores in our study and 
Dutch population reference scores were 
found for the subscales role-physical and 
bodily pain (26 and 18 points, respectively).
Comparing scores in our study to postpar-
tum reference scores demonstrated that 
all SF-36 subscale scores in our study had 
a lower average (all p < 0.001), except for 
the subscales physical functioning and 
role-emotional that were similar, and gener-
al health perception that was equal. Again, 
largest differences were found for the sub-
scales role-physical and bodily pain (14 and 
17 points, respectively). 
Univariable regression analyses
Results of the univariable analyses are tab-
ulated in Appendix 1. High BMI, gestation-
al hypertension, pre-eclampsia, elective 
and emergency cesarean section, induc-
tion of labor, epidural or spinal anesthetics, 
birth weight below 10th percentile, neonatal 
admission and delivery in an tertiary hospital 
affected the PCS at six weeks postpartum 
negatively (all p < 0.10). High education, mul-
tiparity, perineal laceration, manual placenta 
removal and PPH were positively associated 
with PCS (all p < 0.10). 
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Parameters influencing the MCS negatively 
(all p < 0.10) were foreign country of birth, 
low education, pre-eclampsia, induction of 
labor, birth weight below the 10th percen-
tile, neonatal admission, neonatal congenital 
anomaly, and delivery in a tertiary hospital, 
while the MCS was higher (all p < 0.10) in 
women who had had perineal laceration, 
MPV or curettage and PPH. 
Multivariable regression analyses
We used multivariable regression analyses to 
assess the influence of socio-demographic 
and clinical parameters on PCS and MCS. 
Gestational hypertension, elective cesare-
an section, emergency cesarean section, 
neonatal admission and delivery at a tertiary 
hospital were negatively related to PCS (Ta-
ble 3): the PCS score was on average 1.5 
points lower in women with gestational hy-
pertension, 1.3 points lower in case of neo-
natal admission, 1.2 points lower after deliv-
ery at a tertiary hospital and respectively 5.6 
and 6.3 points lower after elective or emer-
gency cesarean section. As demonstrated in 
Table 3, the MCS was found to be influ-
enced negatively by a foreign country of birth 
(1.9 points lower) and induction of labor (1.4 
points lower) while the score of women who 
had had a PPH was 1.8 points higher than 
the score of women who had not suffered 
from PPH. scores than PPH. 
Discussion
Determinants of postpartum HRQoL after 
obstetric complications were investigated. 
We found that women with pregnancies 
complicated by IUGR and hypertensive 
disorders overall had lower mental HRQoL. 
Gestational hypertension, delivery by cesar-
ean section, neonatal admission and deliv-
ery in a tertiary hospital were found to be 
negatively related to PCS in this study. The 
impact of a cesarean section was the larg-
est. MCS was, only mildly, influenced by for-
eign country of birth, induction of labor (both 
negatively) and PPH (positively). 
Figure 2 The SF-36 summary scores PCS and MCS, demonstrated per trial.
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For the interpretation of results, it is import-
ant to realize that a significant difference in 
HRQoL score does not necessarily indicate 
that this difference is meaningful. The magni-
tude of the difference determines whether the 
difference is of clinical importance. Estimates 
of the minimal clinical important change in 
the scores PCS and MCS vary from 5 to 
10.110 This implies that the differences in av-
erage scores between trials, as found in this 
study, were relatively small. Also, all effects 
on PCS and MCS seem small, except for 
the negative influence of mode of delivery by 
cesarean section on PCS: after elective and 
emergency cesarean section women scored 
on average 6 points lower than after spon-
taneous vaginal delivery. Consequently, only 
mode of delivery seems to have a profound 
impact on HRQoL postpartum.
All parameters, found to be related to either 
PCS or MCS, can be reasonably explained, 
though the finding that women after PPH 
were found to have a relatively high MCS 
was unexpected. All women in our study 
suffered from an obstetric complication and 
PPH apparently had a relatively positive ef-
fect in comparison to the other complica-
tions (IUGR and hypertensive disorders).
Compared to US-based population,184 our 
study population demonstrated overall lower 
PCS though higher MCS scores. Further-
more, our population had on average lower 
scores on all subscales, except for general 
health, role-emotional and mental health, 
compared to Dutch reference scores (un-
published data, provided by Aaronson et 
al.).93 Presumably physical HRQoL is sub-
optimal after delivery and even worsened 
by obstetric complications; while mental 
HRQoL is most likely positively influenced by 
new motherhood.
Our population had significantly lower scores 
on all subscales than the postpartum refer-
ence scores demonstrated in Table 2,69 ex-
cept for physical functioning and role-emo-
tional (similar) and general health (equal). The 
obstetric complications that our study popu-
lation suffered from, presumably account for 
these differences.
Factors associated with HRQoL as de-
scribed in previous literature like ethnicity, 
education, and preterm birth were not con-
firmed in this study. However, HRQoL scores 
might already have normalized to a large ex-
tent at six weeks postpartum: findings in this 
study and the pilot study indicate that mea-
suring SF-36 scores at one or two addition-
al time points (earlier than six weeks post-
partum) might have been very informative.69 
Previous literature regarding the influence of 
mode of delivery on HRQoL is contradictive. 
Of previous studies that used the SF-36, two 
studies demonstrated similar results, one 
study found better HRQoL after a cesar-
ean section than after vaginal delivery and 
one study described no influence of mode 
of delivery on physical HRQoL.68,69,186,187 
These studies however, were based on 
much smaller populations. Two studies that 
used different HRQoL measures did not find 
lower HRQoL after a cesarean section.164,188 
Although numbers in these studies were rel-
atively large (n > 1000), results cannot be 
compared due to the different measurement 
methods. 
The selection of women with an obstetric 
complication in this study should be taken 
into consideration. Another limitation of the 
current study is the use of combined data 
collected in three randomized controlled 
trials, although no effect of randomiza-
tion on postpartum HRQoL was detected. 
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Furthermore, Bijlenga et al. found no treat-
ment effect on HRQoL in women random-
ized to induction of labor or expectant 
management in the DIGITAT and HYPITAT 
trial189,190 while in WOMB trial differences in 
HRQoL between study groups were small at 
six weeks postpartum.88 The effect of both 
randomization and treatment strategy on our 
results seems therefore minimal. 
Many differences between responders and 
non-responders were found. These were 
partly predictable, as socio-demographic 
differences like age, ethnicity and education 
are parameters known to influence response 
rates.191 Due to the large numbers many 
differences were significant even when the 
magnitude of the difference was small.
 
The major strengths of this study are the 
nationally collected data and the large num-
bers. 
In a heterogeneous obstetric population, 
delivery by elective and emergency cesar-
ean section are the only factors that have 
a profound, negative impact on physical 
HRQoL. No profound impacts on mental 
HRQoL were detected. Of the studied ob-
stetric complications, PPH seems to influ-
ence postpartum HRQoL less than IUGR 
and hypertensive disorders. These results 
emphasize the need for careful consider-
ation while determining mode of delivery 
and bring in reliable information to support 
discussions about (determinants of) HRQoL 
after obstetric complications. 
Appendix 1 Univariable associations between socio-demographic parameters, clinical para- 
 meters and obstetric complications, and the Physical and Mental Component 
 Score. 
Physical Component Score Mental Component Score
Estimate SE p Estimate SE p
Parameter
Randomization status
not randomized ref ref
randomized 0.041 0.528 0.94 0.158 0.523 0.76
Maternal age 0.014 0.051 0.78 0.008 0.051 0.88
BMI 
< 18.5 -0.416 1.352 0.76 -0.570 1.363 0.68
18.5-25 ref ref
> 25 -2.165 0.550 < 0.001 0.133 0.549 0.81
Country of birth
Dutch ref ref
not Dutch -1.059 0.859 0.22 -1.675 0.844 0.05
Highest education
none/ primary education 1.070 1.089 0.33 -2.401 1.164 0.04
secondary education ref ref
higher professional education/ university 1.838 0.632 0.004 0.566 0.565 0.32
Parity
primiparous ref ref
multiparous 1.981 0.529 < 0.001 -0.802 0.526 0.13
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Physical Component Score Mental Component Score
Estimate SE p Estimate SE p
Hypertensive disorder
none ref ref
gestational hypertension -2.847 0.564 < 0.001 -0.626 0.565 0.27
pre-eclampsia -3.031 0.702 < 0.001 -1.379 0.703 0.05
Mode of delivery
vaginal, spontaneous ref ref
vaginal, operative -0.803 0.669 0.23 0.306 0.684 0.66
CS, elective -4.289 1.784 0.02 0.136 1.823 0.94
CS, emergency -6.868 0.746 < 0.001 -1.194 0.762 0.12
Induction of labor
no ref ref
yes -1.333 0.520 0.01 -2.009 0.505 < 0.001
Analgesics
none ref ref
opiates -0.773 0.796 0.33 -0.102 0.791 0.90
EDA/ spinal -1.930 0.595 0.001 -0.522 0.596 0.38
general anesthetics -2.565 1.951 0.19 -0.929 2.519 0.72
Perineal laceration
none or first degreea ref ref
second degree or higher 1.792 0.504 < 0.001 1.229 0.500 0.01
Delivery placenta
spontaneousa ref ref
MPV or curettage 2.861 0.726 < 0.001 1.371 0.723 0.06
Birth weight
< 10th percentile -1.061 0.584 0.07 -1.502 0.578 0.01
10th-90st percentile ref ref
> 90st percentile 0.312 0.790 0.69 -0.550 0.784 0.48
Postpartum hemorrhage
no ref ref
yes 2.780 0.514 < 0.001 2.486 0.511 < 0.001
Neonatal admission
no ref ref
yes -3.395 0.496 < 0.001 -2.159 0.496 < 0.001
Congenital anomaly (severe)
no ref ref
yes 3.445 2.682 0.20 -4.528 2.657 0.09
Urinary tract infection
no ref ref
yes 0.165 1.742 0.93 2.279 1.823 0.21
Thromboembolic event
no ref ref
yes -0.093 2.813 0.97 -0.417 2.367 0.86
Endometritis
no ref ref
yes 2.410 2.708 0.38 1.862 2.803 0.51
Hospital setting
non-teaching 0.194 1.152 0.89 0.488 1.143 0.67
teaching ref ref
tertiary -1.513 0.574 0.01 -1.199 0.570 0.04
aincluding cesarean sections.
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Chapter 6
Discussion
Worldwide, postpartum hemorrhage is still 
the most prevalent cause of maternal death. 
One of the Millennium Development Goals, 
set by the United Nations in 2000, is to re-
duce maternal mortality by three-quarters by 
2015:1,192 although hypertensive disorders of 
pregnancy are the leading cause of maternal 
death in developed countries, postpartum 
hemorrhage remains among one of the most 
frequent causes.23 Incidence, prevention 
and treatment of postpartum hemorrhage 
are therefore of great importance, especial-
ly with an increasing incidence reported in 
several developed countries.4-11 This trend 
has been related to factors as the advanced 
maternal age at childbirth and the increase 
in the cesarean section rate in theory, but till 
now factors causing the rise in the incidence 
of postpartum hemorrhage have not been 
identified.193 
Apart from the observed increase, a wide 
variation in the postpartum hemorrhage in-
cidence is described across continents and 
between urban and rural populations.2 Fong 
et al. also described a wide variation in post-
partum hemorrhage incidence across Cali-
fornian regions.22 In this thesis, we demon-
strated comparable results: large regional 
differences in the incidence of postpartum 
hemorrhage (range 1.8 to 8.1%) were found 
in the Netherlands.
A major issue in studies on postpartum 
hemorrhage is the subjectivity of its diag-
nosis, which depends on the accoucheur’s 
estimate of blood loss.42 Although a more 
accurate estimation of blood loss in the last 
decade might have contributed to the in-
crease in postpartum hemorrhage, regional 
differences are less likely to be explained by 
this feature. We studied the incidence and 
variance of postpartum hemorrhage from 
2000 to 2008 in the Netherlands using data 
of the Dutch Perinatal Registry. Strengths 
of this study are the completeness of data 
and the large sample size of almost 2 mil-
lion Dutch deliveries. A limitation of the 
Dutch Perinatal Registry data is that these 
comprise only basic elements of labor and 
delivery: data on active management of the 
third stage, the exact amount of blood loss 
and causes of postpartum hemorrhage are 
lacking. Also, the effect of registration errors 
is unknown.194 The wide variation in postpar-
tum hemorrhage incidence across regions in 
the Netherlands could not been explained. 
Therefore, future research should focus on 
detection of parameters which explain this 
variance. Identification of these parameters 
would allow for improvement of health care 
and could also put the increase in postpar-
tum hemorrhage incidence to a stop. 
Apart from awareness of postpartum hem-
orrhage, focus on prevention is essential. 
In this thesis, adherence to the guideline of 
active third stage of labor by the Interna-
tional Confederation of Midwives (ICM) and 
the International Federation of Gynecology 
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and Obstetrics (FIGO)51 was investigated. 
Interventions described in the guideline are 
intended to prevent postpartum hemor-
rhage, but adherence was found to be low. 
In less than 50% of the studied deliveries, all 
three recommended interventions (adminis-
tration of oxytocin, controlled cord traction 
and uterine massage) were performed. Pre-
vious studies found similar results: a com-
parable study performed in Nigeria showed 
42% adherence,65 while a nested case-con-
trol study in Australia reported lower perfor-
mance rates of oxytocin administration, but 
higher rates of controlled cord traction.66 
Although our study was performed in two 
hospitals only, it accurately reflected all vagi-
nal deliveries in the defined study period and 
missing data were minimal. We assume that 
adherence to the guideline was low due to 
low awareness and contradicting literature 
on the effectiveness of controlled cord trac-
tion and uterine massage.63,195-198 Besides 
a training program to enhance awareness, 
more research is needed to investigate the 
effectiveness of the intervention controlled 
cord traction and uterine massage.
Postpartum hemorrhage may lead to acute 
anemia. Hallmark of the treatment of the 
acute anemic patient is red blood cell 
transfusion. In the Netherlands, 4% of all 
red blood cell transfusions are prescribed 
in obstetrics.13 A Dutch retrospective au-
dit reported that a significant proportion of 
the postpartum red blood cell transfusions 
are possibly inappropriate, partly due to 
over-transfusion.199 Conclusions of this au-
dit, however, were based on hemoglobin 
concentrations alone which is, to our opin-
ion, not accurate enough.200 The effective-
ness of red blood cell transfusion is contro-
versial. Previous trials investigating red blood 
cell transfusion policy in the intensive care 
unit and among orthopedic and surgical pa-
tients demonstrated that a restrictive policy 
was not inferior to red blood cell transfu-
sion regarding complications, mortality and 
length of hospital stay.97,99,102 In this thesis, 
we found similar results in an obstetric pop-
ulation (the WOMB trial). Red blood cell 
transfusion, compared to non-intervention, 
in women with acute anemia after post-
partum hemorrhage led only to a small im-
provement in physical fatigue. The clinical 
relevance of the difference in physical fatigue 
seems small while no differences in compli-
cation rates or length of hospital stay were 
found between study arms.95,201 Therefore, 
a restrictive red blood cell transfusion policy 
seems justified in women with acute anemia 
due to postpartum hemorrhage. The clinical 
relevance of these findings is high as results 
of previously trials cannot be extrapolated to 
obstetrics due to the hemodynamic chang-
es during pregnancy and especially in the 
first days of the postpartum period.202,203 Al-
though the randomized design of the WOMB 
study strengthens results, the chosen prima-
ry outcome was, retrospectively, not optimal. 
The most important disadvantage was that 
no minimal clinical relevant difference of the 
HRQoL score physical fatigue (primary out-
come) had been determined yet. Although 
a pilot study69 demonstrated that differenc-
es could be observed, interpretation of the 
magnitude of differences remained unclear. 
Additionally, as primary outcome was ob-
tained by questionnaires, 20% of the data 
were missing; although this is a common 
percentage in HRQoL studies, it is not ideal 
for primary outcome analysis. Moreover, to 
add strength to interpretation of the trial re-
sults, addition of a more objective physical 
measure like a physical performance test or 
Karnofsky performance score should have 
been considered.204
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In the WOMB trial, over 10% of women treat-
ed without red blood cell transfusion needed 
an escape red blood cell transfusion, mostly 
for anemic complaints. We therefore devel-
oped prediction models to identify women 
prone for escape red blood cell transfusion. 
Although external validation yet needs to be 
investigated, these models are the first in-
struments to calculate a woman’s individual 
probability of escape transfusion. Implemen-
tation of these formulas, that use both clin-
ical features and HRQoL scores, could im-
prove postpartum care and lead to informed 
consent in this population. 
For the development of our prediction 
models, WOMB data on randomized and 
non-randomized women were analyzed to-
gether. Although the participation factor (e.g. 
randomized or non-randomized) was no pre-
dictor for escape red blood cell transfusion, 
this may be considered to be a limitation. 
While health care costs resume their rise, 
especially in times of financial crisis, one 
should evaluate treatment costs and use this 
knowledge in daily clinical practice. Previous 
literature reported that red blood cell trans-
fusion is beneficial and cost-effective in case 
of severe symptomatic anemia,161 though lit-
tle was known about costs-effectiveness of 
red blood cell transfusion in anemic women 
without severe complaints in the obstetric 
field. These are young and healthy women in 
whom a red blood cell transfusion was often 
not necessary in the acute phase of postpar-
tum; they represent a specific population as 
vital functions are not easily threatened by 
postpartum hemorrhage. 
We performed a cost-effectiveness analysis 
alongside the WOMB trial and demonstrat-
ed the following. In acutely anemic women 
after postpartum hemorrhage, direct medi-
cal costs were significantly higher in women 
receiving red blood cell transfusion than in 
women managed with non-intervention (re-
spectively €1957 versus €1707). Moreover, 
full nationwide implementation of a non-in-
tervention policy would reduce health care 
costs in these women with €619.478 per 
year, while costs of performing the WOMB 
trial were just once €225.000. Although a 
cost-effectiveness analysis alongside a ran-
domized clinical trial provide timely informa-
tion with high internal validity,205 some vari-
ables were not collected in as much detail 
as would have been preferred for the costs 
effectiveness analyses. 
Use of HRQoL measures is gaining more 
importance in medical decision making pro-
cesses. Although HRQoL is frequently used 
in neurologic and oncologic populations, its 
use is relatively unknown in obstetrics. It is 
impossible to separate disease from an in-
dividual’s personal and social context.206 
We therefore believe that the use of HRQoL 
measures in clinical trials should be expand-
ed as improvement of our patient’s well-be-
ing is the primary goal for each physician. 
To improve interpretation of HRQoL results, 
it needs to be investigated in various popu-
lations.
 
In this thesis we investigated postpartum 
health-related quality of life in women who 
suffered from an obstetric complication and 
demonstrated that this is influenced by var-
ious clinical variables. Physical health at six 
weeks postpartum is influenced by gesta-
tional hypertension, elective cesarean sec-
tion, emergency cesarean section, neonatal 
admission and delivery at a tertiary hospital. 
Birth country, onset of labor and postpartum 
hemorrhage were related to scores of men-
tal health, measured by the SF-36. 
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Compared to an US-based population,184 
our study demonstrated lower physical 
HRQoL while mental HRQoL was higher. 
Compared to a Dutch population reference 
(unpublished data based on 367 wom-
en aged from 16 to 40 years, Aaronson et 
al.93), only mental health scored higher than 
in the reference population. Presumably, 
physical HRQoL is reduced after delivery 
while mental HRQoL is positively influenced 
in a new mother. Compared to a relatively 
healthy postpartum reference population,69 
subscales in the current study scored gen-
erally lower. The obstetric complications 
(intra-uterine growth restriction, pregnan-
cy-induced hypertension, pre-eclampsia 
or postpartum hemorrhage), that our study 
population suffered from, presumably ac-
count for the lower scores. 
Selection bias by the use of combined data 
of three trials (on intra-uterine growth re-
striction, pregnancy-induced hypertension, 
pre-eclampsia or postpartum hemorrhage) 
is a limitation in our study. For the interpre-
tation of results, it is important to realize that 
HRQoL scores are reflected against HRQoL 
in mothers with an obstetric complication, 
not against healthy controls. Also, HRQoL 
scores were only available at six weeks 
postpartum; we cannot rule out other pa-
rameters influencing HRQoL scores earlier 
postpartum. The strength of this study how-
ever is the large number that was created 
by merging data of these three trials. Since 
all trials were conducted through the Dutch 
Obstetric Consortium, data were collected in 
a similar manner, and information bias was 
minimal.
Conclusions
This thesis has increased our knowledge 
and insights regarding postpartum hemor-
rhage and health-related quality of life in the 
postpartum period. Postpartum hemorrhage 
was, is and will remain a topic that requires 
alertness. With the increasing incidence of 
postpartum hemorrhage in developed coun-
tries,4-11 it becomes more and more import-
ant to focus on prevention. Better imple-
mentation and evaluation of the FIGO/ ICM 
guideline on active third stage management 
of labor should be achieved. Furthermore, 
the large variation in postpartum hemor-
rhage indicates that there is an opportunity 
to lower the risk at postpartum hemorrhage 
by identifying and altering the unidentified 
causes. 
Red blood cell transfusion, often used in the 
treatment of anemic women postpartum af-
ter postpartum hemorrhage, carries a seri-
ous risk at adverse events like transmission 
of infectious disease and is a financial bur-
den for our society. More than ever in times 
of financial crisis, red blood cell transfusion 
should only be provided when undeniable 
beneficial compared to non-intervention. 
Although non-inferiority of non-intervention 
(in acutely anemic women after postpartum 
hemorrhage) could not be proven, the dif-
ference in physical fatigue was small and 
seems clinically irrelevant. Implementation 
of a non-intervention policy would therefore 
prevent transfusion adverse events and di-
minish the financial burden, without disad-
vantages for these women. 
HRQoL should play a role in the decision to 
transfuse: the aim of each physician is to op-
timize well-being of women postpartum and 
HRQoL can contribute by indicating proba-
bility of the need for escape transfusion. The 
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formulas on the probability of the need for 
escape red blood cell transfusion, in which 
HRQoL were used, may be of great value 
while counseling these women. 
HRQoL in the postpartum period is influ-
enced by several socio-demographic and 
clinical parameters though only mode of 
delivery influences postpartum HRQoL to a 
large extent. Awareness of the influence of 
socio-demographic and clinical parameters 
on HRQoL will improve both counseling of 
women and health care. 
recommendations for 
clinical practice
Based on results presented in this thesis, we 
recommend the following actions:
1. Increase awareness of postpartum hem-
orrhage, especially in regions with a rela-
tively high incidence, and improve accu-
racy of estimated blood loss by routinely 
weighing.
2. Provide training on active third stage man-
agement for midwives, residents and ob-
stetricians to improve adherence to the 
FIGO/ ICM guideline.
3. Implement a non-intervention policy in 
acutely anemic women after postpartum 
hemorrhage without severe anemic com-
plaints. 
Counsel these women regarding the ef-
fects on physical fatigue, the risks of red 
blood cell transfusion and the chance of 
needing a red blood cell transfusion on 
second instance. 
Once formulas will have been externally 
validated, an individual probability of the 
need for escape red blood cell transfusion 
should be used for counseling.
4. Increase awareness of socio-demograph-
ic and clinical parameters that influence 
HRQoL in the postpartum period. When 
counseling women for cesarean section 
or vaginal delivery the effect of mode of 
delivery on physical HRQoL, up to six 
weeks postpartum, should be taken into 
account. 
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Chapter 7
Summary
The aim of this thesis was to study variation 
in the incidence of postpartum hemorrhage 
in the Netherlands, adherence to active third 
stage management and treatment of women 
with acute anemia after postpartum hemor-
rhage with red blood cell transfusion. 
This thesis describes a large cohort study 
investigating variation in postpartum hem-
orrhage incidence across regions in the 
Netherlands, a cross-sectional study inves-
tigating implementation of active third stage 
management of labor in daily clinical practice 
and a multicenter randomized controlled tri-
al studying red blood cell transfusion policy 
in acutely anemic women after postpartum 
hemorrhage. Alongside this trial, a cost-ef-
fectiveness analysis of red blood cell transfu-
sion versus non-intervention was performed. 
At last, determinants of health-related quality 
of life in the postpartum period were studied 
in a large cohort created by merging data of 
three randomized controlled trials. 
The incidence of postpartum hemorrhage 
across regions in the Netherlands in 2000 to 
2008 was determined. A large cohort based 
on the Dutch Perinatal Registry, including al-
most 2 million Dutch deliveries, was used. 
Incidence of postpartum hemorrhage was 
determined for each province and for the 
four largest cities (Amsterdam, Rotterdam, 
Utrecht, The Hague). Within the two largest 
cities, Amsterdam and Rotterdam, variation 
in incidence across neighborhoods was also 
examined. The incidence of postpartum 
hemorrhage in the Netherlands during the 
study period was 4.5% while variation in in-
cidence across regions ranged from 1.8 to 
8.1%. The four largest cities had a relatively 
high incidence of postpartum hemorrhage 
(4.9% compared to 4.4% in the provinces 
(p < 0.001). Variance across neighborhoods 
in the two largest cities was, as incidence 
across regions nationwide, large. Adjust-
ment for maternal characteristics, pregnan-
cy characteristics, medical interventions and 
health care setting did not account for vari-
ation across regions. Regional variation is 
either unavoidable or subsequent to regional 
variation of a yet unregistered variable.
Implementation of the FIGO/ ICM guideline 
on active third stage management of labor, 
recommending administration of uteroton-
ic medication, controlled cord traction and 
uterine massage, was studied in an obser-
vational prospective setting. Birth attendants 
completed a case record form after every 
vaginal delivery and registered which inter-
ventions, recommended in the guideline, 
had been performed. Results of this study 
showed low adherence to the guideline: in 
less than 50% of the deliveries in our study, 
all three interventions were performed. 
Prevention of postpartum hemorrhage be-
comes even more important considering 
the increasing incidence that has been ob-
served in several developed countries. The 
results of this study address the requisite for 
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a training program to enhance adherence to 
the ICM/ FIGO guideline.
The WOMB trial (Well-being of Obstetric 
patients on Minimal Blood transfusions) is 
a non-inferiority trial that included women 
with acute anemia after postpartum hem-
orrhage (Hb concentration 4.8 to 7.9 g/dL 
[3.0 to 4.9 mmol]), without severe anemic 
complaints, to either red blood cell transfu-
sion or non-intervention. Primary outcome 
was physical fatigue, measured by the Mul-
tidimensional Fatigue Inventory, at day three 
postpartum. 
Prior beliefs in daily clinical practice, collect-
ed using an inventorial survey, regarding the 
WOMB trial are presented. With regard to 
WOMB trial results, 91% of respondents de-
clared to be prepared to adjust their current 
red blood cell transfusion policy if trial results 
would indicate so.
Results of the WOMB trial demonstrate 
that red blood cell transfusion mildly im-
proved physical fatigue. Non-inferiority of a 
non-intervention policy could not be prov-
en. However, the difference in physical fa-
tigue was small and clinical significance of 
the difference is doubtful. Complication rate 
and length of hospital stay were compara-
ble between study arms though women al-
located to non-intervention, had a 10-15% 
chance of receiving an escape transfusion. 
In the light of these results, we believe that 
a non-intervention policy is safe and with-
out disadvantages for women when proper 
counseling is provided. 
Prediction models on the need for escape red 
blood cell transfusion in women with acute 
anemia after postpartum hemorrhage that 
were initially treated with a non-intervention 
policy were created. Several clinical vari-
ables (primiparity, multiple pregnancy, total 
blood loss during delivery and Hb concen-
tration postpartum) were identified to predict 
the need for escape red blood cell trans-
fusion. Addition of health-related quality of 
life-scores improved the prediction model 
that was created. After external validation, 
the extended model and its formula (to cal-
culate an individual’s probability of needing 
an escape red blood cell transfusion after 
non-intervention) may be an important tool 
for counseling and decision making in clin-
ical practice. 
A cost-effectiveness analysis on the WOMB 
trial is presented, using a direct medical 
perspective to estimate costs for both treat-
ment strategies. Costs for women in the red 
blood cell transfusion arm were significant-
ly higher than costs in the non-intervention 
arm (respectively €1957 versus €1707). Re-
sults of this economic analysis strengthen 
our recommendation for a non-intervention 
strategy in women with acute anemia after 
postpartum hemorrhage.
Finally, we merged data of three randomized 
controlled trials to create a large cohort: the 
DIGITAT, the HYPITAT and the WOMB trial. 
The DIGITAT trial included women with in-
tra-uterine growth restriction and the HYP-
ITAT included women with a hypertensive 
disorder. Both trials randomized patients 
to either induction of labor or expectant 
management. The protocol of the WOMB 
trial was previously described in detail. We 
aimed to investigate determinants of physi-
cal and mental health, measured by the SF-
36, at six weeks postpartum. The physical 
component score (PCS) and mental compo-
nent score (MCS) were studied to assess re-
spectively physical health and mental health.
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Physical health at six weeks postpartum was 
negatively influenced by pregnancy-induced 
hypertension, delivery by elective or emer-
gency cesarean section, delivery at a tertiary 
hospital and neonatal admission. A non-
Dutch birth country and induction of labor 
negatively influenced mental health, while 
surprisingly postpartum hemorrhage had a 
positive influence. However, all women in the 
study population suffered from an obstetric 
complication; postpartum hemorrhage ap-
parently results in better mental health than 
intra-uterine growth restriction and hyper-
tensive disorders. Awareness of parame-
ters that influence health-related quality of 
life postpartum, can improve counseling of 
women and health care.
Postpartum hemorrhage was, is and re-
mains a topic that requires continuous alert-
ness. Results presented in this thesis will 
promote prevention and optimize treatment 
of women after postpartum hemorrhage.
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Samenvatting
Het doel van dit proefschrift is om de inci-
dentie van fluxus postpartum in Nederland 
in kaart te brengen, om na te gaan of de 
richtlijn van de FIGO/ ICM omtrent het actief 
nageboortetijdperk wordt nageleefd en om 
de optimale behandeling van kraamvrouwen 
met een acute anemie, na fluxus postpar-
tum, middels erytrocytentransfusie te onder-
zoeken. 
In dit proefschrift beschrijven we een grote 
cohort studie waarin de regionale variatie 
(en mogelijke determinanten hiervan) van de 
incidentie van fluxus postpartum in Neder-
land werd onderzocht. Verder worden een 
cross-sectionele studie, die de naleving van 
actief nageboortetijdperk in de dagelijkse 
praktijk in kaart bracht, en een multicentrum 
gerandomiseerde studie naar het transfu-
siebeleid in kraamvrouwen met een acute 
anemie na een fluxus postpartum beschre-
ven. Parallel aan deze laatste studie werd 
een kosteneffectiviteitsanalyse verricht. Tot 
slot werden de determinanten van kwaliteit 
van leven onderzocht in een cohort dat was 
gebaseerd op data van drie multicenter ge-
randomiseerde studies.
De incidentie van fluxus postpartum in ver-
schillende regio’s in Nederland werd on-
derzocht in een dataset die beschikbaar 
was gesteld door de Perinatale Registratie 
Nederland. Dit cohort omvatte bijna 2 mil-
joen bevallingen; 96% van alle bevallingen 
in Nederland in de jaren 2000 tot en met 
2008. De incidentie van fluxus postpartum 
in elke provincie en de vier grootste ste-
den (Amsterdam, Rotterdam, Utrecht en 
Den Haag) werd onderling vergeleken. Van 
Amsterdam en Rotterdam werd de variatie in 
kaart gebracht van de incidentie van fluxus 
postpartum tussen wijken. De Nederlandse 
incidentie van fluxus postpartum bedroeg 
4,5% in de studieperiode; variatie tussen 
regio’s en steden was groot met incidenties 
die varieerden tussen 1,8% en 8,1%. De vier 
grootste Nederlandse steden hadden een 
relatief hoge incidentie van fluxus postpar-
tum. Ook tussen wijken van zowel Amster-
dam als Rotterdam was de variatie van de 
fluxus incidentie, net als bij regionale variatie, 
groot. Na correctie voor maternale karakte-
ristieken, zwangerschapskarakteristieken, 
medische interventies en zorginstelling bleef 
deze variatie bestaan. De regionale variatie 
van de incidentie van fluxus postpartum lijkt 
derhalve onvermijdbaar of is gebaseerd op 
de regionale variatie van een nog niet ge-
identificeerde variabele.
Implementatie van de FIGO/ ICM richt-
lijn werd onderzocht in een observationele 
prospectieve setting. Deze richtlijn adviseert 
een actief nageboortetijdperk toe te passen 
middels toediening van uterotonica, ge-
controleerde tractie aan de navelstreng en 
uterusmassage. Na elke bevalling werd een 
case record form ingevuld: zodoende werd 
geregistreerd welke handelingen, beschre-
ven in de richtlijn, accuraat verricht waren. 
Deze studie toonde aan dat de richtlijn niet 
goed wordt nageleefd: in minder dan 50% 
van de bevallingen werden alle drie de voor-
geschreven handelingen uitgevoerd. 
De preventie van fluxus postpartum wordt 
meer en meer van belang gezien de toene-
mende incidentie in verschillende westerse 
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landen. Deze studie toont de noodzaak aan 
van trainingsprogramma’s om de naleving 
van de richtlijn te optimaliseren.
De WOMB studie (‘Well-being of Obstetric 
patients on Minimal Blood transfusions’) is 
een gerandomiseerde studie waarin kraam-
vrouwen met een acute anemie na fluxus 
postpartum, zonder ernstige anemische 
klachten, werden geïncludeerd. Het doel 
was om aan te tonen dat een expectatief 
beleid niet slechter is dan het geven van een 
erytrocytentransfusie; de primaire uitkomst-
maat was fysieke vermoeidheid, gemeten 
met de Multidimensional Fatigue Inventory, 
op dag drie postpartum.
De hedendaagse overtuigingen in de dage-
lijkse praktijk betreffende erytrocytentrans-
fusies in het kraambed werden geïnventari-
seerd met behulp van een enquête die naar 
alle opleiders gynecologie werd verzonden. 
Uit deze enquête bleek dat 91% van de res-
pondenten bereid zou zijn om het huidige 
transfusiebeleid in het kraambed aan te pas-
sen indien de WOMB resultaten hierop aan 
zouden sturen.
De resultaten van de WOMB studie toonden 
aan dat een erytrocytentransfusie bij een 
acute anemie, na een fluxus postpartum, 
de fysieke vermoeidheid in het kraambed 
licht verbetert; de hypothese dat expectatief 
beleid niet slechter is dan erytrocytentrans-
fusie, kon echter niet worden bewezen. Het 
gevonden verschil in fysieke vermoeidheid 
tussen studie armen was echter klein en de 
klinisch relevantie ervan dubieus. Het optre-
den van fysieke complicaties en de opname 
duur in het ziekenhuis verschilden niet tus-
sen de studie armen. Vrouwen die werden 
gerandomiseerd voor een expectatief beleid, 
kregen in 10-15% in tweede instantie alsnog 
een erytrocytentransfusie, in de meeste ge-
vallen wegens anemische klachten. Gezien 
de resultaten van de WOMB studie lijkt een 
expectatief beleid veilig en zonder nadelen 
voor de kraamvrouw wanneer adequate 
counseling wordt gegeven.
Naar aanleiding van de WOMB studie wer-
den bij anemische kraamvrouwen met een 
initieel expectatief beleid, de determinanten 
van de noodzaak tot een transfusie in twee-
de instantie onderzocht. Door de ontwik-
keling van een predictiemodel, werden ver-
schillende klinische variabelen (primipariteit, 
meerling zwangerschap, hoeveelheid bloed-
verlies tijdens de bevalling en Hb concentra-
tie postpartum) als determinanten geïdenti-
ficeerd. Toevoeging van kwaliteit van leven 
scores verbeterde het ontwikkelde predictie-
model. Op basis van de beschreven deter-
minanten werd een formule gecreëerd die de 
individuele kans op noodzaak tot transfusie 
kan berekenen. Na externe validatie, kan het 
predictiemodel en de bijbehorende formu-
le een belangrijke rol gaan spelen bij zowel 
counselen als besluitvorming in de dagelijk-
se praktijk.
De kosteneffectiviteitsanalyse, welke parallel 
aan de WOMB studie werd verricht, maakt 
gebruik van een direct medisch perspectief 
om de kosten voor beide behandelingsop-
ties te schatten. Kosten voor vrouwen in de 
transfusie arm waren significant hoger dan 
kosten voor vrouwen in de expectatieve arm 
(€1957 versus €1707, respectievelijk). Re-
sultaten van deze economische analyse on-
derschrijven een expectatief beleid in acuut 
anemische kraamvrouwen, zonder ernstige 
klachten, na fluxus postpartum.
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Tot slot werden data van drie gerandomi-
seerd gecontroleerde studies samenge-
voegd om een groot cohort te creëren. 
Hiervoor werd gebruikt gemaakt van data 
van de DIGITAT, HYPITAT en WOMB stu-
die. De DIGITAT studie includeerde vrouwen 
met een intra-uteriene groeirestrictie en de 
HYPITAT studie includeerde vrouwen met 
een hypertensieve aandoening in de zwan-
gerschap. Beide studies randomiseerden 
vrouwen voor inleiding van de baring dan 
wel een expectatief beleid. Het protocol van 
de WOMB studie is in dit proefschrift in de-
tail beschreven. Het doel van deze cohort-
studie was om determinanten van fysieke en 
mentale gezondheid, zes weken postpartum 
te identificeren. De fysieke component sco-
re (PCS) en de mentale component score 
(MCS), gemeten met de SF-36 vragenlijst, 
werden bestudeerd om de fysieke en men-
tale gezondheid in kaart te brengen.
Resultaten van deze cohort studie toonden 
aan dat de fysieke gezondheid op zes we-
ken postpartum negatief werd beïnvloed 
door de factoren zwangerschapshyperten-
sie, bevalling middels primaire en secundaire 
sectio cesarea, bevalling in een academisch 
ziekenhuis en opname van de neonaat. 
Een niet-westers geboorteland en inleiding 
van de baring beïnvloedden de mentale ge-
zondheid negatief, terwijl fluxus postpartum 
verassend genoeg een positieve invloed op 
de mentale gezondheid liet zien. Doordat 
alle zwangerschappen in deze studie wer-
den gecompliceerd door een obstetrische 
complicatie, kunnen we hieruit herleiden dat 
vrouwen na een fluxus postpartum een rela-
tief betere mentale gezondheid ervaren dan 
na intra-uteriene groeirestrictie of een hyper-
tensieve aandoening van de zwangerschap.
Bewustzijn van parameters die de kwaliteit 
van leven in het kraambed beïnvloeden, kan 
leiden tot betere counseling en zorg in het 
kraambed.
Fluxus postpartum was, is en blijft een ob-
stetrische complicatie die alertheid vereist. 
Resultaten in dit proefschrift moedigen aan 
tot preventie en bieden mogelijkheden tot 
het optimaliseren van de zorg voor vrouwen 
na fluxus postpartum.
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